World Patents in Skin Care Actives Published in 2012
WORLD PATENTS IN ACTIVES FOR SKIN CARE GRANTED IN  2012
This list includes patent documents published by the World Intellectual Property Organization (WIPO). The list was retrieved by searching the claims section of all patent applications
published. Salient search terms include skin care active ingredients having properties such as anti-ageing, anti-wrinkle, antioxidant, acne control benefits, skin whitening or lightening,
blemish removal, etc. This category includes technology related to the synthesis and delivery of actives such as peptides, exfoliants, α-hydroxy acids, herbals, free radical scavenger, "green"
derived molecules, etc.

Thank you for visiting FormulaScan . Please click on the WO Patent No to study the full patent document

WIPO - WORLD PATENTS IN SKIN CARE ACTIVES PUBLISHED IN 2012



Publication No.: WO2012001053A1  Published: 05/Jan/2012

Title: METRONIDAZOLE ESTERS FOR TREATING ROSACEA

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT

Application No.: WO2011EP60923 (PCT/EP2011/60923)   Filing Date: 29/Jun/2011

Abstract:

The present invention relates to a compound chosen from the compound of formula (I) below: enantiomers thereof and pharmaceutically acceptable salts thereof, and also to the uses thereof.

Priority: FR20100055241 Applic. Date: 2010-06-29

Inventor: BOITEAU JEAN-GUY [FR]; LINGET JEAN-MICHEL [FR]


Publication No.: WO2012001054A1  Published: 05/Jan/2012

Title: METRONIDAZOLE ESTERS FOR TREATING ROSACEA

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT

Application No.: WO2011EP60924 (PCT/EP2011/60924)   Filing Date: 29/Jun/2011

Abstract:

The present invention relates to a compound chosen from the compound of formula (I) enantiomers thereof and pharmaceutically acceptable salts thereof, for its use as a medicament.

Priority: FR20100055242 Applic. Date: 2010-06-29

Inventor: BOITEAU JEAN-GUY [FR]; LINGET JEAN-MICHEL [FR]


Publication No.: WO2012001055A1  Published: 05/Jan/2012

Title: METRONIDAZOLE ESTERS FOR TREATING ROSACEA

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT

Application No.: WO2011EP60925 (PCT/EP2011/60925)   Filing Date: 29/Jun/2011

Abstract:

The present invention relates to a compound chosen from the compound of formula (I) below: and pharmaceutically acceptable salts thereof, and also to the uses thereof.

Priority: FR20100055244 Applic. Date: 2010-06-29

Inventor: BOITEAU JEAN-GUY [FR]; LINGET JEAN-MICHEL [FR]


Publication No.: WO2012001076A1  Published: 05/Jan/2012

Title: USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT

Application No.: WO2011EP60953 (PCT/EP2011/60953)   Filing Date: 29/Jun/2011

Abstract:

The present invention relates to a novel use of a compound of the formula (I) or of one of its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, or hydrates, in the preparation of a medicament intended to prevent and/or treat rosacea.

Priority: FR20100055245 Applic. Date: 2010-06-29

Inventor: AUBERT JEROME [FR]


Publication No.: WO2012002322A1  Published: 05/Jan/2012

Title: SKIN PROPERTIES IMPROVING AGENT FOR ORAL ADMINISTRATION

Applicant/Assignee: KABUSHIKI KAISHA YAKULT HONSHA

Application No.: WO2011JP64681 (PCT/JP2011/64681)   Filing Date: 27/Jun/2011

Abstract:

Disclosed is a skin properties improving agent which is administered orally and has excellent advantageous effects. The skin properties improving agent for oral administration has, as an active ingredient, fermented milk containing Streptococcus bacteria, bifidobacteria, or both types of bacteria.

Priority: JP20100145766 Applic. Date: 2010-06-28

Inventor: MASUOKA NORIE [JP]; KANO MITSUYOSHI [JP]; MIYAZAKI KOUJI [JP]; SONE TOSHIRO [JP]


Publication No.: WO2012002536A1  Published: 05/Jan/2012

Title: VEGF PRODUCTION PROMOTER

Applicant/Assignee: KAO CORPORATION

Application No.: WO2011JP65189 (PCT/JP2011/65189)   Filing Date: 01/Jul/2011

Abstract:

Disclosed is a VEGF production promoter, an agent for improving the nature of hair, or an external preparation for the skin, which has a VEGF production promoting activity and can be used as a pharmaceutical agent, a cosmetic, a food or a material for the pharmaceutical agent, the cosmetic or the food. Specifically disclosed is a VEGF production promoter, an agent for improving the nature of hair, or an external preparation for the skin, which contains, as an active ingredient, a cycloartane-type triterpenoid glycoside represented by general formula (1) [wherein R represents a xylose residue or an arabinose residue

and the ring D moiety represents any one of the moieties a to f shown below (wherein R1 represents a hydrogen atom or a methyl group

R2 represents a hydrogen atom or an acetyl group

R3 represents a hydrogen atom or a hydroxy group

R4 represents a hydrogen atom or a hydroxy group

and Ac represents an acetyl group)].

Priority: JP20100152195 Applic. Date: 2010-07-02

Inventor: KAMEYAMA AKIYO [JP]; UEDA SACHIE [JP]


Publication No.: WO2012002782A2  Published: 05/Jan/2012

Title: SKIN-WHITENING COMPOSITION FOR EXTERNAL APPLICATION ON SKIN CONTAINING EXTRACTS FROM PAPER MULBERRY FLOWERS AND FRUITS

Applicant/Assignee: AMOREPACIFIC CORPORATION

Application No.: WO2011KR04885 (PCT/KR2011/04885)   Filing Date: 04/Jul/2011

Abstract:

The present invention relates to a composition for external application on skin, the composition containing extracts from flowers and fruits of paper mulberry, more specifically containing extracts from flowers and fruits of paper mulberry as an active ingredient, thereby enabling excellent skin-whitening effects through effective suppression of melanin formation.

Priority: KR20100063992 Applic. Date: 2010-07-02

Inventor: LEE JIN YOUNG [KR]; LIM HYUNG JUN [KR]


Publication No.: WO2012002784A2  Published: 05/Jan/2012

Title: COMPOSITION CONTAINING PAPER MULBERRY EXTRACTS

Applicant/Assignee: AMOREPACIFIC CORPORATION

Application No.: WO2011KR04890 (PCT/KR2011/04890)   Filing Date: 04/Jul/2011

Abstract:

The present invention relates to a composition containing paper mulberry extracts, more specifically containing paper mulberry extracts as an active ingredient, and thereby better moisturizes the skin, improves de-aging effects, provides better infection relief, antibiotic effects, and pore reduction and sebum control effects, improves blood circulation, decomposes subcutaneous fat, and prevents hair whitening by stimulating melanin synthesis.

Priority: KR20100067463 Applic. Date: 2010-07-13; KR20100064367 Applic. Date: 2010-07-05; KR20100064296 Applic. Date: 2010-07-05; KR20100063990 Applic. Date: 2010-07-02; KR20100063879 Applic. Date: 2010-07-02; KR20100063878 Applic. Date: 2010-07-02; KR20100063736 Applic. Date: 2010-07-02

Inventor: LEE JIN YOUNG [KR]; CHOI HYANG TAE [KR]; KIM HAN BYUL [KR]; KIM JI SEONG [KR]


Publication No.: WO2012003810A1  Published: 12/Jan/2012

Title: REGULATORY FACTOR OF FOXP3 AND REGULATORY T CELLS AND USE THEREOF

Applicant/Assignee: INSTITUT PASTEUR OF SHANGHAI, CAS

Application No.: WO2011CN77032 (PCT/CN2011/77032)   Filing Date: 11/Jul/2011

Abstract:

Disclosed are uses of a ubiquitination pathway-related factor and an activating agent or antagonist thereof in the preparation of a composition regulating FOXP3, IL-2 and/or IFN-? activity. The ubiquitination pathway related-factor is selected from: a Toll-like receptor, a ubiquitination ligase, a proinflammatory cytokine family receptor and/or a coding sequence thereof. The composition regulating FOXP3, IL-2 and/or IFN-? activity can also be used as an immunoadjuvant or a vaccine.

Priority: CN20101222995 Applic. Date: 2010-07-09

Inventor: LI BIN [CN]; LIN FANG [CN]; CHEN ZUOJIA [CN]; LI ZHIYUAN [CN]; PAN FAN [CN]


Publication No.: WO2012004748A1  Published: 12/Jan/2012

Title: NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS

Applicant/Assignee: WYETH LLC

Application No.: WO2011IB52984 (PCT/IB2011/52984)   Filing Date: 05/Jul/2011

Abstract:

Disclosed are quinoline esters of Formula (I):(I) which are useful as Liver X receptors (LXR) modulators. Pharmaceutical compositions containing quinoline esters of Formula (I) and the use of quinoline esters of Formula (I) in the safe treatment of various skin disorders are also disclosed. Methods for preparing and using quinoline esters are further described.

Priority: US20100362320P Applic. Date: 2010-07-08

Inventor: BERNOTAS RONALD CHARLES [US]; SINGHAUS ROBERT [US]; NAGPAL SUNIL [US]; THOMPSON CATHERINE [US]


Publication No.: WO2012004799A1  Published: 12/Jan/2012

Title: TREATMENT OF DELAYED CUTANEOUS HYPERSENSITIVITY CONDITIONS WITH S-FARNESYLTHIOSALICYLIC ACID AND ANALOGS THEREOF

Applicant/Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD

Application No.: WO2011IL00540 (PCT/IL2011/00540)   Filing Date: 07/Jul/2011

Abstract:

Disclosed are methods of treating a mammalian subject afflicted with a delayed cutaneous hypersensitivity condition, comprising administering to the subject a pharmaceutical composition comprising an effective amount of S farnesylthiosalicylic acid (FTS) or a structural analog thereof, and compositions for use in the methods.

Priority: US20100362496P Applic. Date: 2010-07-08

Inventor: MEKORI YOSEPH A [IL]; MOR ADAM [IL]; KLOOG YOEL [IL]


Publication No.: WO2012005227A1  Published: 12/Jan/2012

Title: TETRAHYDROCARBOLINE DERIVATIVE

Applicant/Assignee: ONO PHARMACEUTICAL CO., LTD

Application No.: WO2011JP65312 (PCT/JP2011/65312)   Filing Date: 05/Jul/2011

Abstract:

As a pharmaceutical product useful for patients with urine evacuation disorders for whom conventional drugs are ineffective, a drug is disclosed having inhibitory activity on ENPP2, which is a target different from that of already existing drugs. Disclosed are a compound represented by formula (I) (wherein definitions of the groups are as in the description) having ENPP2 inhibitory activity, a salt or solvate thereof, a prodrug of either of these, or an agent for prevention, treatment and/or symptomatic improvement of urine evacuation disorders containing either of these as an active ingredient.

Priority: JP20110060765 Applic. Date: 2011-03-18; JP20100154280 Applic. Date: 2010-07-06

Inventor: OHATA AKIRA [JP]; NAKATANI SHINGO [JP]; SUGIYAMA TETSUYA [JP]; MORIMOTO TAKASHI [JP]


Publication No.: WO2012005229A1  Published: 12/Jan/2012

Title: N-HYDROXYFORMAMIDE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME

Applicant/Assignee: KAKEN PHARMACEUTICAL CO., LTD

Application No.: WO2011JP65317 (PCT/JP2011/65317)   Filing Date: 05/Jul/2011

Abstract:

Disclosed is a compound which is represented by general formula (I) and has an inhibitory effect on ADAM17, a salt thereof, or a solvate thereof. In formula (I), X represents a phenylene group, Y represents a hydrogen atom, -(CH2)mR1, or the like, R1 represents -NR5COR2, -NR5SO2R2, or -NR3R4, R2 represents a C1-C6 alkyl group, an aryl group, or a C1-C6 alkoxy group, R3 and R4 each represent a C1-C6 alkyl group or the like, R5 represents a hydrogen atom, a C1-C6 alkyl group, or the like, m represents an integer of 0 to 4, and Z represents a hydrogen atom or a C1-C6 alkyl group.

Priority: JP20100156025 Applic. Date: 2010-07-08

Inventor: KAWAI KENTARO [JP]; MIYAMOTO SHIGERU [JP]; SHIMANO MASANAO [JP]; HAINO MAKOTO [JP]


Publication No.: WO2012006397A2  Published: 12/Jan/2012

Title: ANTIPERSPIRANT PRODUCTS COMPRISING NATURAL PHOSPHOLIPIDS AND METHODS FOR MANUFACTURING THE SAME

Applicant/Assignee: THE DIAL CORPORATION

Application No.: WO2011US43141 (PCT/US2011/43141)   Filing Date: 07/Jul/2011

Abstract:

Antiperspirant products comprising natural phospholipids and methods for manufacturing the same are provided. In an embodiment, an antiperspirant product comprises an active antiperspirant compound and a natural phospholipid. In another embodiment, a method of manufacturing an antiperspirant product comprises combining an active antiperspirant compound and a natural phospholipid at a first temperature to form a mixture, pouring the mixture into molds at a second temperature that is lower than the first temperature, and cooling the mixture to a third temperature that is lower than the second temperature.

Priority: US2010-833141 Applic. Date: 2010-07-09

Inventor: YARLAGADDA TRAVIS T [US]; DOERING THOMAS [DE]


Publication No.: WO2012006958A1  Published: 19/Jan/2012

Title: AMIDS SUBSTITUTED INDAZOLE DERIVATIVEES AS PLOY(ADP-RIBOSE)POLYMERASE INHIBITORS

Applicant/Assignee: ZHEJIANG BETA PHARMA INC

Application No.: WO2011CN77165 (PCT/CN2011/77165)   Filing Date: 14/Jul/2011

Abstract:

Amide substituted indazoles and benzotriazoles as inhibitors of the enzyme poly(ADP-ribose)polymerase(PARP). The compounds of the present invention are useful as mono-therapies in tumors with specific defects in DNA-repair pathways, as enhancers of certain DNA-damaging agents such as anticancer agents and radiotherapy, for reducing cell necrosis (in stroke and myocardial infarction), regulating inflammation and tissue injury, treating retroviral infections, and protecting against the toxicity of chemotherapy.

Priority: WO2010CN01058 Applic. Date: 2010-07-14

Inventor: HU SHAOJING [CN]; LI HAIJUN [CN]; LONG WEI [CN]; SHEN XIAOYAN [CN]; TAN FENLAI [CN]; WANG YINXIANG [CN]


Publication No.: WO2012007572A1  Published: 19/Jan/2012

Title: COMPOUNDS WITH A SKIN PIGMENTING ACTIVITY AND PHARMACEUTICAL OR COSMETIC COMPOSITIONS CONTAINING THEM

Applicant/Assignee: GIULIANI S.P.A

Application No.: WO2011EP62129 (PCT/EP2011/62129)   Filing Date: 15/Jul/2011

Abstract:

The present invention relates to compounds having general formula (I): CH3-(CH=CH)n-R (I) where: n = 3, 5, 7

R is chosen from -CH2-O-CO-R', -CO-OR' or -CO-O(-), R' is chosen from H, C1 -C22 alkyl or alkenyl, aryl or aralkyl, or sugars

and their pharmaceutically acceptable salts, such as sodium, potassium and lysine salts, for use as the active ingredient in pharmaceutical or cosmetic compositions for improving the pigmentation of the human skin, treating pigmentation disorders and/or improve both the photoprotective capacity of the skin and the intensity of its suntan.

Priority: EP20100425243 Applic. Date: 2010-07-16

Inventor: GIULIANI GIAMMARIA [IT]; PAUS RALF [DE]; RAMOT YUVAL [IL]; BECKER ASTRID [DE]; BARONI SERGIO [IT]


Publication No.: WO2012007777A1  Published: 19/Jan/2012

Title: NOVEL PROTEINS, PROCESS FOR PREPARATION THEREOF, AND USE THEREOF

Applicant/Assignee: EOETVOES LORAND TUDOMANYEGYETEM, MAGYAR TUDOMANYOS AKADEMIA SZEGEDI BIOLOGIAI KOEZPONT ENZIMOLOGIAI INTEZETE

Application No.: WO2011HU00066 (PCT/HU2011/00066)   Filing Date: 13/Jul/2011

Abstract:

The invention relates to peptides with general formula (I), X1CTX2X3X4CX5 (I) where X1 is: M, F, V, A, I, and X2 is: R, K, and X3 is: K, R, L, A and X4 is: L, G, M, A, W, Y, and X5 is: W, Y, L, M, N, E, G

and their pharmaceutically acceptable salts, esters and prodrugs. The invention also relates to pharmaceutical preparations and kits containing them, and to screening and isolation procedures containing them, and to their use in the production of pharmaceutical preparations.

Priority: HU20100000366 Applic. Date: 2010-07-13

Inventor: GAL PETER [HU]; PAL GABOR [HU]; HEJA DAVID [HU]; ZAVODSKY PETER [HU]


Publication No.: WO2012008231A1  Published: 19/Jan/2012

Title: 4-ALKYLRESORCINOL DERIVATIVE AND EXTERNAL PREPARATION FOR SKIN CONTAINING SAME

Applicant/Assignee: SHISEIDO COMPANY, LTD

Application No.: WO2011JP62575 (PCT/JP2011/62575)   Filing Date: 01/Jun/2011

Abstract:

Provided is a compound having a good skin lightening effect and excellent safety and stability, and an external agent for skin to which this compound is added. The compound is a 4-alkylresorcinol derivative represented by general formula (1) or a salt thereof. (In the formula, R1 is a branched or cyclic C3-7 alkyl group or a linear C2-5 alkyl group, R2 and R3 are each independently a hydrogen atom or group represented by -P(O)(OR4)(OR5) and at least one of R2 and R3 is a group represented by -P(O)(OR4)(OR5), and R4 and R5 are each independently a hydrogen atom or linear or branched C2-5 alkyl group.)

Priority: JP20100161274 Applic. Date: 2010-07-16

Inventor: FUKUNISHI HIROTADA [JP]; SUZUKI RIKAKO [JP]; SATO KIYOSHI [JP]; SUETSUGU MASARU [JP]


Publication No.: WO2012008549A1  Published: 19/Jan/2012

Title: HETEROCYCLIC RING COMPOUND

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: WO2011JP66153 (PCT/JP2011/66153)   Filing Date: 14/Jul/2011

Abstract:

Disclosed is a compound which has an activity of regulating the differentiation of a muscle cell or an adipocyte, is effective for the prevention or treatment of diseases including diabetes, obesity and dyslipidemia, and has excellent pharmacological efficacy. Specifically disclosed is a compound represented by formula (I) [wherein each symbol is as defined in the description] or a salt thereof.

Priority: JP20100160240 Applic. Date: 2010-07-15

Inventor: UJIKAWA OSAMU [JP]; TAKAMI KAZUAKI [JP]; TAKAKURA NOBUYUKI [JP]; SAKAI NOZOMU [JP]


Publication No.: WO2012008718A2  Published: 19/Jan/2012

Title: PATCH FOR TREATING AND ALLEVIATING SYMPTOMS OF SKIN DISEASES ACCOMPANIED BY EFFUSION OF BLOOD PROTEINS

Applicant/Assignee: BIOPID CORPORATION

Application No.: WO2011KR05061 (PCT/KR2011/05061)   Filing Date: 11/Jul/2011

Abstract:

The present invention relates to a patch for treating and alleviating the symptoms of skin diseases which are accompanied by the effusion of blood proteins, or to a patch for the adsorption of the blood proteins that effuse from the skin.

Priority: KR20100066981 Applic. Date: 2010-07-12

Inventor: CHOI SEONG HYUN [KR]


Publication No.: WO2012009134A1  Published: 19/Jan/2012

Title: CRTH2 MODULATORS

Applicant/Assignee: IRONWOOD PHARMACEUTICALS, INC

Application No.: WO2011US41772 (PCT/US2011/41772)   Filing Date: 24/Jun/2011

Abstract:

Modulators of CRTH2, particularly antagonists of CRTH2, that are useful for treating various disorders, including asthma and respiratory disorders are disclosed. The compounds fall within a genus described by Formula I:

Priority: US20100363501P Applic. Date: 2010-07-12

Inventor: BARDEN TIMOTHY [GB]; HUDSON COLLEEN [US]; JIA JAMES [US]; KIM CHARLES [US]; GRAUL REGINA [US]; MERMERIAN ARA [US]; MOORE JOEL [US]; SPROTT KEVIN [US]; CHIEN YUEH-TYNG [US]


Publication No.: WO2012009290A2  Published: 19/Jan/2012

Title: FORMULATIONS FOR THE TREATMENT OF URUSHIOL-INDUCED CONTACT DERMATITIS

Applicant/Assignee:

Application No.: WO2011US43601 (PCT/US2011/43601)   Filing Date: 11/Jul/2011

Abstract:

Disclosed herein are compositions comprising: a pharmaceutically acceptable oxidizing agent

a pharmaceutically acceptable base

and a pharmaceutically acceptable solvent or mixture of solvents. Also disclosed are methods of treating urushiol-induced contact dermatitis in a patient, the method comprising: identifying a patient in need thereof

and administering to the patient a composition as described herein. Further disclosed herein are devices for the treatment of urushiol-induced contact dermatitis, the device comprising: an absorbent material, contained therein a composition as described herein

and means for attaching the device to the skin of a patient in need thereof.

Priority: US20100399507P Applic. Date: 2010-07-13

Inventor: TREIBER LASZLO [US]; HANSEN ANGELA [US]


Publication No.: WO2012010022A1  Published: 26/Jan/2012

Title: NEW USE OF HESPERETIN

Applicant/Assignee: NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD

Application No.: WO2011CN75765 (PCT/CN2011/75765)   Filing Date: 15/Jun/2011

Abstract:

The present invention discloses a use of hesperetin or a plant extract containing hesperetin in manufacture of products for improving and/or promoting cutaneous microcirculation, or eliminating and/or relieving diseases or conditions related to poor cutaneous microcirculation. The present invention also discloses a composition comprising an effective amount of hesperetin or plant extract containing hesperetin, as well as a method for improving and/or promoting cutaneous microcirculation, or eliminating and/or relieving diseases or conditions related to poor cutaneous microcirculation by using hesperetin. The cutaneous microcirculation in the present invention is preferably cutaneous microcirculation of ocular region.

Priority: CN20101231389 Applic. Date: 2010-07-20

Inventor: HU LIU [CN]; LAN HONGYING [CN]


Publication No.: WO2012010120A2  Published: 26/Jan/2012

Title: USE OF CORRINOIDS FOR COSMETIC APPLICATION IN THE CASE OF HEALTHY COATS AND/OR HEALTHY SKIN, AND FOR COSMETIC CARE IN THE CASE OF COAT AND SKIN ILLNESSES FOR SMALL AND LARGE ANIMALS (WARM- AND COLD-BLOODED) {FOR EXAMPLE, FOR FISH, BIRDS, HORSES, COWS

Applicant/Assignee:

Application No.: WO2011DE01285 (PCT/DE2011/01285)   Filing Date: 09/Jun/2011

Abstract:

The invention relates to the use of compounds of formula (I), where R stands for CN, OH, CH3, or H2O, in order to build and improve the resistance of the skin by means of cosmetic application. The compounds are suitable in particular for cosmetic prophylaxis in the case of disposition to chronic skin illnesses, for the prophylaxis and care of allergic skin reactions, and for the cosmetic care of acute skin damage, e.g., in the case of burns and wounds, and in the case of skin aging.

Priority: DE201010023324 Applic. Date: 2010-06-10

Inventor: SCHUETZ THOMAS [DE]


Publication No.: WO2012011192A1  Published: 26/Jan/2012

Title: TACROLIMUS-CONTAINING OIL-IN-WATER TYPE CREAMY COMPOSITION

Applicant/Assignee: MARUHO CO., LTD

Application No.: WO2010JP62467 (PCT/JP2010/62467)   Filing Date: 23/Jul/2010

Abstract:

The purpose is to provide a tacrolimus-containing pharmaceutical composition which is a creamy preparation for external application having good feeling upon use and has high stability of the main ingredient contained therein (a high main ingredient residual ratio), and of which the concentration in the skin can be controlled readily. Specifically disclosed is an oil-in-water type creamy composition which is characterized by comprising (A) tacrolimus, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, (B) an oil prepared by mixing (a) a medium-chain fatty acid triglyceride with (b) salicylic acid ethylene glycol and/or diisopropyl sebacate, (C) an emulsifying agent having an HLB value of 12 or more, and (D) a hydrophilic polymer, and is also characterized by having a pH value of 4-7.

Priority: WO2010JP62467 Applic. Date: 2010-07-23

Inventor: IHARA MIKITO [JP]; UEDA YOSHINORI [JP]


Publication No.: WO2012011591A1  Published: 26/Jan/2012

Title: FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: WO2011JP66766 (PCT/JP2011/66766)   Filing Date: 22/Jul/2011

Abstract:

Disclosed is a compound that has excellent pharmacological activity, physicochemical qualities, and the like, and is useful in the prevention/treatment of eicosanoid-related conditions including arteriosclerosis, diabetes, obesity, atherothrombosis, asthma, fever, pain, cancer, rheumatism, osteoarthritis, and atopic dermatitis. The compound is the compound represented by the belowmentioned formula (each symbol in the formula is as described in the specification) or a salt thereof.

Priority: JP20110122796 Applic. Date: 2011-05-31; JP20100166475 Applic. Date: 2010-07-23

Inventor: MATSUNAGA NOBUYUKI [JP]; SUZUKI HIDEO [JP]; ASANO KOUHEI [JP]; TOKUHARA HIDEKAZU [JP]; YAMAMOTO TAKESHI [JP]; OKAMOTO REI [JP]


Publication No.: WO2012011875A1  Published: 26/Jan/2012

Title: COMPOUNDS FOR PHOTODYNAMIC THERAPY

Applicant/Assignee: REPUBLIC POLYTECHNIC

Application No.: WO2011SG00261 (PCT/SG2011/00261)   Filing Date: 21/Jul/2011

Abstract:

A metal-ligand complex comprising a transition metal complexed with at least one Schiff base ligand comprising an additional nitrogen atom from a heterocycle and at least one heteroaromatic nucleic acid intercalating moiety. A pharmaceutical composition comprising the compound in admixture with a pharmaceutically acceptable carrier togther with use of the compound in the treatment of cancer, macular degeneration, human papilloma virus (HPV) warts and a skin disorder is also provided.

Priority: GB20100012217 Applic. Date: 2010-07-21

Inventor: BANDYOPADHYAY SUSMITA [SG]


Publication No.: WO2012012370A1  Published: 26/Jan/2012

Title: VITAMIN C AND CHROMIUM-FREE VITAMIN K, AND COMPOSITIONS THEREOF FOR TREATING AN NFKB-MEDIATED CONDITION OR DISEASE

Applicant/Assignee: SUMMA HEALTH SYSTEM

Application No.: WO2011US44443 (PCT/US2011/44443)   Filing Date: 19/Jul/2011

Abstract:

Provided herein is a pharmaceutical composition comprising vitamin C and chromium-free vitamin K, and optionally one or more pharmaceutically acceptable excipient(s). Also provided herein is a chromium-free pharmaceutical composition comprising vitamin C and vitamin K, and optionally one or more pharmaceutically acceptable excipient(s). Further provided herein is a method of treating, preventing, or managing an NFKB-mediated condition, disorder, or disease, comprising administering to the subject a therapeutically effective amount of vitamin C and chromium-free vitamin K.

Priority: US20100365715P Applic. Date: 2010-07-19

Inventor: JAMISON JAMES M [US]; MILLER THOMAS M [US]; NEAL DEBORAH R [US]; KOVACIK MARK WILLIAM [US]; ASKEW MICHAEL JOHN [US]; MOSTARDI RICHARD ALBERT [US]; MCGUIRE KAREN M [US]


Publication No.: WO2012012809A2  Published: 26/Jan/2012

Title: APPLICATION OF ss-FUNCTIONALIZED DIHYDROXY-CHLORINS FOR PDT

Applicant/Assignee: CERAMOPTEC GMBH, CERAMOPTEC INDUSTRIES, INC

Application No.: WO2011US47576 (PCT/US2011/47576)   Filing Date: 12/Aug/2011

Abstract:

The present invention provides methods to obtain biologically active compounds that can be used as photosensitizers for diagnostic and therapeutic applications, particularly for PDT of cancer, infections and other hyperproliferative diseases, fluorescence diagnosis and PDT treatment of a non-tumorous indication such as arthritis, inflammatory diseases, viral or bacterial infections, dermatological, ophthalmological or urological disorders. An embodiment of the present invention consists of a method to synthesize diketo-chlorins as precursors. In yet another embodiment these precursors are converted to ss-unctionalized hydroxy- and dihydroxy-chlorins. Another embodiment is to provide amphiphilic compounds with a higher membrane affinity and increased PDT-efficacy.

Another embodiment consists of the formulation of the desired isomer into a liposomal formulation to be injected avoiding undesirable effects like precipitation at the injection site or delayed pharmacokinetics of the tetrapyrrole systems.

Priority: US20100366707P Applic. Date: 2010-07-22

Inventor: AICHER DANIEL [DE]; WIEHE ARNO [DE]; STARK CHRISTIAN B W [DE]; ALBRECHT VOLKER [DE]; GRAFE SUSANNA [DE]


Publication No.: WO2012012843A1  Published: 02/Feb/2012

Title: MODULATORS OF PROTEASE ACTIVATED RECEPTORS

Applicant/Assignee: THE UNIVERSITY OF QUEENSLAND

Application No.: WO2011AU00959 (PCT/AU2011/00959)   Filing Date: 28/Jul/2011

Abstract:

The present invention provides novel compounds of the Formula (1), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of -or susceptible to- a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity.

Priority: AU20100903378 Applic. Date: 2010-07-28

Inventor: FAIRLIE DAVID PAUL [AU]; LIU LIGONG [AU]; YAU MEI KWAN [AU]; SUEN JACKY YUNG [AU]


Publication No.: WO2012013418A2  Published: 02/Feb/2012

Title: SKIN CARE COMPOSITIONS COMPRISING SUBSTITUTED MONOAMINES

Applicant/Assignee: UNILEVER PLC, UNILEVER N.V, HINDUSTAN UNILEVER LIMITED

Application No.: WO2011EP59996 (PCT/EP2011/59996)   Filing Date: 16/Jun/2011

Abstract:

Skin care compositions comprising certain substituted monoamines, which are particularly beneficial for skin lightening and achieving evenness of color, especially for face and underarm skin.

Priority: US2010-845814 Applic. Date: 2010-07-29

Inventor: ROSA JOSE GUILLERMO [US]; HARICHIAN BIJAN [US]; DRENNAN DIANA JEAN [US]; BAJOR JOHN STEVEN [US]; BOSKO CAROL ANNETTE [US]


Publication No.: WO2012013736A1  Published: 02/Feb/2012

Title: PRESERVATIVE-FREE COMPOSITION FOR TOPICAL USE INCLUDING HYALURONIC ACID

Applicant/Assignee: HORUS PHARMA

Application No.: WO2011EP62971 (PCT/EP2011/62971)   Filing Date: 28/Jul/2011

Abstract:

The present invention relates to a sterile and/or decontaminated composition for topical use, including hyaluronic acid at a concentration of greater than or equal to 0.1 wt % relative to the total weight of the composition, at least one skin wound healing agent, optionally at least one plant extract, and at least one solvent. The invention also relates to a unit including such a composition, to a method for preparing such a composition, and to the uses thereof.

Priority: FR20100056221 Applic. Date: 2010-07-28

Inventor: CLARET CLAUDE [FR]; CLARET MARTINE [FR]; GARD CAROLE [FR]


Publication No.: WO2012014085A2  Published: 02/Feb/2012

Title: USES OF CIMIRACEMATE AND RELATED COMPOUNDS FOR TREATING INFLAMMATION AND MODULATING IMMUNE RESPONSES

Applicant/Assignee: PURAPHARM INTERNATIONAL (HK) LIMITED, VERSITECH LIMITED

Application No.: WO2011IB02582 (PCT/IB2011/02582)   Filing Date: 29/Jul/2011

Abstract:

The present invention pertains to Cimiracemate A and related compounds that are useful as inhibitors of 5 -lipoxygenase (5-1. OX) activity and various proinflammatory mediators such as lipoxins, leukotrienes (e.g., LTA4, LTB4, LTC4, LTD4, and LTE4), prostaglandins, and thromboxanes. The present invention also provides therapeutic methods and compositions for treatment of inflammation and inflammatory conditions, including allergenic reactions, diseases associated with cell proliferation, neoangiogenesis, and cardiovascular diseases.

Priority: US20100369428P Applic. Date: 2010-07-30

Inventor: LAU ALLAN SIK YIN [CN]; YANG CINDY LAI HUNG [CN]


Publication No.: WO2012014417A1  Published: 02/Feb/2012

Title: USE OF PLANT OR LIKE FOR IMPROVING PORES, METHOD FOR IMPROVING PORES AND ORAL PREPARATION FOR IMPROVING PORES

Applicant/Assignee: SHISEIDO COMPANY, LTD

Application No.: WO2011JP04136 (PCT/JP2011/04136)   Filing Date: 22/Jul/2011

Abstract:

[Problem] To make the bucket-shaped structure of pores inconspicuous by preventing parakeratosis caused by stimulatory components in the sebum around the pores and maintaining the skin around the pores in the normal state. [Solution] An oral preparation for improving pores which comprises one or more plants selected from the plants belonging to the genus of the Psophocarpus in the family of Leguminosae or an extract of the same.

Priority: JP20100168870 Applic. Date: 2010-07-28

Inventor: MUTA KEIKO [JP]; YOKOO MIHOSHI [JP]; HASEGAWA TATSUYA [JP]; UCHIYAMA TARO [JP]; OSHIMA NANA [JP]; FUKAYA YUKITAKA [JP]; HONDA EMIKO [JP]; YOSHIDA SEIICHI [JP]


Publication No.: WO2012014630A1  Published: 02/Feb/2012

Title: ASTAXANTHIN-CONTAINING AQUEOUS COMPOSITION, COSMETIC PREPARATION, AND METHOD FOR SUPPRESSING DEGRADATION OF ASTAXANTHIN

Applicant/Assignee: FUJIFILM CORPORATION

Application No.: WO2011JP65228 (PCT/JP2011/65228)   Filing Date: 01/Jul/2011

Abstract:

Disclosed are: an aqueous cosmetic preparation which contains at least (A) astaxanthin, (B) 20 [mu]g/L or more of iron and (C) an iron chelating agent

and a method for suppressing degradation of astaxanthin, wherein an aqueous composition containing at least (A) astaxanthin and (B) 20 [mu]g/L or more of iron is made to contain (C) an iron chelating agent.

Priority: JP20100169443 Applic. Date: 2010-07-28

Inventor: KUSUDA FUMI [JP]


Publication No.: WO2012014994A1  Published: 02/Feb/2012

Title: NAPHTHALENE DERIVATIVE

Applicant/Assignee: DAITO CHEMIX CORPORATION, KYOTO UNIVERSITY

Application No.: WO2011JP67320 (PCT/JP2011/67320)   Filing Date: 28/Jul/2011

Abstract:

Provided is a compound which can regulate a VCP activity. Specifically provided is a compound represented by formula (I) (wherein R is as defined in the description) or an oxide, ester, prodrug, pharmaceutically acceptable salt or solvate thereof. The compound can regulate a VCP activity and is therefore useful for the treatment of VCP-mediated disorders such as neurodegenerative diseases.

Priority: JP20100172467 Applic. Date: 2010-07-30

Inventor: KAKIZUKA AKIRA [JP]; HORI SEIJI [JP]; SHUDO TOSHIYUKI [JP]; FUCHIGAMI TOMOHIRO [JP]


Publication No.: WO2012015789A2  Published: 02/Feb/2012

Title: COMPOSITION AND METHOD FOR THE TOPICALTREATMENT OF DERMATITIS

Applicant/Assignee:

Application No.: WO2011US45300 (PCT/US2011/45300)   Filing Date: 26/Jul/2011

Abstract:

A composition for topical treatment of dermatitis is provided. The composition includes one or more anti-histamines or a pharmaceutically acceptable salt thereof

one or more polysaccharides

and one or more Group 1, 2, or 13 metal hydroxides. The dermatitis may be a poison ivy, poison oak, poison sumac, diaper rash, eczema, lichen simplex chronicus, rashes, dermatoses, seborrheic dermatitis, psoriasis, atopic dermatitis, or the combination thereof. A method of treatment of dermatitis is also provided.

Priority: US2010-844770 Applic. Date: 2010-07-27

Inventor: FORD SARA BETH [US]


Publication No.: WO2012015820A1  Published: 02/Feb/2012

Title: COMPOSITION AND METHOD FOR PHOTODYNAMIC DISINFECTION

Applicant/Assignee: ADVANCED PHOTODYNAMIC TECHNOLOGIES, INC

Application No.: WO2011US45367 (PCT/US2011/45367)   Filing Date: 26/Jul/2011

Abstract:

The present invention includes a composition for photoablation comprising a photosensitizer and ethylenediaminetetraacetic acid ("EDTA") at a very low concentration (e.g., ranging from about 0.01 mM to about 1.25 mM), wherein the composition is used for photoablation of at least one targeted organism. The present invention also includes a method for photoablation comprising applying the composition to a treatment site containing at least one targeted organism and applying light to the treatment site at a wavelength absorbed by the photosensitizer so as to inhibit the at least one targeted organism.

Priority: US20100369166P Applic. Date: 2010-07-30

Inventor: BIEL MERRILL [US]


Publication No.: WO2012016145A2  Published: 02/Feb/2012

Title: MITOCHONDRIAL APOPTOSIS-INDUCED INFLAMMATION

Applicant/Assignee: CEDARS-SINAI MEDICAL CENTER

Application No.: WO2011US45893 (PCT/US2011/45893)   Filing Date: 29/Jul/2011

Abstract:

Various embodiments of the present invention describe a method of treating inflammation, an inflammatory disease, an inflammatory disease condition and/or an autoimmune disease in a subject in need thereof. The method can comprise providing a composition comprising a mitochondrial apoptosis inhibitor or an oxidative nucleotide and administering the composition to the subject to treat the inflammation, the inflammatory disease, the inflammatory disease condition and/or the autoimmune disease. Various embodiments of the present invention is based on the mitochondria acting as a unifying point that integrates diverse NLRP3 stimuli and that mitochondrial dysfunction and apoptosis of macrophages are critical steps in various danger signal-induced NLRP3 inflammasome activation.

Priority: US201161494819P Applic. Date: 2011-06-08; US20100369010P Applic. Date: 2010-07-29

Inventor: SHIMADA KENICHI [US]; ARDITI MOSHE [US]


Publication No.: WO2012016690A1  Published: 09/Feb/2012

Title: USE OF GLYCERYL TRINITRATE FOR TREATING HEMATOMAS

Applicant/Assignee: G. POHL-BOSKAMP GMBH & CO. KG

Application No.: WO2011EP03888 (PCT/EP2011/03888)   Filing Date: 03/Aug/2011

Abstract:

Use of glyceryl trinitrate (GTN) for treating hematomas.

Priority: DE201010033182 Applic. Date: 2010-08-03

Inventor: BOSKAMP MARIANNE [DE]


Publication No.: WO2012016691A1  Published: 09/Feb/2012

Title: USE OF GLYCERYL TRINITRATE FOR TREATING TRAUMATIC EDEMA

Applicant/Assignee: G. POHL-BOSKAMP GMBH & CO. KG

Application No.: WO2011EP03890 (PCT/EP2011/03890)   Filing Date: 03/Aug/2011

Abstract:

Use of glyceryl trinitrate (GTN) for treating traumatic edemas.

Priority: DE201010033182 Applic. Date: 2010-08-03

Inventor: BOSKAMP MARIANNE [DE]


Publication No.: WO2012017077A1  Published: 09/Feb/2012

Title: COMBINATION OF COMPOUNDS FOR TREATING OR PREVENTING SKIN DISEASES

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT

Application No.: WO2011EP63528 (PCT/EP2011/63528)   Filing Date: 05/Aug/2011

Abstract:

The invention relates to a combination of compounds for treating skin diseases and particularly rosacea and ocular rosacea. It is the combination of a compound selected from azelaic acid and salts thereof with a compound of the alpha-1 or alpha-2 adrenergic receptor agonist family. The invention also relates to a product in the form of a kit containing: (a) a first composition comprising a compound selected from azelaic acid and salts thereof, and (b) a second composition different from the first one and comprising a compound of the alpha-1 or alpha-2 adrenergic receptor agonist family, as a combination product for application thereof as a medicament for treating and/or preventing skin diseases and in particular rosacea and ocular rosacea, wherein said first and second compositions can be applied simultaneously, separately or with a time delay.

Priority: US20100344499P Applic. Date: 2010-08-06

Inventor: CHAPPUIS JEAN-PAUL [FR]; AT EMMANUELLE [FR]


Publication No.: WO2012017141A1  Published: 09/Feb/2012

Title: PLANT EXTRACT FOR THE PRODUCTION OF A SLIMMING COMPOSITION AND METHOD OF CONTROL FOR SLIMMING USING SUCH A COMPOSITION

Applicant/Assignee: EPHYLA SAS

Application No.: WO2011FR00430 (PCT/FR2011/00430)   Filing Date: 20/Jul/2011

Abstract:

The invention relates to an extract of a plant chosen from the group made up of the family Balanitaceae and the genus Vitellaria belonging to the family Sapotaceae for use thereof both as a control agent that is active on lipolysis and as an adipocyte differentiation inhibitor, for the production of a slimming composition.

Priority: FR20100003063 Applic. Date: 2010-07-21

Inventor: NDING NGUB [FR]; BOURGETEAU VINCENT [FR]


Publication No.: WO2012017471A1  Published: 09/Feb/2012

Title: NATURAL MEDICINAL COMPOUND

Applicant/Assignee: LOMBARDATRADING S.R.L

Application No.: WO2011IT00288 (PCT/IT2011/00288)   Filing Date: 03/Aug/2011

Abstract:

This invention refers to the sector of drugs intended for both human and animal use, and it particularly concerns a natural medicinal compound that contains a tannin-based vegetal active ingredient combined with carriers and with a synergic effect, wherein said vegetal active ingredient is natural chestnut extract (Castanea sativa), with tannin as the highest constituent substance, and said natural chestnut extract is contained in the compound in a weight rate between 5% and 80%.

Priority: IT2010CR00025 Applic. Date: 2010-08-05

Inventor: GRAZIANI RODOLFO [IT]; MERCORELLA GIOVANNI [IT]; ROSSI PIERENRICO [IT]; BIGNETTI GUIDO [IT]; PIGNACCA MICHELE [IT]


Publication No.: WO2012017555A1  Published: 09/Feb/2012

Title: ELASTASE INHIBITOR

Applicant/Assignee: SHISEIDO COMPANY, LTD

Application No.: WO2010JP63414 (PCT/JP2010/63414)   Filing Date: 06/Aug/2010

Abstract:

An elastase inhibitor contains raspberry extract and hydroxyproline as active ingredients, and optionally contains yeast extract.

Priority: WO2010JP63414 Applic. Date: 2010-08-06

Inventor: IINO MASATO [JP]


Publication No.: WO2012018643A2  Published: 09/Feb/2012

Title: COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS

Applicant/Assignee: THE HOSPITAL FOR SICK CHILDREN

Application No.: WO2011US45416 (PCT/US2011/45416)   Filing Date: 26/Jul/2011

Abstract:

We have discovered that p63 inhibition results in increased cellular proliferation. We have also performed a screen for agents capable of increasing cellular proliferation, (e.g., of stem cells such as skin-derived precursors (SKPs)). The invention therefore invention provides compositions, methods, and kits for increasing proliferation of cells, using compounds that decrease p63 expression or activity or using the compounds described herein. The invention also features methods of using these compounds for increasing hair growth, improving skin health, or promoting skin repair in a subject.

Priority: US201061426160P Applic. Date: 2010-12-22; US20100367780P Applic. Date: 2010-07-26; US201113075647 Applic. Date: 2011-03-30

Inventor: MILLER FREDA [CA]; KAPLAN DAVID [CA]; SMITH KRISTEN [US]; PARIS MARYLINE [CA]; NASKA SIBEL [CA]


Publication No.: WO2012018932A2  Published: 09/Feb/2012

Title: COMPOUNDS AND COMPOSITIONS FOR MITIGATING TISSUE DAMAGE AND LETHALITY

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: WO2011US46451 (PCT/US2011/46451)   Filing Date: 03/Aug/2011

Abstract:

Embodiments of the present invention provide compounds and compositions thereof, which are effective for mitigating tissue damage or lethality induced by an agent, and methods of making and using the same.

Priority: US20100370386P Applic. Date: 2010-08-03

Inventor: SCHIESTL ROBERT H [US]; RIVINA YELENA O [US]; JUNG MICHAEL E [US]


Publication No.: WO2012020021A1  Published: 16/Feb/2012

Title: GLYCYRRHETINIC ACID AMINE ANALOGUES FOR USE IN THE TREATMENT OF INFLAMMATION, INFECTIOUS DISEASES, CANCER, AUTOIMMUNE DISEASES, SKIN DISEASES, BONE DISEASES AND METABOLIC DISEASES

Applicant/Assignee: ONEPHARM RESEARCH & DEVELOPMENT GMBH

Application No.: WO2011EP63702 (PCT/EP2011/63702)   Filing Date: 09/Aug/2011

Abstract:

The present invention encompasses compounds of general formula (I) wherein R3a to R31 and X are defined as in claim 1, which are suitable for the treatment of and/or prevention of chronic inflammatory diseases, autoimmune diseases, skin diseases, bone diseases, metabolic diseases, infectious diseases and cancer.

Priority: EP20100172411 Applic. Date: 2010-08-10

Inventor: CLASSEN-HOUBEN DIRK [AT]; KUEENBURG BERNHARD [AT]; KOSMA PAUL [AT]; JORDIS ULRICH [AT]; CZOLLNER LASZLO [AT]


Publication No.: WO2012020217A1  Published: 16/Feb/2012

Title: AMINO- IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN OR LIPID KINASE INHIBITORS

Applicant/Assignee: CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO)

Application No.: WO2011GB01189 (PCT/GB2011/01189)   Filing Date: 09/Aug/2011

Abstract:

There is provided compounds of formula (I), wherein Ra, Rb, R2a, R2b, R2c, R2d, R2e and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PIM family kinase, such as PIM-1, PIM-2 and/or PIM-3, and/or Flt-3) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.

Priority: EP20100380102 Applic. Date: 2010-08-09

Inventor: PASTOR FERNANDEZ JOAQUIN [ES]; GARCIA COLLAZO ANA MARIA [ES]; NOYA MARINO BEATRIZ [ES]; GONZALEZ CANTALAPIEDRA ESTHER [ES]


Publication No.: WO2012020989A2  Published: 16/Feb/2012

Title: PHARMACEUTICAL OR COSMETIC COMPOSITION CONTAINING NICOTINIC ACID ADENINE DINUCLEOTIDE PHOSPHATE OR DERIVATIVE THEREOF

Applicant/Assignee: DAMY CHEMICAL CO., LTD

Application No.: WO2011KR05848 (PCT/KR2011/05848)   Filing Date: 10/Aug/2011

Abstract:

The present invention relates to a use of nicotinic acid adenine dinucleotide phosphate or a derivative thereof for promoting the differentiation of keratinocytes into fibroblasts. The present invention provides a pharmaceutical or cosmetic use of a composition containing NAADP or a derivative thereof for regenerating and improving a skin barrier, or preventing, improving or treating stratum corneum disorders such as psoriasis or atopy, and a use for promoting the differentiation of separated keratinocytes.

Priority: KR20100076973 Applic. Date: 2010-08-10

Inventor: KIM KWANG-NYEON [KR]; CHO JUNG-MIN [KR]; SON JOO-HYUN [KR]; KIM UH-HYUN [KR]; PARK KWANG-HYUN [KR]


Publication No.: WO2012021165A2  Published: 16/Feb/2012

Title: METHODS AND COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH HYPERACTIVE IMMUNE SYSTEM

Applicant/Assignee: THE SCRIPPS RESEARCH INSTITUTE

Application No.: WO2011US01405 (PCT/US2011/01405)   Filing Date: 09/Aug/2011

Abstract:

The present invention provides methods and compositions for treating disorders associated with hyperactive immune responses. The invention also provides methods for inhibiting activation of CD4+ T cells and/or suppressing proliferation other overactivated T cells (e.g., CD4.CD8. T cells). These methods typically involve the administration to the subject a therapeutically effective amount of a compound that inhibits or suppresses IL-7 signaling or IL-15 signaling.

Priority: US20100401235P Applic. Date: 2010-08-10

Inventor: GONZALEZ-QUINTIAL ROSA ANA [US]; BACCALA ROBERTO G [US]; LAWSON BRIAN R [US]; THEOFILOPOULOS ARGYRIOS N [US]


Publication No.: WO2012022795A1  Published: 23/Feb/2012

Title: DISUBSTITUTED TETRAHYDOFURANYL COMPOUNDS AS ANTAGONISTS OF THE BRADYKININ B1 RECEPTOR

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: WO2011EP64260 (PCT/EP2011/64260)   Filing Date: 19/Aug/2011

Abstract:

The invention relates to disubstituted tetrahydrofuranyl compounds of general formula (I), wherein the variables R1, R2 and X are defined as below, to the enantiomers, diastereomers, mixtures and salts thereof, especially the physiologically acceptable salts thereof with organic or inorganic acids or bases, which have valuable properties, to methods for producing the same, to the drugs containing the pharmacologically active compounds and to the production and use thereof.

Priority: EP20100173489 Applic. Date: 2010-08-20

Inventor: HAUEL NORBERT [DE]; CECI ANGELO [DE]; DOODS HENRI [DE]; JUNG BIRGIT [DE]; KUELZER RAIMUND [DE]


Publication No.: WO2012024161A1  Published: 23/Feb/2012

Title: METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS

Applicant/Assignee: ALLERGAN, INC

Application No.: WO2011US47426 (PCT/US2011/47426)   Filing Date: 11/Aug/2011

Abstract:

Disclosed herein is a method of upregulating regulatory T-cells, and treating diseases that would benefit from such upregulation, by administering an alpha 2 receptor agonist.

Priority: US20100374124P Applic. Date: 2010-08-16

Inventor: GIL DANIEL W [US]; DONELLO JOHN E [US]; LUHRS LAUREN M B [US]; VISWANATH VEENA [US]


Publication No.: WO2012026765A2  Published: 01/Mar/2012

Title: NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME

Applicant/Assignee: NEOPHARM CO.,LTD

Application No.: WO2011KR06278 (PCT/KR2011/06278)   Filing Date: 25/Aug/2011

Abstract:

The present invention relates to a heterocyclic compound having the effects of treating and preventing inflammatory diseases and healing skin wounds, and particularly, having the effects of restoring damaged skin barriers and relieving inflammation and pruritus resulting from inflammatory skin diseases. A composition including the compound of the present invention as an active ingredient may be used to relieve various inflammatory diseases and diseases in which the expression of protease activated receptor-2 (PAR-2) is increased. Particularly, the composition including the compound of the present invention as an active ingredient inhibits the activity of PAR-2 in the skin, and therefore can be used as an anti-inflammatory composition for inflammatory skin diseases such as atopic dermatitis.

Priority: KR20100082258 Applic. Date: 2010-08-25

Inventor: GWAK HYUNG SUB [KR]; KIM YONG ZU [KR]; KIM UK IL [KR]; PARK BYEONG DEOG [KR]; PARK TAE KYO [KR]; WOO SUNG HO [KR]; YUN JOUNG YUL [KR]; LEE DAE YON [KR]; LEE HYANG SOOK [KR]; JEON JEONG EUN [KR]; JEONG SE KYOO [KR]; CHOI HYUNG MOOK [KR]


Publication No.: WO2012026766A2  Published: 01/Mar/2012

Title: NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME

Applicant/Assignee: NEOPHARM CO.,LTD

Application No.: WO2011KR06281 (PCT/KR2011/06281)   Filing Date: 25/Aug/2011

Abstract:

The present invention relates to a heterocyclic compound having the effects of treating and preventing inflammatory diseases and healing skin wounds, and particularly, having the effects of restoring damaged skin barriers and relieving inflammation and pruritus resulting from inflammatory skin diseases. A composition including the compound of the present invention as an active ingredient may be used to relieve various inflammatory diseases and diseases in which the expression of protease activated receptor-2 (PAR-2) is increased. Particularly, the composition including the compound of the present invention as an active ingredient inhibits the activity of PAR-2 in the skin, and therefore can be used as an anti-inflammatory composition for inflammatory skin diseases such as atopic dermatitis.

Priority: KR20100082258 Applic. Date: 2010-08-25

Inventor: GWAK HYUNG SUB [KR]; KIM YONG ZU [KR]; KIM UK IL [KR]; PARK BYEONG DEOG [KR]; PARK TAE KYO [KR]; WOO SUNG HO [KR]; YUN JOUNG YUL [KR]; LEE DAE YON [KR]; LEE HYANG SOOK [KR]; JEON JEONG EUN [KR]; JEONG SE KYOO [KR]; CHOI HYUNG MOOK [KR]


Publication No.: WO2012027603A2  Published: 01/Mar/2012

Title: THERAPEUTIC CONSUMABLE COMPOSITIONS FOR REDUCTION OF FACIAL FLUSH EFFECT INCIDENT TO ALCOHOL CONSUMPTION IN PERSONS WITH DEFICIENT ACTIVITY OF THE ALDEHYDE DEHYDROGENASE GENE-ALDH2

Applicant/Assignee: CLARITY PRODUCTS, LIMITED LIABILITY COMPANY

Application No.: WO2011US49210 (PCT/US2011/49210)   Filing Date: 25/Aug/2011

Abstract:

Therapeutic consumable compositions reduce facial flush effect incident to alcohol consumption in some persons of Asian descent or persons with ALDH2 gene deficiency.

Priority: US20100377418P Applic. Date: 2010-08-26

Inventor: HASKINS BRIAN [US]; JOHNSON BARRY [US]


Publication No.: WO2012030984A2  Published: 08/Mar/2012

Title: SKIN COMPOSITIONS AND METHODS OF USE THEREOF

Applicant/Assignee: LIVING PROOF, INC

Application No.: WO2011US50003 (PCT/US2011/50003)   Filing Date: 31/Aug/2011

Abstract:

Provided are body corrective cosmetic formulations and methods of use thereof.

Priority: US201161500455P Applic. Date: 2011-06-23; US201161432458P Applic. Date: 2011-01-13; US201161493020P Applic. Date: 2011-06-03; US201161486643P Applic. Date: 2011-05-16; US20100378504P Applic. Date: 2010-08-31; US201161472995P Applic. Date: 2011-04-07; US201161496420P Applic. Date: 2011-06-13; US201161446377P Applic. Date: 2011-02-24; US201161489119P Applic. Date: 2011-05-23; US201161499002P Applic. Date: 2011-06-20; US20100412531P Applic. Date: 2010-11-11

Inventor: YU BETTY [US]; LOMAKIN JOSEPH [US]; KANG SOO-YOUNG [US]; ADAMS BENJAMIN W [US]


Publication No.: WO2012033162A1  Published: 15/Mar/2012

Title: METHOD FOR CONTROLLING HAIR GROWTH, METHOD FOR SELECTING OR EVALUATING HAIR GROWTH CONTROL AGENT, AND HAIR GROWTH SUPPRESSION AGENT

Applicant/Assignee: KAO CORPORATION

Application No.: WO2011JP70481 (PCT/JP2011/70481)   Filing Date: 08/Sep/2011

Abstract:

The present invention provides a method for controlling hair growth, a method for selecting or evaluating a hair growth control agent, and a hair growth suppression agent. The method for selecting or evaluating a hair growth control agent includes: a step for administering a test substance to cells that can express DnaJC6

a step for measuring the expression of DnaJC6 in the cells

and a step for evaluating the hair growth control effect of the test substance on the basis of the expression. Also, the hair growth suppression agent contains Cynanchum atratum or an extract thereof as the active ingredient.

Priority: JP20100201838 Applic. Date: 2010-09-09; JP20100201837 Applic. Date: 2010-09-09

Inventor: NAGASAWA AZUMI [JP]; ICHINOSE SUSUMU [JP]


Publication No.: WO2012033368A2  Published: 15/Mar/2012

Title: COMPOSITION CONTAINING PRUNUS MUME EXTRACT FOR EXTERNAL APPLICATION TO THE SKIN

Applicant/Assignee: AMOREPACIFIC CORPORATION

Application No.: WO2011KR06670 (PCT/KR2011/06670)   Filing Date: 08/Sep/2011

Abstract:

The present invention relates to a composition for external application to the skin for skin care after a laser operation, wherein the composition contains Prunus mume extract as an active ingredient. The composition for external application to the skin according to the present invention has skin-soothing, skin barrier recovery, and pain relief effects, and therefore can be developed into a cosmetic composition having the additional effects of protecting sensitive skin, preventing skin sensitivity, providing skin stability, and moisturizing the skin.

Priority: KR20100088082 Applic. Date: 2010-09-08

Inventor: KIM HYUK [KR]; KOH HYUN JU [KR]; SHIN HONG JU [KR]; KIM JEONG HWAN [KR]; PARK WON SEOK [KR]


Publication No.: WO2012033789A2  Published: 15/Mar/2012

Title: TREATMENT OF DISEASES

Applicant/Assignee: DMI ACQUISITION CORP

Application No.: WO2011US50612 (PCT/US2011/50612)   Filing Date: 07/Sep/2011

Abstract:

The invention provides a method of inhibiting vascular hyperpermeability in an animal in need thereof. The method comprises administering an effective amount of a diketopiperazme, a prodrug of a diketopiperazme or a pharmaceutically-acceptable salt of either of them to the animal, wherein the diketopiperazme has the formula set forth in the specification. The invention also provides a method of modulating the cytoskeleton of an endothelial cell in an animal. The method comprises administering an effective amount of a diketopiperazme, a prodrug of a diketopiperazme or a pharmaceutically-acceptable salt of either of them to the animal, wherein the diketopiperazme has the formula set forth in the specification. The invention further provides a kit.

The kit comprises a diketopiperazme, a prodrug of a diketopiperazme or a pharmaceutically-acceptable salt of either of them to the animal, wherein the diketopiperazme has the formula set forth in the specification.

Priority: US20100380404P Applic. Date: 2010-09-07

Inventor: BAR-OR DAVID [US]


Publication No.: WO2012035374A1  Published: 22/Mar/2012

Title: A DERMACEUTICAL CREAM MADE USING SODIUM FUSIDATE, CLOTRIMAZOLE AND FLUTICASONE PROPIONATE

Applicant/Assignee:

Application No.: WO2010IB56120 (PCT/IB2010/56120)   Filing Date: 30/Dec/2010

Abstract:

The invention discloses a dermaceutical cream containing Fluticasone Propionate as a corticosteroid, an antifungal agent in the form of Clotrimazole and an antibacterial agent in the form of Fusidic acid, which Fusidic acid is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic acid under oxygen-free environment. The cream of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic acid. The cream of the present invention contains Fusidic acid as the API that has been formed in situ from Sodium Fusidate, Fluticasone Propionate and Clotrimazole, in a cream base comprising a preservative, an acid, a co-solvent, emulsifiers and a waxy material along with water, preferably purified water.

Priority: IN2010MU02527 Applic. Date: 2010-09-14

Inventor: VANANGAMUDI SULUR SUBRAMANIAM [IN]; SRINIVASAN MADHAVAN [IN]; CHULLIEL NEELAKANDAN NARAYANAN [IN]; SELVARAJ BALKRISHNANA [IN]


Publication No.: WO2012035375A1  Published: 22/Mar/2012

Title: A NOVEL DERMACEUTICAL CREAM MADE USING SODIUM FUSIDATE AND MOMETASONE FUROATE, A PROCESS TO MAKE THE SAME, AND A METHOD OF TREATMENT USING IT

Applicant/Assignee:

Application No.: WO2010IB56121 (PCT/IB2010/56121)   Filing Date: 30/Dec/2010

Abstract:

The invention discloses a dermaceutical cream containing Mometasone furoate as a corticosteroid, and an antibacterial agent in the form of Fusidic acid, which Fusidic acid is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic acid under oxygen-free environment. The cream of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic acid. The cream of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic acid. The cream of the present invention contains Fusidic acid as the API that has been formed in situ from Sodium Fusidate, and Mometasone furoate, in a cream base comprising a preservative, an acid, a co-solvent, emulsifiers and a waxy material along with water, preferably purified water.

Priority: IN2010MU02528 Applic. Date: 2010-09-14

Inventor: VANANGAMUDI SULUR SUBRAMANIAM [IN]; SRINIVASAN MADHAVAN [IN]; CHULLIEL NEELAKANDAN NARAYANAN [IN]; GHOSH KAUSIK [IN]


Publication No.: WO2012035376A1  Published: 22/Mar/2012

Title: A DERMACEUTICAL CREAM MADE USING SODIUM FUSIDATE, MICONAZOLE AND MOMETASONE FUROATE

Applicant/Assignee:

Application No.: WO2010IB56122 (PCT/IB2010/56122)   Filing Date: 30/Dec/2010

Abstract:

The invention discloses a dermaceutical cream containing Mometasone Furoate as a steroid, Miconazole Nitrate as an antifungal, and an antibacterial agent in the form of Fusidic acid, which Fusidic acid is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic acid under oxygen-free environment. The cream of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic acid. The cream of the present invention contains Fusidic acid as the API that has been formed in situ from Sodium Fusidate, and Mometasone Furoate as a steroid, Miconazole Nitrate as an antifungal, in a cream base comprising a preservative, an acid, a co-solvent, emulsifiers and a waxy material along with water, preferably purified water.

Priority: IN2010MU02529 Applic. Date: 2010-09-14

Inventor: VANANGAMUDI SULUR SUBRAMANIAM [IN]; SRINIVASAN MADHAVAN [IN]; CHULLIEL NEELAKANDAN NARAYANAN [IN]; SENTHILKUMAR KUPPUSAMY [IN]


Publication No.: WO2012035904A1  Published: 22/Mar/2012

Title: AGENT FOR PROMOTING HYALURONIC ACID PRODUCTION

Applicant/Assignee: SHISEIDO COMPANY, LTD

Application No.: WO2011JP67829 (PCT/JP2011/67829)   Filing Date: 04/Aug/2011

Abstract:

Provided is an agent for promoting hyaluronic acid production that has excellent hyaluronic acid production-promoting capability and is effective in the prevention of aging of human skin, particularly in the maintenance of skin firmness and elasticity, and in the prevention and treatment of arthritis etc., and also in the early treatment etc. of sunburn. The agent for promoting hyaluronic acid production provided by the present invention comprises Dioscorea esculenta or an extract thereof. The Dioscorea esculenta is used in the form of a dried power or tuber of the plant in the agent for promoting hyaluronic acid production of the present invention.

Priority: JP20100204407 Applic. Date: 2010-09-13

Inventor: UCHIYAMA TARO [JP]; HASEGAWA TATSUYA [JP]


Publication No.: WO2012036283A1  Published: 22/Mar/2012

Title: COSMETIC MATERIAL, BATHWATER ADDITIVE AND PHARMACEUTICAL COMPOSITION CONTAINING CHITIN NANOFIBERS OR CHITOSAN NANOFIBERS

Applicant/Assignee: NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY, SHALLBE CO., LTD

Application No.: WO2011JP71255 (PCT/JP2011/71255)   Filing Date: 16/Sep/2011

Abstract:

The present invention provides a cosmetic material, a bathwater additive and a pharmaceutical composition containing chitin nanofibers or chitosan nanofibers. Preferably, the chitin nanofibers are produced according to a method characterized in that chitin-containing biological materials are submitted to at least one deproteinization step and at least one decalcification step, and then submitted to a defibration step

the widths of the fibers are approximately 2 nm to approximately 200 nm

and the fibers are extended chain crystals. Preferably, the chitosan nanofibers are produced according to a method characterized in that chitin-containing biological materials are submitted to at least one deproteinization step, at least one decalcification step, and at least one deacetylation step, and then submitted to a defibration step

the widths of the fibers are approximately 2 nm to approximately 200 nm

and the fibers are extended chain crystals

Priority: JP20100207802 Applic. Date: 2010-09-16

Inventor: MINAMI SABURO [JP]; IMAGAWA TOMOHIRO [JP]; OKAMOTO YOSHIHARU [JP]; TSUKA TAKESHI [JP]; SAIMOTO HIROYUKI [JP]; IFUKU SHINSUKE [JP]; KUDO YUJI [JP]


Publication No.: WO2012036446A2  Published: 22/Mar/2012

Title: COMPOSITION FOR TREATING ATOPIC DERMATITIS USING NATURAL MATERIALS

Applicant/Assignee:

Application No.: WO2011KR06754 (PCT/KR2011/06754)   Filing Date: 10/Sep/2011

Abstract:

The present invention relates to a composition for treating atopic dermatitis, which contains a hot water extract as an active ingredient, obtained by: mixing 3-15 wt % of rhei rhizoma, 3-10 wt % of akebia quinata, 3-10 wt % of gardenia seeds, 8 wt % of plantain seeds, 8 wt % of dianthi herba, and 8 wt % of polygoni avicularis herba

and performing hot water extraction on the resultant mixture.

The present invention relates to a composition for treating atopic dermatitis, which contains a hot water extract as an active ingredient, obtained by: mixing 1-15 wt % of each of amomum xanthoides, amomi cardamomi fructus, clove, elecampane, zingiberis rhizoma, ginseng, angelica gigas root, white poria, atractylodes rhizoma alba, platycodon, citrus unshiu, myristica fragrans, zedoariae rhizoma, acorus gramineus, bupleurum falcatum, areca catechu, coptidis rhizoma, ledebouriellae radix, evodiae fructus, magnoliae cortex, rhei rhizome, asparagus lucidus, aurantii fructus, phellodendri cortex, rubia cordifolia, osterici radix, patrinia scabiosaefolia Fischer, cyperi rhizoma, glycyrrhizae radix, foeniculum vulgare, akebia quinata, liriopis tuber, scirpus maritimus, chinese paeony root, cinnamon, plantain seed, dianthi herba, polygoni avicularis herba, and citri reticulatae viride pericarpium

and performing hot water extraction on the resultant mixture.

Priority: KR20100090022 Applic. Date: 2010-09-14

Inventor: SONG YONG-WON [KR]


Publication No.: WO2012037519A2  Published: 22/Mar/2012

Title: ACCELERATION OF WOUND HEALING BY GROWTH HORMONE RELEASING HORMONE AND ITS AGONISTS

Applicant/Assignee: UNIVERSITY OF MIAMI, NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS, UNITED STATES DEPARTMENT OF VETERANS AFFAIRS

Application No.: WO2011US52031 (PCT/US2011/52031)   Filing Date: 16/Sep/2011

Abstract:

Agonists of growth hormone releasing hormone promote islet graft growth and proliferation in patients. Methods of treating patients comprise the use of these agonists.

Priority: US20100383507P Applic. Date: 2010-09-16

Inventor: SCHALLY ANDREW V [US]; KIARIS HIPPOKRATIS [GR]; BLOCK NORMAN L [US]


Publication No.: WO2012037912A2  Published: 29/Mar/2012

Title: USE OF CORRINOIDS FOR PHARMACEUTICAL APPLICATION IN THE EVENT OF COAT AND SKIN DISORDERS IN SMALL AND LARGE ANIMALS (WARM- AND COLD-BLOODED) {FOR EXAMPLE IN FISH, BIRDS, HORSES, CATTLE, CAMELS, DOGS, CATS, REPTILES}

Applicant/Assignee:

Application No.: WO2011DE01342 (PCT/DE2011/01342)   Filing Date: 09/Jun/2011

Abstract:

The use of compounds with the formula (I) in which R is CN, OH, CH3 or H2O is claimed for upgrading and improvement of the durability of the skin. The compounds are especially suitable for prophylaxis in the case of disposition to chronic skin disorders, for prophylaxis and pharmaceutical treatment of allergic skin reactions, for pharmaceutical treatment of chronic coat and skin disorders, for pharmaceutical treatment of acute coat and skin damage, for example in the event of burns and wounds, and in the case of skin aging.

Priority: DE201010023626 Applic. Date: 2010-06-14

Inventor: SCHUETZ THOMAS [DE]


Publication No.: WO2012039525A1  Published: 29/Mar/2012

Title: MATERIAL AND METHOD FOR ENABLING THE ABSORPTION OF CARBON DIOXIDE INTO SKIN MUCOSA FOR PROVIDING A V-SHAPED JAW LINE AND REDUCING THE SIZE OF THE FACE BY BREAKING DOWN EXCESSIVE FACIAL FAT AND PROTEINS

Applicant/Assignee:

Application No.: WO2010KR06921 (PCT/KR2010/06921)   Filing Date: 11/Oct/2010

Abstract:

The present invention relates to a material and method enabling the absorption of carbon dioxide into skin mucosa using citric acid and sodium bicarbonate. More particularly, the present invention relates to a useful material and to a method for enabling the absorption of carbon dioxide into skin mucosa using citric acid and sodium bicarbonate, which can minimize the amount of carbon dioxide, generated by a reaction between citric acid and sodium bicarbonate, released into the air, by means of an adhesion pad, and can thus increase the amount of carbon dioxide absorbed into the skin mucosa and maintain an absorption time, by coating the skin with a serum containing citric acid and attaching the adhesion pad coated with a sheet of liquid containing sodium bicarbonate, and can also relax the muscles and break down excessive fat and superfluous proteins to provide a V-shaped jaw line when it is applied to the jaw, neck, portions of the face behind the ears, etc., as the material contains lipase and protease, which enable fat and proteins to be broken down.

Priority: KR20100092417 Applic. Date: 2010-09-20; KR20100092416 Applic. Date: 2010-09-20

Inventor: LEE KYEUNG JU [KR]; KANG KENG PILL [KR]


Publication No.: WO2012042970A1  Published: 05/Apr/2012

Title: PROPHYLACTIC OR THERAPEUTIC AGENT FOR ATOPIC DERMATITIS, AND PREPARATION FOR EXTERNAL APPLICATION

Applicant/Assignee: KOCHI UNIVERSITY

Application No.: WO2011JP61910 (PCT/JP2011/61910)   Filing Date: 24/May/2011

Abstract:

Provided is a technique which has an anti-pruritogenic activity and an anti-inflammatory activity at levels equivalent to or higher than those of steroid drugs and is useful as a prophylactic or therapeutic agent for atopic dermatitis. This prophylactic or therapeutic agent for atopic dermatitis contains an extract of leaves of a plant Vernonia Amygdalina with an alcohol and/or water as an active ingredient.

Priority: JP20100217400 Applic. Date: 2010-09-28

Inventor: HIROTA RYOJI [JP]; NGATU NLANDU ROGER [JP]


Publication No.: WO2012043185A1  Published: 05/Apr/2012

Title: COMPOSITION FOR INHIBITING IL-8 EXPRESSION

Applicant/Assignee: SHISEIDO COMPANY, LTD

Application No.: WO2011JP70482 (PCT/JP2011/70482)   Filing Date: 08/Sep/2011

Abstract:

Developed are a composition for inhibiting IL-8 expression which can be used daily and which is stable and safe, and an external preparation for the skin, a pharmaceutical composition and a food composition containing same. The present invention provides a composition for inhibiting IL-8 expression which comprises 1 type or more of a compound selected from a group consisting of a D-methionine, a derivative thereof and/or a salt thereof. The composition may be an external preparation for the skin, a pharmaceutical composition for treating and/or preventing skin diseases, or a food composition. This composition may be used to treat diseases in which IL-8 is expressed, but in which IL-6 and TNF-a are not expressed.

Priority: JP20100222654 Applic. Date: 2010-09-30

Inventor: MATSUMOTO KAYO [JP]; TOUJO YOUSUKE [JP]


Publication No.: WO2012043393A1  Published: 05/Apr/2012

Title: EMULSION COMPOSITION

Applicant/Assignee: KOBAYASHI PHARMACEUTICAL CO., LTD

Application No.: WO2011JP71658 (PCT/JP2011/71658)   Filing Date: 22/Sep/2011

Abstract:

[Problem] To provide an emulsion composition, an external skin preparation, and an analgesic, each of which is in a semi-solid state, has excellent thermal stability, and gives a good use sensation when applied to the skin. [Solution] An emulsion composition containing water, an oily component, a hydrophilic surfactant, and terpene, characterized in that the oily component is contained in an amount of 0.2 to 0.7 parts by weight with respect to 1 part by weight of the water, and the hydrophilic surfactant and the terpene are contained in amounts of 0.37 to 1.0 parts by weight and 0.08 to 0.45 parts by weight with respect to 1 part by weight of the oily component, respectively.

Priority: JP20100223056 Applic. Date: 2010-09-30

Inventor: ADO KAZUYOSHI [JP]


Publication No.: WO2012043533A1  Published: 05/Apr/2012

Title: ANTIHUMAN CCR7 ANTIBODIES, HYBRIDOMA, NUCLEIC ACID, VECTOR, CELL, MEDICINAL COMPOSITION, AND ANTIBODY-IMMOBILIZED CARRIER

Applicant/Assignee: SEKISUI CHEMICAL CO., LTD, NB HEALTH LABORATORY CO., LTD

Application No.: WO2011JP72014 (PCT/JP2011/72014)   Filing Date: 27/Sep/2011

Abstract:

The purpose of the present invention is to provide a novel antihuman CCR7 antibody which is useful as a therapeutic agent for tissue fibrosis or cancer, a medicinal composition which comprises the antihuman CCR7 antibody, and so on. Provided is an antihuman CCR7 antibody binding specifically to the extracellular domain of human CCR7, said antihuman CCR7 antibody having a heavy chain CDR3 which comprises an amino acid sequence represented by SEQ ID NO: 7, 17, 27, 37, 47, 57, 67 or 77. Also provided is an antihuman CCR7 antibody which has heavy chain CDRs 1-3 and light chain CDRs 1-3, said heavy chain CDRs 1-3 and light chain CDRs 1-3 respectively comprising amino acid sequences represented by SEQ ID NOS:5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70 or 75-80. Preferably, such an antihuman CCR7 antibody has an activity of blocking CCR7-dependent intracellular signal transduction mechanism that is induced by stimulation with CCR7 ligands. The antihuman CCR7 antibodies according to the present invention are usable as the active ingredient of a therapeutic agent for tissue fibrosis or cancer.

Priority: JP20100217096 Applic. Date: 2010-09-28

Inventor: NISHIGUCHI NAOKI [JP]; YOON MYUNG-EUI [JP]; FURUTANI MASAHIRO [JP]; SHIMIZU TATSUO [JP]; TAKAYAMA KIYOSHI [JP]; SHIMIZU TOMOKO [JP]; SUZUKI KAZUYA [JP]


Publication No.: WO2012043680A1  Published: 05/Apr/2012

Title: ???????AQUEOUS TOPICAL PREPARATION FOR USE ON SKIN

Applicant/Assignee: FUJIFILM CORPORATION

Application No.: WO2011JP72289 (PCT/JP2011/72289)   Filing Date: 28/Sep/2011

Abstract:

An aqueous topical preparation for use on skin, said preparation containing: water

casein nanoparticles containing a hydroxystilbene such as resveratrol

and a compound that has a thiol group such as cysteine.

Priority: JP20100219898 Applic. Date: 2010-09-29

Inventor: MURAGUCHI TAICHI [JP]


Publication No.: WO2012043711A1  Published: 05/Apr/2012

Title: SKIN COLLAGEN PRODUCTION-PROMOTING AGENT

Applicant/Assignee: MEGMILK SNOW BRAND CO., LTD

Application No.: WO2011JP72359 (PCT/JP2011/72359)   Filing Date: 29/Sep/2011

Abstract:

The present invention addresses the problem of providing a novel skin collagen production-promoting agent for promoting the biosynthesis of skin collagen, which is capable of preventing dry skin, rough skin, wrinkles and sagging, and can also be used as a food material without any safety problems. The present invention also addresses the problem of providing foods, drinks and cosmetic materials containing the skin collagen production-promoting agent. The skin collagen production-promoting agent uses milk protein fractions having the following characteristics (a) to (c) as the active ingredient. (a) The milk protein fractions are derived from milk. (b) The fractions, obtained by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), contain proteins with molecular masses ranging from 80,000 to 85,000 daltons. (c) The constituent amino acid composition contains 16 to 18 wt % basic amino acids, and the ratio of basic amino acids/acidic amino acids ranges from 0.65 to 0.85.

Priority: JP20100222096 Applic. Date: 2010-09-30

Inventor: KATO KEN [JP]; ONO AIKO [JP]; UENO HIROSHI [JP]; UEDA NORIKO [JP]; MATSUYAMA HIROAKI [JP]


Publication No.: WO2012043712A1  Published: 05/Apr/2012

Title: SKIN COLLAGEN PRODUCTION-PROMOTING AGENT

Applicant/Assignee: MEGMILK SNOW BRAND CO., LTD

Application No.: WO2011JP72360 (PCT/JP2011/72360)   Filing Date: 29/Sep/2011

Abstract:

The present invention addresses the problem of providing a novel skin collagen production-promoting agent for promoting the biosynthesis of skin collagen, which is capable of preventing dry skin, rough skin, wrinkles and sagging, and can also be used as a food material without any safety problems. The present invention also addresses the problem of providing foods, drinks and cosmetic materials containing the skin collagen production-promoting agent. The skin collagen production-promoting agent uses milk protein fractions having the following characteristics (a) to (c) as the active ingredient. (a) The milk protein fractions are derived from milk. (b) The fractions, obtained by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), contain proteins with molecular masses ranging from 12,000 to 16,000 daltons. (c) The constituent amino acid composition contains 18 to 20 wt % basic amino acids, and the ratio of basic amino acids/acidic amino acids ranges from 0.7 to 0.9.

Priority: JP20100222097 Applic. Date: 2010-09-30

Inventor: KATO KEN [JP]; ONO AIKO [JP]; UENO HIROSHI [JP]; UEDA NORIKO [JP]; MATSUYAMA HIROAKI [JP]


Publication No.: WO2012043713A1  Published: 05/Apr/2012

Title: SKIN COLLAGEN PRODUCTION-PROMOTING AGENT

Applicant/Assignee: MEGMILK SNOW BRAND CO., LTD

Application No.: WO2011JP72361 (PCT/JP2011/72361)   Filing Date: 29/Sep/2011

Abstract:

The present invention addresses the problem of providing a novel skin collagen production-promoting agent for promoting the biosynthesis of skin collagen, which is capable of preventing dry skin, rough skin, wrinkles and sagging, and can also be used as a food material without any safety problems. The present invention also addresses the problem of providing foods, drinks and cosmetic materials containing the skin collagen production-promoting agent. The skin collagen production-promoting agent uses milk protein fractions having the following characteristics (a) to (c) as the active ingredient. (a) The milk protein fractions are derived from milk. (b) The fractions, obtained by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), contain proteins with molecular masses ranging from 75,000 to 80,000 daltons. (c) The constituent amino acid composition contains 13 to 15 wt % basic amino acids, and the ratio of basic amino acids/acidic amino acids ranges from 0.5 to 0.7.

Priority: JP20100222098 Applic. Date: 2010-09-30

Inventor: KATO KEN [JP]; ONO AIKO [JP]; UENO HIROSHI [JP]; UEDA NORIKO [JP]; MATSUYAMA HIROAKI [JP]


Publication No.: WO2012043714A1  Published: 05/Apr/2012

Title: SKIN COLLAGEN PRODUCTION-PROMOTING AGENT

Applicant/Assignee: MEGMILK SNOW BRAND CO., LTD

Application No.: WO2011JP72362 (PCT/JP2011/72362)   Filing Date: 29/Sep/2011

Abstract:

The present invention addresses the problem of providing a novel skin collagen production-promoting agent for promoting the biosynthesis of skin collagen, which is capable of preventing dry skin, rough skin, wrinkles and sagging, and can also be used as a food material without any safety problems. The present invention also addresses the problem of providing foods, drinks and cosmetic materials containing the skin collagen production-promoting agent. The skin collagen production-promoting agent uses milk protein fractions having the following characteristics (a) to (c) as the active ingredient. (a) The milk protein fractions are derived from milk. (b) The fractions, obtained by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), contain proteins with molecular masses ranging from 6,000 to 150,000 daltons. (c) The constituent amino acid composition contains 12 to 14 wt % basic amino acids, and the ratio of basic amino acids/acidic amino acids ranges from 0.5 to 0.7.

Priority: JP20100222099 Applic. Date: 2010-09-30

Inventor: KATO KEN [JP]; ONO AIKO [JP]; UENO HIROSHI [JP]; UEDA NORIKO [JP]; MATSUYAMA HIROAKI [JP]


Publication No.: WO2012043715A1  Published: 05/Apr/2012

Title: SKIN COLLAGEN PRODUCTION-PROMOTING AGENT

Applicant/Assignee: MEGMILK SNOW BRAND CO., LTD

Application No.: WO2011JP72363 (PCT/JP2011/72363)   Filing Date: 29/Sep/2011

Abstract:

The present invention addresses the problem of providing a skin collagen production-promoting agent that is free of safety problems. The present invention also addresses the problem of providing foods and drinks for promoting skin collagen production and cosmetic materials for promoting skin collagen production, which contain such a substance. Cystatins and/or cystatin decomposition products, obtained by decomposing cystatins with a protease such as pepsin or pancreatin, are used as the active ingredient of the skin collagen production-promoting agent, the foods and drinks for promoting skin collagen production, and the cosmetic materials for promoting skin collagen production. These cystatins and cystatin decomposition products have the effect of increasing the collagen content of skin.

Priority: JP20100222101 Applic. Date: 2010-09-30

Inventor: KATO KEN [JP]; ONO AIKO [JP]; UENO HIROSHI [JP]; UEDA NORIKO [JP]; MATSUYAMA HIROAKI [JP]


Publication No.: WO2012043920A1  Published: 05/Apr/2012

Title: COMPOSITION FOR PREVENTING OR TREATING ATOPIC DERMATITIS INCLUDING GALENICAL EXTRACT OR LACTOBACILLUS FERMENTATION THEREOF

Applicant/Assignee: KOREA INSTITUTE OF ORIENTAL MEDICINE

Application No.: WO2010KR07523 (PCT/KR2010/07523)   Filing Date: 29/Oct/2010

Abstract:

The present invention relates to a composition for preventing or treating atopic dermatitis, and more specifically to a pharmaceutical composition and a health supplement for preventing or treating atopic dermatitis, the composition and the supplement having as active ingredients extract of a galenical mixture including sophora root, licorice, lonicer aflower, Korean angelica root, Korean aralia root, saussurea root, seselos radix, zizyphus spinosi, Houttuynia cordata, forsythia fruit, lappa fruit, Epimedium koreanum Nakai, ginseng, lithospermum, oleoresin, cnidium, scorophulariae radix, and reynoutria, or lactobacillus fermentation of the galenical extract prepared by inoculating lactobacillus to the galenical extract and fermenting same. The galenical extract or the galenical extract fermentation of the present invention shows reduction in the number of scratching, a trend of decrease in clinical features of atopic symptoms such as erythema, itchiness and dry skin, edema and hematoma, erosion, and lichenification, and reduces the IgE concentration in blood, which is related to exogenous atopic dermatitis, among laboratory animal models having atopic dermatitis, and is thereby, useful for the prevention and/or treatment of atopic dermatitis.

Priority: KR20100093901 Applic. Date: 2010-09-28

Inventor: MA JIN YEUL [KR]; CHUNG TAE HO [KR]; IM GA YOUNG [KR]; KIM DONG SEON [KR]; UM YOUNG RAN [KR]; EUM HYUN AE [KR]; LEE JAE HOON [KR]; CHOI SUNG UP [KR]; CHO BYOUNG HEON [KR]


Publication No.: WO2012043949A1  Published: 05/Apr/2012

Title: COMPOSITION FOR ENHANCING IMMUNITY CONTAINING COMPOUNDS REPRESENTED BY CHEMICAL FORMULAS 1-8 OR SOPHORA FLAVESCENS EXTRACT AS ACTIVE INGREDIENT

Applicant/Assignee: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Application No.: WO2011KR02120 (PCT/KR2011/02120)   Filing Date: 28/Mar/2011

Abstract:

The present invention relates to a composition for enhancing immunity by inducing the expression of interferon-ss containing compounds represented by chemical formulas 1-8, or a Sophora Flavescens extract containing the same, and using a fraction thereof as an active ingredient, a feed additive, a feed composition, a pharmaceutical composition, a food composition and a quasi-drug composition which contain the same, and a method for enhancing immunity by administering the composition.According to the present invention, the composition for inducing the expression of interferon, containing compounds represented by chemical formulas 1-8, or a Sophora Flavescens extract containing the same and a fraction thereof as an active ingredient can prevent, improve or treat diseases which can be prevented or treated by increasing interferon expression.

Priority: KR20100093423 Applic. Date: 2010-09-27

Inventor: RHO MUN CHUAL [KR]; LEE WOO SONG [KR]; CHO KYOUNG OH [KR]; PARK SU JIN [KR]; RYU YOUNG BAE [KR]; KIM YOUNG MIN [KR]; LEE SEUNG WOONG [KR]; JEONG JI HAK [KR]; PARK MI HYE [KR]; CHANG JONG SUN [KR]


Publication No.: WO2012045072A2  Published: 05/Apr/2012

Title: SUGAR-BASED DISPERSION

Applicant/Assignee: MARY KAY INC

Application No.: WO2011US54596 (PCT/US2011/54596)   Filing Date: 03/Oct/2011

Abstract:

Disclosed is a stable anhydrous dispersion comprising a dispersed sugar phase comprising granulated sugar and powdered sugar, wherein the dispersion comprises 55% to 75% by weight, based on the total weight of the composition, of a combination of granulated sugar and powdered sugar, and a continuous oil phase, wherein the dispersion comprises at least 20% by weight, based on the total weight of the composition, of an oil.

Priority: US20100388803P Applic. Date: 2010-10-01

Inventor: SWANZY JAMES [US]


Publication No.: WO2012046046A1  Published: 12/Apr/2012

Title: COMPOSITION FOR SKIN TREATMENT

Applicant/Assignee: BIO SKINCARE LIMITED

Application No.: WO2011GB51893 (PCT/GB2011/51893)   Filing Date: 05/Oct/2011

Abstract:

A composition comprising from 10 to 15 % by weight of sucrose palmitate. The composition can be used to treat eczema.

Priority: GB20110010653 Applic. Date: 2011-06-23; GB20100016834 Applic. Date: 2010-10-06

Inventor: JAMES KENNETH [GB]


Publication No.: WO2012046922A1  Published: 12/Apr/2012

Title: NOVEL USE OF ANTIMICROBIAL PEPTIDES IN REGENERATION OF SKIN CELLS

Applicant/Assignee: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY

Application No.: WO2010KR09558 (PCT/KR2010/09558)   Filing Date: 30/Dec/2010

Abstract:

Disclosed are novel antimicrobial peptides which can promote the regeneration of skin cells, thus healing wounds. Pharmaceutical compositions comprising the peptides as active ingredients are also provided for wound healing and skin rejuvenation. The antimicrobial peptides exhibit inhibitory activity against antibiotic-resistant strains, and their antimicrobial activity is maintained without loss of structural stability even under a high salt condition. Also, being proven to promote the migration and regeneration of skin cells in mice as well as in vitro, the antimicrobial peptides may be widely used as an agent for regenerating skin cells. Further, they can find applications in various fields including the medical industry and the cosmetic industry. Hence, the novel antimicrobial peptides are anticipated to have considerable repercussions in the market for antibiotics, wound healing agents and cosmetics.

Priority: KR20100098259 Applic. Date: 2010-10-08

Inventor: KIM SUN-CHANG [KR]; KIM DA-JUNG [KR]; JANG SU-A [KR]; SUNG BONG HYUN [KR]; LIM KI-JUNG [KR]; SHIN JU-RI [KR]; LEE YOUNG WOONG [KR]


Publication No.: WO2012047645A2  Published: 12/Apr/2012

Title: COMBINATION TREATMENT FOR ROSACEA

Applicant/Assignee: GALDERMA LABORATORIES INC

Application No.: WO2011US53440 (PCT/US2011/53440)   Filing Date: 27/Sep/2011

Abstract:

The invention relates to a method of treating erythema and/or telangiectasia associated with rosacea in a patient in need thereof by topically administering an effective amount of a combination of brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or a pharmaceutically acceptable salt thereof to the site of erythema and/or telangiectasia on the skin of the patient. The invention further relates to topical compositions including the combination of compounds and a pharmaceutically acceptable carrier.

Priority: US20100387260P Applic. Date: 2010-09-28; US201113232134 Applic. Date: 2011-09-14

Inventor: GRAEBER MICHAEL [US]; LEONI MATTHEW JAMES [US]; WAGNER NATHALIE [FR]


Publication No.: WO2012047733A2  Published: 12/Apr/2012

Title: TREATMENT OF ACNE BY CONDITIONED MEDIA

Applicant/Assignee: AIDAN RESEARCH AND CONSULTING, LLC

Application No.: WO2011US54094 (PCT/US2011/54094)   Filing Date: 29/Sep/2011

Abstract:

Disclosed are methods and compositions for treatment of acne or acneform conditions, particularly but not limited to, acne vulgaris with products generated from culture of stem or progenitor cells. Specifically, compositions of matter are disclosed which are useful for the treatment of acne and acne associated disease states, in particular acne vulgaris, by topical administration of products derived from stem cells or progenitor cells.

Priority: US20100387885P Applic. Date: 2010-09-29

Inventor: RIORDAN NEIL H [US]; RIORDAN TIEMEY M [US]


Publication No.: WO2012050162A1  Published: 19/Apr/2012

Title: CELLULAR LIFE SPAN EXTENDING AGENT, AND TELOMERASE ACTIVATOR

Applicant/Assignee: SHISEIDO COMPANY, LTD

Application No.: WO2011JP73548 (PCT/JP2011/73548)   Filing Date: 13/Oct/2011

Abstract:

The present invention provides: a novel cellular life span extending agent, particularly an agent for extending the life span of an endothelial cell, which comprises an extract derived from a plant belonging to the genus Cinnamomum

and a telomerase activator.

Priority: JP20100232664 Applic. Date: 2010-10-15

Inventor: KAJIYA KENTARO [JP]; TAKAKURA NOBUYUKI [JP]


Publication No.: WO2012050745A2  Published: 19/Apr/2012

Title: COMPOSITIONS CONTAINING ZINC PCA AND ANOGEISSUS EXTRACT

Applicant/Assignee: ELC MANAGEMENT LLC

Application No.: WO2011US52184 (PCT/US2011/52184)   Filing Date: 19/Sep/2011

Abstract:

A topical composition comprising at least one extract from the Anogeissus genus and at zinc PCA and a method for treating human skin for improvement comprising applying to the skin a topical composition comprising at least one extract from the Anogeissus genus zinc PCA.

Priority: US20100388153P Applic. Date: 2010-09-30

Inventor: DALY SUSAN M [US]; DECLERCQ LIEVE [BE]


Publication No.: WO2012050831A2  Published: 19/Apr/2012

Title: COMBINATION TREATMENT FOR DERMATOLOGICAL CONDITIONS

Applicant/Assignee: GALDERMA LABORATORIES INC

Application No.: WO2011US53455 (PCT/US2011/53455)   Filing Date: 27/Sep/2011

Abstract:

The invention relates to a method of treating dermatological conditions or symptoms associated therewith in a patient in need thereof by topically administering an effective amount of a combination of brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or a pharmaceutically acceptable salt thereof to the affected area of skin on the patient. The invention further relates to topical compositions including the combination of compounds and a pharmaceutically acceptable carrier.

Priority: US201113232139 Applic. Date: 2011-09-14; US20100387268P Applic. Date: 2010-09-28

Inventor: GRAEBER MICHAEL [US]; LEONI MATTHEW JAMES [US]; WAGNER NATHALIE [FR]


Publication No.: WO2012051416A1  Published: 19/Apr/2012

Title: PHARMACEUTICAL FORMULATION FOR HISTONE DEACETYLASE INHIBITORS

Applicant/Assignee: SHAPE PHARMACEUTICALS, INC

Application No.: WO2011US56148 (PCT/US2011/56148)   Filing Date: 13/Oct/2011

Abstract:

A pharmaceutical composition, comprising a therapeutically effective amount of an active pharmaceutical ingredient (API) compound represented by the following structural formula at least one acidifying agent

and a vehicle base comprising at least one pharmaceutically acceptable non-aqueous solvent. Values and preferred values of the variables in structural formula (I) are defined herein.

Priority: US20100392855P Applic. Date: 2010-10-13

Inventor: CHAPPELL TODD W [US]; JOHNSON KEITH A [US]


Publication No.: WO2012051614A2  Published: 19/Apr/2012

Title: DELIVERY OF HYDROPHOBIC BIOACTIVE AGENTS

Applicant/Assignee:

Application No.: WO2011US56558 (PCT/US2011/56558)   Filing Date: 17/Oct/2011

Abstract:

A composition for delivery of a hydrophobic bioactive agent is provided that provides for a partially solubilized storage solution that upon exposure to the air results in a fully solubilized bioactive agent in a molecular form for optimal delivery to the skin of a subject. The composition is used for the therapeutic treatment or diagnosis of numerous skin conditions such as acne, wrinkles, inflammation, and epidermal or musculoskeletal pain.

Priority: US20100393615P Applic. Date: 2010-10-15

Inventor: KULESZA JOHN E [US]


Publication No.: WO2012051745A1  Published: 26/Apr/2012

Title: A METHOD OF EXTRACTING BIOACTIVE SUBSTANCES BY BREAKING WALL OF CHLORELLA PYRENOIDOSA

Applicant/Assignee:

Application No.: WO2010CN02172 (PCT/CN2010/02172)   Filing Date: 27/Dec/2010

Abstract:

A method of extracting bioactive substances by breaking wall of Chlorella Pyrenoidosa includes the following steps: A) freezing slurry of Chlorella Pyrenoidosa living body at minus 20 (approx.) 40?, then placing the obtained frozen block into a container, rapidly extruding the frozen block by physical extrusion process to break and dissolve the frozen block instantly

B) placing the wall-broken liquid obtained by extrusion into a stirrer and stirring

and C) performing membrane separation to obtain bioactive substances at 0 (approx.) 5?. Through freezing the Chlorella Pyrenoidosa living body, the cell wall is extruded by the cytochyma, and the frozen block is broken rapidly by a physical extrusion process. Combination of these two kinds of means can fully make the cell wall of Chlorella Pyrenoidosa break and make cytochyma flow out

thereby the bioactive substances in Chlorella Pyrenoidosa cytochyma are extracted effectively. The whole extraction process is performed at low temperatures using physical processes, thus no causing the bioactive substances will not cause chemical change and impact.

Priority: CN20101513417 Applic. Date: 2010-10-20

Inventor: TANG YONGQIANG [CN]


Publication No.: WO2012052179A1  Published: 26/Apr/2012

Title: AMINO DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE SKIN DISORDERS

Applicant/Assignee: ALMIRALL, S.A

Application No.: WO2011EP05302 (PCT/EP2011/05302)   Filing Date: 20/Oct/2011

Abstract:

Compositions comprising specific amino derivatives for their use in treating proliferative skin diseases or disorders and the use of specific amino derivatives in such a treatment is disclosed.

Priority: EP20100382277 Applic. Date: 2010-10-22; US201061425895P Applic. Date: 2010-12-22

Inventor: GODESSART MARINA NURIA [ES]; BALAGUE PELAEZ CRISTINA [ES]


Publication No.: WO2012052180A1  Published: 26/Apr/2012

Title: COMBINATIONS COMPRISING DHODH INHIBITORS AND COX INHIBITORS

Applicant/Assignee: ALMIRALL, S.A

Application No.: WO2011EP05303 (PCT/EP2011/05303)   Filing Date: 20/Oct/2011

Abstract:

Combinations comprising (a) DHODH inhibitors and (b) COX inhibitors and their treating skin diseases or disorders are disclosed.

Priority: EP20100382276 Applic. Date: 2010-10-22; US201061425889P Applic. Date: 2010-12-22

Inventor: GODESSART MARINA NURIA [ES]; BALAGUE PELAEZ CRISTINA [ES]


Publication No.: WO2012052395A1  Published: 26/Apr/2012

Title: ISOXAZOLE DERIVATIVES USED AS OESTROGEN MODULATORS

Applicant/Assignee: N. V. ORGANON

Application No.: WO2011EP68099 (PCT/EP2011/68099)   Filing Date: 17/Oct/2011

Abstract:

The present invention relates to a substituted isoxazole derivative according to formula (I), wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt, solvate or prodrug thereof. The present invention also relates to a pharmaceutical composition comprising said substituted isoxazole derivatives and to their use as a contraceptive or in therapy, for instance in the treatment or prevention of estrogen-receptor mediated disorders or estrogen-receptor related physiological conditions such as climacteric disorders and osteoporosis.

Priority: US20100393986P Applic. Date: 2010-10-18; EP20100187838 Applic. Date: 2010-10-18

Inventor: DIJCKS FREDRICUS ANTONIUS [NL]; VEENEMAN GERRIT HERMAN [NL]; PETERS JOHANNES LAMBERTUS MARIA [NL]


Publication No.: WO2012052562A1  Published: 26/Apr/2012

Title: COMPOSITIONS COMPRISING A FILLER PRODUCT AND A CHEMICALLY MODIFIED TETRACYCLINE

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT

Application No.: WO2011EP68516 (PCT/EP2011/68516)   Filing Date: 24/Oct/2011

Abstract:

The invention relates to a combination product comprising: - a composition A comprising at least one filler product, and - a composition B comprising at least one chemically modified tetracycline, for the treatment of skin aging and scars, compositions A and B being used simultaneously, separately or sequentially over time. The invention also relates to a single pharmaceutical composition or a injectable fixed combination product comprising, in the same physiologically acceptable medium, at least one filler product and at least one chemically modified tetracycline.

Priority: FR20100058648 Applic. Date: 2010-10-22; US20100344847P Applic. Date: 2010-10-22

Inventor: BOUVIER GUY [FR]


Publication No.: WO2012052563A1  Published: 26/Apr/2012

Title: COMPOSITIONS COMPRISING A FILLER PRODUCT AND A COMPOUND OF THE TETRACYCLINE FAMILY USED AT A SUBANTIMICROBIAL DOSE

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT

Application No.: WO2011EP68517 (PCT/EP2011/68517)   Filing Date: 24/Oct/2011

Abstract:

The invention relates to a combination product comprising: a composition A comprising at least one filler product, and a composition B comprising at least one compound of the tetracycline family used at a subantimicrobial dose, for the treatment of skin aging and scars, compositions A and B being used simultaneously, separately or sequentially over time. The invention also relates to a single pharmaceutical composition comprising, in the same physiologically acceptable medium, at least one filler product and at least one compound of the tetracycline family used at a subantimicrobial dose.

Priority: US20100344846P Applic. Date: 2010-10-22; FR20100058649 Applic. Date: 2010-10-22

Inventor: BOUVIER GUY [FR]


Publication No.: WO2012052753A1  Published: 26/Apr/2012

Title: QUINAZOLIN-4 (3H) -ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS

Applicant/Assignee: RESPIVERT LIMITED

Application No.: WO2011GB52015 (PCT/GB2011/52015)   Filing Date: 18/Oct/2011

Abstract:

The present invention relates to the compound of formula (I) and to compositions comprising the same and to the use of the compound and to compositions of the compound in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compound.

Priority: TW20100135360 Applic. Date: 2010-10-18; WO2010EP65746 Applic. Date: 2010-10-19

Inventor: KING-UNDERWOOD JOHN [GB]; ITO KAZUHIRO [GB]; MURRAY PETER JOHN [GB]; HARDY GEORGE [GB]; BROOKFIELD FREDERICK ARTHUR [GB]; BROWN CHRISTOPHER JOHN [GB]


Publication No.: WO2012054447A2  Published: 26/Apr/2012

Title: USE OF STORAGE STABLE VISCOUS PHOSPHOLIPID DEPOT TO TREAT WOUNDS

Applicant/Assignee: DR. REDDY'S LABORATORIES, INC

Application No.: WO2011US56661 (PCT/US2011/56661)   Filing Date: 18/Oct/2011

Abstract:

The present invention provides a method of preventing and/or treating a wound infection by introducing to a wound a clear depot comprising a hydrophilic water-soluble pharmaceutically active agent(s) selected from the group consisting of vancomycin, gentamicin, and a mixture thereof, water, a phospholipid, an oil, a pH adjusting agent, and a viscosity modifying agent, wherein the water present in the viscous depot is no more than about 4 wt %, no more than about 2 wt %, or no more than about 0.5 wt % of water relative to the total weight of the depot.

Priority: US20100405715P Applic. Date: 2010-10-22

Inventor: CHEN HAILIANG [US]; CHEN ANDREW XIAN [US]; SURAKANTI DUSHYANTH [US]; OKUMU FRANKLIN [US]


Publication No.: WO2012054862A2  Published: 26/Apr/2012

Title: AGENTS, COMPOSITIONS, AND METHODS FOR TREATING PRURITIS AND RELATED SKIN CONDITIONS

Applicant/Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC

Application No.: WO2011US57336 (PCT/US2011/57336)   Filing Date: 21/Oct/2011

Abstract:

This invention relates generally to a therapeutic use of TLR3 and TLR7 inhibitors to treat or reduce pruritus in a subject.

Priority: US20100405452P Applic. Date: 2010-10-21

Inventor: JI RU-RONG [US]; BERTA TEMUGIN [US]; XU ZHEN-ZHONG [US]; LIU TONG [US]; PARK CHUL-KYU [US]


Publication No.: WO2012056387A2  Published: 03/May/2012

Title: A DERMACEUTICAL GEL MADE USING SODIUM FUSIDATE AND A PROCESS TO MAKE IT

Applicant/Assignee:

Application No.: WO2011IB54729 (PCT/IB2011/54729)   Filing Date: 24/Oct/2011

Abstract:

The invention discloses a process to make dermaceutical gel containing Fusidic acid which is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic acid under oxygen-free environment comprising an inert gas, preferably nitrogen. The gel produced by the process of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic acid. The gel also contains Fusidic acid as the API that has been formed in situ from Sodium Fusidate, in a gel base

said gel base comprising a natural, semi-synthetic or synthetic polymers, a preservative, an acid, an alkali, a co-solvent, along with water, preferably purified water.

The gel produced by the process of the present invention further optionally contains an ingredient selected from a group comprising, an anti oxidant, a chelating agent, and a humectant, or any combination thereof.

Priority: IN2010MU02352 Applic. Date: 2010-10-26

Inventor: VANANGAMUDI SULUR SUBRAMANIAM [IN]; SRINIVASAN MADHAVAN [IN]; CHULLIEL NEELAKANDAN NARAYANAN [IN]; SELVARAJ BALKRISHNANA [IN]; HARIDAS SANKAR [IN]


Publication No.: WO2012057123A1  Published: 03/May/2012

Title: COLLAGEN PRODUCTION PROMOTER, HYALURONAN PRODUCTION PROMOTER, FIBROBLAST PROLIFERATION PROMOTER, AND ANTI-WRINKLE AGENT

Applicant/Assignee: SHISEIDO COMPANY, LTD

Application No.: WO2011JP74529 (PCT/JP2011/74529)   Filing Date: 25/Oct/2011

Abstract:

Provided in the present invention is a material which is produced by processing a material extracted from a plant seed using an organic solvent, and which is highly effective in promoting collagen production, promoting hyaluronan production, and diminishing the appearance of wrinkles. The collagen production promoter related to the present invention is characterized by being obtained through a process in which: an extracted material containing an oil component is extracted from a seed of a plant belonging to the family Cupressaceae and the genus Platycadus by using an organic solvent

part or all of the solvent is removed from the extracted material by distillation

an aqueous alkali solution having a concentration of 0.5-15 N is added and mixed

acid treatment is performed

and the resultant material is subsequently washed with water.

Priority: JP20100240674 Applic. Date: 2010-10-27

Inventor: TSUNENAGA MAKOTO [JP]; IINO MASATO [JP]; KUSAKARI KEN [JP]


Publication No.: WO2012057262A1  Published: 03/May/2012

Title: PYRIDINE DERIVATIVE AND MEDICINAL AGENT

Applicant/Assignee: NIPPON SHINYAKU CO., LTD

Application No.: WO2011JP74813 (PCT/JP2011/74813)   Filing Date: 27/Oct/2011

Abstract:

A pyridine derivative represented by general formula [1] or a pharmaceutically acceptable salt thereof. In formula [1], R represents an aryl group or a heteroaryl group, wherein each of the aryl group and the heteroaryl group may be substituted by one or two substituents independently selected from the group consisting of an optionally substituted alkyl group, a hydroxy group, a halogen atom and a group represented by general formula [2]. In formula [2], L1 and L3 independently represent a single bond, an alkylene group or a cycloalkylene group

L2 represents a single bond, O, or NRB

RB represents H or an optionally substituted alkyl group

RA represents H, an amino group, a cyano group, a hydroxy group, an alkoxy group, an aryl group, a monoalkylamino group, a dialkylamino group, a carbamoyl group, an alkyloxycarbonyl group, a monoalkylaminocarbonyl group, a dialkylaminocarbonyl group, an alkylcarbonylamino group, a saturated heterocyclic group, an optionally substituted alkyl group, an optionally substituted cycloalkyl group or an optionally substituted heteroaryl group.

Priority: JP20110191449 Applic. Date: 2011-09-02; JP20100242624 Applic. Date: 2010-10-28

Inventor: FUJIHARA HIDETAKA [JP]; SUGIYAMA HIROYUKI [JP]; TSUJI TAKASHI [JP]; INO TAKARA [JP]; HARUTA YOSHINARI [JP]


Publication No.: WO2012057291A1  Published: 03/May/2012

Title: PROCESS FOR PRODUCTION OF PHENOLIC POLYMERIZABLE COMPOUND HAVING PHYSIOLOGICAL ACTIVITY

Applicant/Assignee: UHA MIKAKUTO CO., LTD

Application No.: WO2011JP74869 (PCT/JP2011/74869)   Filing Date: 27/Oct/2011

Abstract:

The present invention relates to a process for producing a phenolic polymerizable compound represented by formula (1) or (2) (wherein X1-X9 independently represent a hydrogen atom, a hydroxy group, a saturated or unsaturated linear or branched alkoxy group having 1-10 carbon atoms, or a saturated or unsaturated linear or branched alkyl group having 1-10 carbon atoms

Y represents a hydrogen atom, a hydroxy group, a saturated or unsaturated linear or branched alkoxy group having 1-10 carbon atoms, a saturated or unsaturated linear or branched alkyl group having 1-10 carbon atoms, or a group represented by formula (6) (wherein X10 and X11 independently represent a hydrogen atom, a hydroxy group, a saturated or unsaturated linear or branched alkoxy group having 1-10 carbon atoms, or a saturated or unsaturated linear or branched alkyl group having 1-10 carbon atoms)

and Z represents a hydrogen atom or a group represented by formula (3)

wherein X1-X11 may be the same as or different from one another), which is characterized by heating a 4-hydroxysilicic acid compound in the presence of a metal salt.

Priority: JP20110096223 Applic. Date: 2011-04-22; JP20110096216 Applic. Date: 2011-04-22; JP20100264779 Applic. Date: 2010-11-29; JP20100264173 Applic. Date: 2010-11-26; JP20100242673 Applic. Date: 2010-10-28; JP20100242661 Applic. Date: 2010-10-28

Inventor: KISHI AKINOBU [JP]; DOI SATOSHI [JP]; MATSUKAWA TAIJI [JP]; MATSUI TAKEKI [JP]; YAMADA YASUMASA [JP]; YAMADA ICHIRO [JP]


Publication No.: WO2012057417A1  Published: 03/May/2012

Title: COMPOSITION CONTAINING OKAMEJEI KENOJEI EXTRACT

Applicant/Assignee:

Application No.: WO2011KR02269 (PCT/KR2011/02269)   Filing Date: 01/Apr/2011

Abstract:

The present invention relates to a composition containing Okamejei kenojei extract, and more particularly, to a composition which contains Okamejei kenojei extract as an active for treating skin diseases such as acne, treating gray hair caused by skin toxins, relieving pain in the back, knees, and shoulders, and treating toothaches resulting from gum infections as well as fevers associated with rhinovirus and influenza.

Priority: KR20110018808 Applic. Date: 2011-03-03; KR20100107127 Applic. Date: 2010-10-29

Inventor: PARK SOON YONG [KR]


Publication No.: WO2012057895A2  Published: 03/May/2012

Title: COMPOSITION AND METHOD FOR TREATING WOUNDS

Applicant/Assignee: QUINNOVA PHARMACEUTICALS, INC

Application No.: WO2011US46793 (PCT/US2011/46793)   Filing Date: 05/Aug/2011

Abstract:

Provided, among other things, is a method of treating a wound comprising: periodically applying to the wound over a course of days an effective amount of a water based formulation (comprising: 0.5 to 5 wt% of an emollient comprising silicone oil, 2 to 10 wt% of fatty acid, humectant(s), emulsifying agent(s), and polymer(s)), wherein the formulation is formulated as a spray, cream, lotion, milk or foam-former.

Priority: US201113204228 Applic. Date: 2011-08-05; US20100406804P Applic. Date: 2010-10-26

Inventor: HENSBY CHRISTOPHER N [FR]; SILVANDER MATS [SE]


Publication No.: WO2012058526A1  Published: 03/May/2012

Title: INHIBITION OF MICROBIAL GROWTH BY ACONITASE INHIBITION

Applicant/Assignee: THE PROCTER & GAMBLE COMPANY

Application No.: WO2011US58269 (PCT/US2011/58269)   Filing Date: 28/Oct/2011

Abstract:

The present invention is directed to a method of inhibiting aconitase activity of fungal cells in an individual, the method comprising administering an inhibitor of aconitase activity to the fungal cell in an amount effective to inhibit activity of aconitase by said fungal cells.

Priority: US20100407757P Applic. Date: 2010-10-28

Inventor: SCHWARTZ JAMES ROBERT [US]; SAUNDERS CHARLES WINSTON [US]; YOUNGQUIST ROBERT SCOTT [US]


Publication No.: WO2012058722A1  Published: 10/May/2012

Title: METHODS AND COMPOSITIONS FOR MAINTAINING AND IMPROVING THE HEALTH OF SKIN

Applicant/Assignee: CIMTECH PTY LIMITED

Application No.: WO2011AU01410 (PCT/AU2011/01410)   Filing Date: 03/Nov/2011

Abstract:

Biologically active extracts of one or more of Vigna sp., Terminalia sp or Cocos nucifera and compositions comprising one or more of the extracts for the maintenance and improvement of the health and/or appearance of the skin and/or an epidermal appendage are described.

Priority: AU20100904905 Applic. Date: 2010-11-03

Inventor: MATHESON GRAHAM [AU]


Publication No.: WO2012060323A1  Published: 10/May/2012

Title: SKIN AND HAIR COLOR-CONTROLLING FACTOR

Applicant/Assignee: KAO CORPORATION

Application No.: WO2011JP75064 (PCT/JP2011/75064)   Filing Date: 31/Oct/2011

Abstract:

Provided is a gene involved in the regulation of the amount of melanin in keratinocytes and the control of skin and hair color, said gene being selected from the group comprising the ATG7 gene, RAB11A gene, CLIP-170 gene, Rubicon gene, and RAB7B gene, and also provided is a molecule encoded by said gene.

Priority: JP20100245039 Applic. Date: 2010-11-01

Inventor: MURASE DAIKI [US]; HACHIYA AKIRA [JP]


Publication No.: WO2012060832A1  Published: 10/May/2012

Title: SKIN WOUND HEALING COMPOSITIONS AND METHODS OF USE THEREOF

Applicant/Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA

Application No.: WO2010US55319 (PCT/US2010/55319)   Filing Date: 03/Nov/2010

Abstract:

A wound healing composition has a class of polypeptide compounds having a polypeptide chain with 5 to 120 amino acid units per chain. The composition includes a pharmaceutical medium to carry the polypeptide compound, such as an aqueous solution, suspension, dispersion, salve, ointment, gel, cream, lotion, spray or paste. Additionally, a method of applying a wound healing composition comprising a class of polypeptide compounds having a polypeptide chain with 5 to 120 amino acid units per chain in a concentration of from about 1 [mu]g/ml to about 100 [mu]g/ml for a time sufficient to heal the wound is disclosed.

Priority: WO2010US55319 Applic. Date: 2010-11-03

Inventor: CHENG CHIEH-FANG [US]; WOODLEY DAVID T [US]; CHEN MEI [US]; LI WEI [US]


Publication No.: WO2012061630A2  Published: 10/May/2012

Title: COMPOSITION AND METHOD FOR TREATING SKIN CONDITIONS

Applicant/Assignee: 442 VENTURES, LLC

Application No.: WO2011US59206 (PCT/US2011/59206)   Filing Date: 03/Nov/2011

Abstract:

Compositions and methods for treatment of conditions affecting skin and/or mucosal surfaces of a subject that make use of an imidazoquinoline compound and a retinoid agent are described.

Priority: US20100410110P Applic. Date: 2010-11-04

Inventor: JACKSON MARK J [US]


Publication No.: WO2012061698A2  Published: 10/May/2012

Title: COMPOUNDS USEFUL AS MODULATORS OF TRPM8

Applicant/Assignee: SENOMYX, INC

Application No.: WO2011US59312 (PCT/US2011/59312)   Filing Date: 04/Nov/2011

Abstract:

The present invention includes compounds useful as modulators of TRPM8, such as compounds of Formula (I) and the subgenus and species thereof

personal products containing those compounds

and the use of those compounds and the personal products, particularly the use of increasing or inducing chemesthetic sensations, such as cooling or cold sensations.

Priority: US201161443490P Applic. Date: 2011-02-16; US20100410634P Applic. Date: 2010-11-05

Inventor: PRIEST CHAD [US]; NONCOVICH ALAIN [US]; PATRON ANDREW [US]; UNG JANE [US]


Publication No.: WO2012064099A2  Published: 18/May/2012

Title: AROMA COMPOSITION WHEREBY THE FRAGRANCE OF CITRUS UNSHIU OF JEJU ISLAND IS REPRODUCED, AND COMPOSITION CONTAINING SAME FOR EXTERNAL APPLICATION TO THE SKIN

Applicant/Assignee: AMOREPACIFIC CORPORATION

Application No.: WO2011KR08501 (PCT/KR2011/08501)   Filing Date: 09/Nov/2011

Abstract:

The present invention relates to an aroma composition whereby the fragrance of Citrus unshiu of Jeju Island is reproduced, and to a composition containing same for external application to the skin. More particularly, the present invention relates to an aroma composition in which methyl anthranilate is added to the fragrance ingredients of Citrus unshiu of Jeju Island, wherein the fragrance ingredients are analyzed by a solid-phase microextraction (SPME) technique, so as to reproduce the unique fragrance of Citrus unshiu of Jeju Island and achieve superior user preference. The present invention also relates to a composition containing the composition for external application to the skin.

Priority: KR20100112880 Applic. Date: 2010-11-12

Inventor: CHOI JI YOUNG [KR]; KO SEUNG HO [KR]; SEO HYUNG JYE [KR]


Publication No.: WO2012064557A2  Published: 18/May/2012

Title: DEODORIZING COMPOSITIONS

Applicant/Assignee: LIPO CHEMICALS INC

Application No.: WO2011US58892 (PCT/US2011/58892)   Filing Date: 02/Nov/2011

Abstract:

Compositions that inhibit the generation of malodor-causing bacteria present in perspiration are disclosed.

Priority: US20100411259P Applic. Date: 2010-11-08

Inventor: DAYAN NAVA [US]


Publication No.: WO2012065121A2  Published: 18/May/2012

Title: METABOLIZED CONDITIONED GROWTH MEDIUM AND METHODS OF USE

Applicant/Assignee: SKINMEDICA, INC, ARCH PERSONAL CARE PRODUCTS, L.P

Application No.: WO2011US60457 (PCT/US2011/60457)   Filing Date: 11/Nov/2011

Abstract:

Compositions comprising metabolized conditioned growth medium and/or metabolized cell extract and methods of use are described. The metabolized conditioned growth medium and metabolized cell extract compositions may be formulated with an acceptable carrier into injectable or topical formulations, for example, as a cream, lotion or gel, and may be used in cosmeceutical or pharmaceutical applications. The metabolized conditioned growth medium and metabolized cell extract may also be further processed to concentrate or reduce one or more factors or components contained within the metabolized conditioned growth medium or metabolized cell extract. The growth medium may be conditioned by any eukaryotic cell. The metabolized conditioned growth medium and metabolized cell extract may be used to prevent or treat a condition, for example, a skin condition.

Priority: US20100413166P Applic. Date: 2010-11-12

Inventor: GRUBER JAMES VINCENT [US]; RAO SMITHA [US]; MEHTA RAHUL [US]; SONTI SUJATHA [US]


Publication No.: WO2012067404A2  Published: 24/May/2012

Title: COMPOSITION FOR ANTI-AGING CONTAINING ARTEMISIA ANNUA L. AS ACTIVE INGREDIENT

Applicant/Assignee: AMOREPACIFIC CORPORATION

Application No.: WO2011KR08700 (PCT/KR2011/08700)   Filing Date: 15/Nov/2011

Abstract:

A composition for anti-aging containing Artemisia annua L. as an active ingredient of the present invention does not cause any side effects on the skin, and can be usefully applied to an external preparation for the skin for anti-aging and improving wrinkles due to superior effectiveness in accelerating biosynthesis of skin cells and collagen.

Priority: KR20100115393 Applic. Date: 2010-11-19

Inventor: LEE OK CHAN [KR]; RHO HO SIK [KR]; HWANG KYEONG HWAN [KR]; CHO GA YOUNG [KR]; KIM DUCK HEE [KR]; KIM HAN KON [KR]


Publication No.: WO2012068299A2  Published: 24/May/2012

Title: CBP/CATENIN ANTAGONISTS FOR ENHANCING ASYMMETRIC DIVISION OF SOMATIC STEM CELLS

Applicant/Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA

Application No.: WO2011US61062 (PCT/US2011/61062)   Filing Date: 16/Nov/2011

Abstract:

Provided are: methods for treating aging or an age-related condition, symptom or disease

methods for stimulating hair growth, regrowth or pigmentation (or preventing hair loss)

methods for increasing the expression of an adenosine receptor in dermal cells (in combination with hair growth)

methods for treating a condition or disease of the skin or at least one symptom thereof, including cosmetic treatment (e.g., wrinkles, hyperpigmentation, redness, rosacea, dryness, cracking, loss of firmness, loss of elasticity, thinning, and loss of vibrance).

The methods comprise administering a sufficient amount of a CBP/catenin (e.g., CBP/ss-catenin) antagonist as disclosed, and particularly wherein administration is in an amount and manner sufficient to provide for increasing the number of asymmetric renewing divisions relative to, or at the expense of symmetric divisions in relevant somatic stem cell population. In particular aspects, the CBP/catenin (e.g., CBP/ss-catenin) antagonist comprises an alkyl and/or fatty acid ester derivative thereof as disclosed herein.

Priority: US20100414334P Applic. Date: 2010-11-16; US20100414348P Applic. Date: 2010-11-16; US201161545033P Applic. Date: 2011-10-07

Inventor: KAHN MICHAEL [US]; TEO JIA-LING [US]; MCMILLAN MICHAEL [US]; ZHAO YI [US]; WU YONGFENG [US]


Publication No.: WO2012069605A1  Published: 31/May/2012

Title: NOVEL E,E-DIENE COMPOUNDS AND THEIR USE AS MEDICAMENTS AND COSMETICS

Applicant/Assignee: DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL

Application No.: WO2011EP70975 (PCT/EP2011/70975)   Filing Date: 24/Nov/2011

Abstract:

The present invention relates to a novel class of E,E-diene compounds and their use as a medicament, preferably as a dermatologic agent, and as a cosmetic. These novel compounds are particularly useful in treating and/or preventing inflammation, irritation, itching, pruritus, pain, oedema and/or pro-allergic or allergic conditions in a patient. Usually they are topically applied to the skin or mucosa in the form of a pharmaceutical or cosmetic composition comprising the compound and a pharmaceutically and/or cosmetically acceptable carrier.

Priority: US20100417324P Applic. Date: 2010-11-26; EP20100015041 Applic. Date: 2010-11-26

Inventor: SOEBERDT MICHAEL [DE]; KNIE ULRICH [DE]; ABELS CHRISTOPH [DE]


Publication No.: WO2012070971A1  Published: 31/May/2012

Title: COSMETIC AND PHARMACEUTICAL COMPOSITION FOR REJUVENATING AND REGENERATING THE SKIN, INTER ALIA AFTER SURGICAL OPERATIONS

Applicant/Assignee:

Application No.: WO2010RU00697 (PCT/RU2010/00697)   Filing Date: 22/Nov/2010

Abstract:

The invention can be used in pharmaceutics and cosmetology as a medicinal and cosmetic agent for rejuvenating the skin, resolving scars, treating post-operative adhesions, accelerating tissue regeneration in the post-operative period, and eliminating cellulite. According to the invention, the cosmetic and pharmaceutical composition for rejuvenating and regenerating the skin, inter alia after surgical operations, which contains liposomes with proteins, and a method for producing same are characterized in that a system based on various ratios of hyaluronidase, insulin and collagenase, which are partially acylated with the substitution of from 0 to 10% of the protein mass, is used as the proteins. The composition in the form of a rejuvenating cosmetic cream can be produced industrially in sufficient amounts on account of the availability of all of the ingredients of the composition.

Priority: WO2010RU00697 Applic. Date: 2010-11-22

Inventor: FARBER BORIS SLAVINOVICH [RU]; FARBER SOF YA BORISOVNA [RU]; MARTYNOV ARTUR VIKTOROVICH [UA]; SITENKO ALEKSANDR NIKOLAEVICH [UA]


Publication No.: WO2012071042A1  Published: 31/May/2012

Title: COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING LUPUS

Applicant/Assignee: GOVERNMENT OF THE U.S.A. REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH & HUMAN SERVICES

Application No.: WO2010US58077 (PCT/US2010/58077)   Filing Date: 24/Nov/2010

Abstract:

The invention features compositions comprising agents that inhibit or reduce self-reactive IgE and/or basophils, and related methods of using the compositions for treating or preventing lupus, lupus nephritis, and lupus-related disorders.

Priority: WO2010US58077 Applic. Date: 2010-11-24

Inventor: RIVER JUAN [US]; CHARLES NICOLAS [FR]


Publication No.: WO2012071654A1  Published: 07/Jun/2012

Title: TREATMENT AND PREVENTION OF ECZEMA

Applicant/Assignee: BIO-K PLUS INTERNATIONAL INC

Application No.: WO2011CA01319 (PCT/CA2011/01319)   Filing Date: 29/Nov/2011

Abstract:

The present invention broadly relates to the use of probiotics for the treatment and prevention of dermatitis. More particularly, the present invention relates to the use of a composition comprising Lactobacillus acidophilus strain I-1492 deposited at the CNCM, a Lactobacillus casei LBC80R TM strain and a carrier for treating or preventing hand dermatitis.

Priority: US20100418158P Applic. Date: 2010-11-30

Inventor: CHEVALIER CLAUDE [CA]; CARRIERE SERGE [CA]


Publication No.: WO2012073184A1  Published: 07/Jun/2012

Title: QUINOLIN-4 (1H) -ONE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASES

Applicant/Assignee: UNIVERSITA DEGLI STUDI DI TORINO, UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE "AMEDEO AVOGADRO"

Application No.: WO2011IB55346 (PCT/IB2011/55346)   Filing Date: 28/Nov/2011

Abstract:

Compounds of Formula (I): able to inhibit kinase activity, in particular Phosphatidylinositol 3-Kinases activity. The disclosure also relates to the use of compounds of Formula (I) for treatment of pathological conditions associated to alterations in Phosphatidylinositol 3-Kinases activity.

Priority: IT2010TO00956 Applic. Date: 2010-12-01

Inventor: SORBA GIOVANNI [IT]; TRON GIAN CESARE [IT]; GALLI UBALDINA [IT]; MASSAROTTI ALBERTO [IT]; HIRSCH EMILIO [IT]; CIRAOLO ELISA [IT]; PIRALI TRACEY [IT]


Publication No.: WO2012074037A1  Published: 07/Jun/2012

Title: BREAST ENHANCEMENT ACCELERATOR

Applicant/Assignee: SOFSERA CORPORATION

Application No.: WO2011JP77743 (PCT/JP2011/77743)   Filing Date: 01/Dec/2011

Abstract:

[Problem] To provide a novel breast enhancement accelerator. [Solution] The present inventor perfected the present invention having discovered a novel attribute in which collagen production is accelerated when calcium phosphate microparticles come into contact with fibroblasts, and having further discovered a novel attribute in which breast enhancement effect is obtained by application of such microparticles to the breasts. More specifically, the present invention is a breast enhancement accelerator characterized by containing calcium phosphate microparticles.

Priority: JP20100268837 Applic. Date: 2010-12-01

Inventor: KAWABE KARL KAZUSHIGE [JP]; KOGAI YASUMICHI [JP]; ISHIKAWA YUMIKO [JP]; KOMAMI AYA [JP]


Publication No.: WO2012074187A1  Published: 07/Jun/2012

Title: PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AUTOPHAGY-RELATED DISEASES, ANGIOGENIC DISEASES OR MELANIN-RELATED DISEASES

Applicant/Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY

Application No.: WO2011KR06581 (PCT/KR2011/06581)   Filing Date: 06/Sep/2011

Abstract:

The present invention relates to a pharmaceutical composition for preventing or treating autophagy-related diseases, angiogenic diseases or hypermelanosis, comprising: (a) a pharmaceutically effective amount of an indatraline derivative or a pharmaceutically acceptable salt thereof

and a pharmaceutically acceptable carrier. The composition of the present invention effectively induces autophagy of cells, and thus is very effective for preventing or treating autophagy-related diseases. In addition, the composition of the present invention inhibits angiogenesis through the mechanism of inhibiting angiogenesis, invasion and metastasis and inhibits melanogenesis, and thus can also be effective for preventing or treating angiogenic diseases or melanin-related diseases.

Priority: KR20100120398 Applic. Date: 2010-11-30

Inventor: KWON HO JEONG [KR]; CHO YOON SUN [KR]


Publication No.: WO2012074926A1  Published: 07/Jun/2012

Title: NOVEL AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS

Applicant/Assignee: ALLERGAN, INC

Application No.: WO2011US62241 (PCT/US2011/62241)   Filing Date: 28/Nov/2011

Abstract:

The present invention relates to novel azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

Priority: US20100419288P Applic. Date: 2010-12-03

Inventor: SINHA SANTOSH C [US]; BHAT SMITA S [US]; CORPUZ EVELYN G [US]; CHOW KEN [US]; FANG WENKUI K [US]; IM WHA BIN [US]


Publication No.: WO2012076321A1  Published: 14/Jun/2012

Title: OLIGOSACCHARIDE COMPOSITION FOR TREATING SKIN DISEASES

Applicant/Assignee: NESTEC S.A

Application No.: WO2011EP70561 (PCT/EP2011/70561)   Filing Date: 21/Nov/2011

Abstract:

The invention discloses a composition comprising at least one N-acetyl-lactosamine, at least one sialylated oligosaccharide and at least one fucosylated oligosaccharide, for use in the prevention and/or treatment of skin conditions and skin diseases. Preferably said composition is a starter infant formula. Said skin disease is in particular atopic dermatitis.

Priority: EP20100192227 Applic. Date: 2010-11-23

Inventor: SPRENGER NORBERT [CH]


Publication No.: WO2012076322A1  Published: 14/Jun/2012

Title: COMPOSITION COMPRISING HYDROLYSED PROTEINS AND OLIGOSACCHARIDES FOR TREATING SKIN DISEASES

Applicant/Assignee: NESTEC S.A

Application No.: WO2011EP70562 (PCT/EP2011/70562)   Filing Date: 21/Nov/2011

Abstract:

The invention discloses a composition comprising at least one N-acetyl lactosamine, at least one sialylated oligosaccharide and at least one fucosylated oligosaccharide, and a hydrolysate comprising partially and/or extensively hydrolysed proteins, for use in the prevention and/or treatment of skin conditions and skin diseases. Preferably said composition is a starter infant formula. Said skin disease is in particular atopic dermatitis.

Priority: EP20100192229 Applic. Date: 2010-11-23

Inventor: SPRENGER NORBERT [CH]


Publication No.: WO2012076352A1  Published: 14/Jun/2012

Title: COMPOSITION FOR TOPICAL USE FOR TREATING SKIN DISORDERS

Applicant/Assignee: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A

Application No.: WO2011EP71151 (PCT/EP2011/71151)   Filing Date: 28/Nov/2011

Abstract:

It is described a composition, topically administrable, comprising as active ingredients L- carnitine o a derivative thereof, biotin, and at least one or more of the following active ingredients: vitamin B 12

vitamin E

bisabolol

and panthenol

useful for treating skin disorders.

Priority: EP20100194329 Applic. Date: 2010-12-09

Inventor: KOVERECH ALEARDO [IT]; VIRMANI ASHRAF [IT]


Publication No.: WO2012076985A2  Published: 14/Jun/2012

Title: GRANZYME B INHIBITOR COMPOSITIONS, METHODS AND USES FOR PROMOTING WOUND HEALING

Applicant/Assignee: THE UNIVERSITY OF BRITISH COLUMBIA

Application No.: WO2011IB03207 (PCT/IB2011/03207)   Filing Date: 06/Dec/2011

Abstract:

Methods of promoting wound healing in a subject is disclosed. The method include applying a Granzyme B (Granzyme B) inhibitor to the wound. The wound may be a skin wound. The Granzyme B inhibitor may be comprised of nucleic acids, or peptides, including but not limited to antibodies, or small molecules.

Priority: US20100420230P Applic. Date: 2010-12-06; US201161493265P Applic. Date: 2011-06-03

Inventor: HIEBERT PAUL R [CA]; KNIGHT DARRYL A [CA]; GRANVILLE DAVID J [CA]; BOIVIN WENDY A [CA]; COOPER DAWN M [CA]


Publication No.: WO2012078072A1  Published: 14/Jun/2012

Title: MEDICINAL PREPARATION, METHOD FOR PRODUCING THE MEDICINAL PREPARATION AND METHOD FOR THE USE THEREOF

Applicant/Assignee: OBSCHESTVO S OGRANITCHENNOI OTVETSTVENNOSTJU "OXYGON"

Application No.: WO2011RU00260 (PCT/RU2011/00260)   Filing Date: 22/Apr/2011

Abstract:

What is claimed is a medicinal preparation produced by the interaction of a selenium-containing compound with alpha, alpha-dichlorocarboxylic acid stabilized with a maximum of 5% by mass, preferably 1-3% by mass, of nitric acid. The selenium-containing compound used for the interaction is a maximum of 20.0% by mass, preferably 0.5-10.0% by mass, of a solution of selenious acid. The preparation may additionally comprise 5-20% of dimethyl sulphoxide. The method for producing the medicinal preparation involves interacting the selenium-containing compound with alpha, alpha-dichloropropionic acid stabilized with a maximum of 5% by mass, preferably 1-3% by mass, of nitric acid, wherein the selenium-containing compound used for the interaction is 0.5-20.0% by mass, preferably 0.5-10.0% by mass, of a solution of selenious acid, and the interaction is carried out at a temperature not higher than 70 DEG C, preferably at 20-30 DEG C. When the medicinal preparation is used for treating benign, viral, premalignant and malignant nonmetastasizing skin lesions, dyplastic lesions of the visible mucous membranes and other skin lesions, said preparation is applied to the lesion site for 1, 2-3, 7-9 and 22-24 days of treatment.

Priority: RU20100150315 Applic. Date: 2010-12-09

Inventor: MARDI SHALVA IOSIFOVITCH [CH]; USTYNYUK LEV ALEXANDROVICH [RU]


Publication No.: WO2012078574A2  Published: 14/Jun/2012

Title: JANUS KINASE 2 (JAK2) INHIBITOR FOR THE TREATMENT OF LUPUS

Applicant/Assignee: CEPHALON, INC

Application No.: WO2011US63427 (PCT/US2011/63427)   Filing Date: 06/Dec/2011

Abstract:

The present invention provides a method for treating lupus in a subject, comprising the step of administering to the subject COMPOUND A.

Priority: US20100420053P Applic. Date: 2010-12-06; US20100420967P Applic. Date: 2010-12-08

Inventor: DOBRZANSKI PAWEL T [US]; SEAVEY MATTHEW M [US]


Publication No.: WO2012078999A1  Published: 14/Jun/2012

Title: COMPOSITIONS FOR TREATING DERMATITIS AND ICHTHYOSIS, AND METHODS FOR TREATING DERMATITIS AND ICHTHYOSIS

Applicant/Assignee: SKINVISIBLE PHARMACEUTICALS, INC

Application No.: WO2011US64190 (PCT/US2011/64190)   Filing Date: 09/Dec/2011

Abstract:

A skin disorder treatment composition and method for treating a skin disorder or symptoms of a skin disorder are provided. The composition includes: about 0.0001 wt.% to about 5 wt.% of a serine protease inhibitor

about 2 wt.% to about 10 wt.% of a hydrophobic polymer/hydrophilic polymer complex comprising a poly(vinylpyrrolidone-alkylene) polymer wherein the alkylene group contains at least 10 carbon atoms and a cellulose containing polymer

about 0.5 wt.% to about 20 wt.% of a release agent

and at least about 50 wt.% water. The skin disorder or the symptom of skin disorder from ichthyosis, dermatitis, eczema, rosacea, psoriasis, inflammation, xerosis, or urticaria.

Priority: US20100421823P Applic. Date: 2010-12-10

Inventor: ROSZELL JAMES A [US]


Publication No.: WO2012080333A1  Published: 21/Jun/2012

Title: COMPOSITIONS BASED ON CLAY AND BEE POLLEN, METHOD FOR PREPARING SAME, AND NUTRITIONAL AND THERAPEUTIC USES THEREOF

Applicant/Assignee: LABORATOIRE BEEPRATTE

Application No.: WO2011EP72756 (PCT/EP2011/72756)   Filing Date: 14/Dec/2011

Abstract:

The present invention relates to complexes of bee pollen and of clay, and also to the method for preparing same and to the uses thereof in therapy or as a food supplement or functional food, in human and animal health.

Priority: FR20100060511 Applic. Date: 2010-12-14

Inventor: FREGONESE ALEXANDRA [FR]


Publication No.: WO2012080466A2  Published: 21/Jun/2012

Title: INGENOLS FOR TREATING SEBORRHEIC KERATOSIS

Applicant/Assignee: LEO PHARMA A/S

Application No.: WO2011EP73046 (PCT/EP2011/73046)   Filing Date: 16/Dec/2011

Abstract:

The invention provides ingenol compounds for treating seborrheic keratosis.

Priority: US201061424409P Applic. Date: 2010-12-17

Inventor: ZIBERT JOHN [DK]; SKAK KRESTEN [DK]; BOE INGE [DK]


Publication No.: WO2012083341A1  Published: 28/Jun/2012

Title: COMPOSITION FOR THE TREATMENT OF SKIN CONDITIONS

Applicant/Assignee:

Application No.: WO2011AU01567 (PCT/AU2011/01567)   Filing Date: 01/Dec/2011

Abstract:

A topical composition for the treatment of skin conditions. The composition comprises an antifungal agent, an anti-inflammatory agent and an antimicrobial agent together with a pharmaceutically acceptable excipient. The anti-inflammatory is present at a concentration of less than 0.01%wt of the composition and the antimicrobial agent has the general formula (I) : (Formula (I)).

Priority: AU20100905529 Applic. Date: 2010-12-20; AU20100905707 Applic. Date: 2010-12-24

Inventor: LE ANDREW TUAN ANH [AU]


Publication No.: WO2012083385A1  Published: 28/Jun/2012

Title: SERINE PROTEASE INHIBITORS

Applicant/Assignee: QUEENSLAND UNIVERSITY OF TECHNOLOGY

Application No.: WO2011AU01691 (PCT/AU2011/01691)   Filing Date: 23/Dec/2011

Abstract:

The invention relates to KLK protease inhibitors. In particular, the invention is directed to KLK14, KLK7 and/or KLK5 protease inhibitors and their uses in the diagnosis, prevention or treatment of a skin disease or pathology, or other undesirable skin condition.

Priority: US201061426651P Applic. Date: 2010-12-23; AU20110900234 Applic. Date: 2011-01-25

Inventor: HARRIS JONATHAN MALCOLM [AU]; DE VEER SIMON JOHN [AU]; SWEDBERG JOAKIM ERIK [AU]


Publication No.: WO2012083397A1  Published: 28/Jun/2012

Title: GUANABENZ-CONTAINING COMPOUND FOR THE TREATMENT OF PRIMARY CUTANEOUS AMYLOIDOSIS

Applicant/Assignee: SILVESTRE LABS QUIMIA E FARMACEUTICA LTDA, SILVESTRE LABS QUIMICA E FARMACEUTICA LTDA

Application No.: WO2011BR00480 (PCT/BR2011/00480)   Filing Date: 20/Dec/2011

Abstract:

This invention refers to the pharmaceutical composition with guanabenz as active ingredient and is indicated for the treatment of primary cutaneous amyloidosis. The composition of this invention can be supplied as cream, gel, jelly cream, ointment, lotion or any other dosage form intended for topical use.

Priority: WO2011BR00480 Applic. Date: 2011-12-20

Inventor: SANTOS OMAR DA ROSA [BR]; DA CRUZ LUIS EDUARDO [BR]


Publication No.: WO2012084869A1  Published: 28/Jun/2012

Title: MODULATORS OF TRPA1 FOR THE TREATMENT OF ROSACEA

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT, UNIVERSITAT MUNSTER

Application No.: WO2011EP73299 (PCT/EP2011/73299)   Filing Date: 19/Dec/2011

Abstract:

An in vitro method of screening of candidate compounds for the preventive or curative treatment of rosacea includes determination of the capacity of a compound to modulate the expression or activity of the Transient Receptor Potential cation channel, subfamily A, member 1(TRPA1), as well as the use of modulators of the expression or activity of this transcription factor for the treatment of rosacea

such method also includes in vitro diagnosis or prognosis of this pathology.

Priority: US201061457076P Applic. Date: 2010-12-22

Inventor: AUBERT JEROME [FR]; STEINHOFF MARTIN [US]


Publication No.: WO2012084870A1  Published: 28/Jun/2012

Title: MODULATORS AND METHODS FOR THE TREATMENT OF ROSACEA

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT, UNIVERSITAT MUNSTER

Application No.: WO2011EP73300 (PCT/EP2011/73300)   Filing Date: 19/Dec/2011

Abstract:

An in vitro method of screening of candidate compounds for the preventive or curative treatment of rosacea includes determination of the capacity of a compound to modulate the expression or activity of the Transient Receptor Potential (TRPs), as well as the use of modulators of the expression or activity of this transcription factor for the treatment of rosacea

such method also includes in vitro diagnosis or prognosis of this pathology.

Priority: US201061457077P Applic. Date: 2010-12-22

Inventor: AUBERT JEROME [FR]; STEINHOFF MARTIN [US]


Publication No.: WO2012085182A1  Published: 28/Jun/2012

Title: NOVEL BACTERIUM AND EXTRACTS OF SAID BACTERIUM AND THE USE OF SAME IN DERMATOLOGY

Applicant/Assignee: PIERRE FABRE DERMO-COSMETIQUE, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

Application No.: WO2011EP73747 (PCT/EP2011/73747)   Filing Date: 22/Dec/2011

Abstract:

The present invention relates to a novel bacterial strain isolated from groundwater. The invention also relates to bacterial extracts and to the use of same in the context of the treatment of inflammations. More particularly, the present invention relates to novel compositions of interest in the treatment and the prevention of inflammatory disorders, notably dermatological pathologies.

Priority: FR20100061081 Applic. Date: 2010-12-22

Inventor: LEBARON PHILIPPE [FR]; BOURRAIN MURIEL [FR]; CASTEX-RIZZI NATHALIE [FR]; NGUYEN THIEN [FR]


Publication No.: WO2012085224A1  Published: 28/Jun/2012

Title: AVOCADO FLESH AND/OR SKIN EXTRACT RICH IN POLYPHENOLS AND COSMETIC, DERMATOLOGICAL AND NUTRACEUTICAL COMPOSITIONS COMPRISING SAME

Applicant/Assignee: LABORATOIRES EXPANSCIENCE

Application No.: WO2011EP73832 (PCT/EP2011/73832)   Filing Date: 22/Dec/2011

Abstract:

The invention relates to an avocado extract rich in polyphenols, containing at least 10% by weight of polyphenols, expressed in gallic acid equivalent relative to the dry extract obtained, wherein said polyphenols contain procyanidins, cafeic acid and cafeic acid derivatives, typically in a proportion of at least 70% by weight, expressed in gallic acid equivalent relative to the total polyphenol content by weight. The invention also relates to a composition comprising an extract according to the invention as active agent and a suitable excipient. The invention also relates to such a composition or such an extract for use thereof in preventing or treating disorders or pathological conditions of the skin, the mucous membranes or the superficial body growths. Finally, the invention relates to a cosmetic care process for the skin, the superficial body growths or the mucous membranes, with a view to improving the condition thereof or the appearance thereof, which consists in administering such a composition or such an extract.

Priority: FR20100061055 Applic. Date: 2010-12-22

Inventor: SAUNOIS ALEX [FR]; BAUDOUIN CAROLINE [FR]; LECLERE-BIENFAIT SOPHIE [FR]; GARNIER SEBASTIEN [FR]; MSIKA PHILIPPE [FR]


Publication No.: WO2012085226A1  Published: 28/Jun/2012

Title: EXTRACT OF AERIAL PARTS OF MACA RICH IN POLYPHENOLS AND COMPOSITION COMPRISING SAME

Applicant/Assignee: LABORATOIRES EXPANSCIENCE

Application No.: WO2011EP73834 (PCT/EP2011/73834)   Filing Date: 22/Dec/2011

Abstract:

The invention relates to an extract of aerial parts of Maca rich in polyphenols, and also to a composition comprising such an extract and, where appropriate, a suitable excipient. The invention also relates to a process for extracting an extract of aerial parts of Maca rich in polyphenols, and also to the extract that can be obtained by means of said process. The invention also relates to such a composition or such an extract for use thereof in preventing or treating disorders or pathological conditions of the skin, the mucous membranes or the superficial body growths and/or for use thereof in preventing and/or treating vascular disorders. Finally, the invention relates to a cosmetic care process for the skin, the superficial body growths or the mucous membranes, with a view to improving the condition thereof or the appearance thereof, which comprises the administration of such a composition or of such an extract.

Priority: FR20100061047 Applic. Date: 2010-12-22

Inventor: SAUNOIS ALEX [FR]; BAUDOUIN CAROLINE [FR]; LECLERE-BIENFAIT SOPHIE [FR]; GARNIER SEBASTIEN [FR]; MSIKA PHILIPPE [FR]


Publication No.: WO2012085230A1  Published: 28/Jun/2012

Title: EXTRACT OF THE ABOVE-GROUND PORTIONS OF GYNANDROPSIS GYNANDRA OR CLEOME GYNANDRA, AND COSMETIC, DERMATOLOGICAL OR PHARMACEUTICAL COMPOSITIONS INCLUDING SAME

Applicant/Assignee: LABORATOIRES EXPANSCIENCE

Application No.: WO2011EP73838 (PCT/EP2011/73838)   Filing Date: 22/Dec/2011

Abstract:

The invention relates to a composition, such as a cosmetic, dermatological, or pharmaceutical composition, including an extract of the above-ground portions of Gynandropsis gynandra, advantageously the leaves and, optionally, a suitable carrier. The invention also relates to such a composition or such an extract to be used in the prevention or treatment of disorders or diseases of the skin, mucous membranes, or nails and hair, to be used in the prevention or treatment of vascular disorders and/or problems linked to hyperseborrhea, or further to be used as an anti-ageing, healing, moisturising, slimming and/or anti-cellulite, anti-allergy and pro-pigmenting product. Finally, the invention relates to a cosmetic care method for the skin, nails and hair, or mucous membranes, with a view to improving the condition or appearance thereof, consisting of administering such a composition or such an extract.

Priority: FR20100061051 Applic. Date: 2010-12-22

Inventor: MSIKA PHILIPPE [FR]; SAUNOIS ALEX [FR]; BAUDOUIN CAROLINE [FR]; LECLERE-BIENFAIT SOPHIE [FR]; DEBROCK SEBASTIEN [FR]


Publication No.: WO2012086760A1  Published: 28/Jun/2012

Title: DISINFECTANT

Applicant/Assignee: MEIJI SEIKA PHARMA CO., LTD

Application No.: WO2011JP79822 (PCT/JP2011/79822)   Filing Date: 22/Dec/2011

Abstract:

Disclosed is a disinfectant (disinfecting composition) comprising iodophor, a polar solvent and a cellulose-type viscosity modifier. The disinfectant (disinfecting composition) rarely undergoes the significant decrease in content of effective iodine which may occur over time, can be held on hands and fingers reliably, does not give chapped hands, can keep a skin-moisturizing effect, is not sticky for the skin, and has excellent safety and usability.

Priority: JP20100287280 Applic. Date: 2010-12-24

Inventor: KOBAYASHI HIROKAZU [JP]; KUBOTA NOBUO [JP]; HIRAKAWA YUMIE [JP]; FUKAI YOSHIHISA [JP]; SUZUKI SHIGEKI [JP]


Publication No.: WO2012087823A2  Published: 28/Jun/2012

Title: PH-INDUCED SILK FIBROIN GELS AND USES THEREOF

Applicant/Assignee: TRUSTEES OF TUFTS COLLEGE

Application No.: WO2011US65488 (PCT/US2011/65488)   Filing Date: 16/Dec/2011

Abstract:

This invention provides for compositions, methods and devices for preparing an adhesive comprising a silk fibroin-based gel and uses thereof. The silk fibroin-based gel can be formed due to reduced local or bulk pH of the silk fibroin solution, e.g., by reducing the pH of the silk fibroin solution to an acidic pH. In some embodiments, the silk fibroin-based gel can be reversibly converted back to a solution state. Active agents can be embedded in the silk gel for various medical applications.

Priority: US2010-974796 Applic. Date: 2010-12-21

Inventor: KAPLAN DAVID L [US]; YUCEL TUNA [US]


Publication No.: WO2012088382A2  Published: 28/Jun/2012

Title: AMYRIS ALCOHOL AND ITS ESTER FOR TREATING ACNE

Applicant/Assignee: TRINITY LABORATORIES, INC

Application No.: WO2011US66751 (PCT/US2011/66751)   Filing Date: 22/Dec/2011

Abstract:

The present invention relates to formulations comprising amyris alcohol or an ester of amyris alcohol or combinations thereof to treat acne in humans. These formulations can further comprise a phytoestrogen such as glabridin and miroestrol, an antioxidant such as tetrahydrocurcumin and naturally occurring peroxides such as artemisinin and dihydroartemisinin and combinations therof for improved effectiveness in treating acne.

Priority: US201061425916P Applic. Date: 2010-12-22

Inventor: SINGH CHANDRA ULAGARAJ [US]; NULU JAGAVEERABHADRA RAO [US]


Publication No.: WO2012089808A1  Published: 05/Jul/2012

Title: NEW ALLIUM PORRUM L. EXTRACT WITH POWERFUL CICATRIZANT, ANTI-INFLAMMATORY AND ANTI-MICROBIC ACTIVITY, FOR CUTANEOUS LESION TREATING AND ITS PREPARATION METHOD

Applicant/Assignee: RI.MOS. S.R.L

Application No.: WO2011EP74231 (PCT/EP2011/74231)   Filing Date: 29/Dec/2011

Abstract:

The invention refers to an innovative oil extract of plants of the Allium porrum L species with powerful cicatrizing activity, (cellular regeneration), to its preparation method and to its therapeutic use for cutaneous injuries treating deriving from wounded, burns, injuries supported by virus microbial agents, bacteria and derived from mycosis, and also injuries supported by circulatory problems, among which bedsores, in both veterinary and human field.

Priority: IT2010LU00015 Applic. Date: 2010-12-30

Inventor: CASELLA SERGIO [IT]; PISTELLI LUISA [IT]


Publication No.: WO2012090205A2  Published: 05/Jul/2012

Title: PLANT EXTRACTS FOR THE TREATMENT AND PREVENTION OF INFECTIONS

Applicant/Assignee: KAMEDIS LTD, BIO-FD&C CO. LTD

Application No.: WO2011IL50081 (PCT/IL2011/50081)   Filing Date: 28/Dec/2011

Abstract:

A composition comprising a Sanguisorbae officinalis plant extract and at least one additional plant extract selected from the group consisting of an Ailanthus altissima plant extract, a Galla rhois gallnut plant extract, a Glycyrrhiza Glabra plant extract, a Rheum palmatum plant extract and a Scutellaria baicalensis plant extract is disclosed. Compositions comprising Ailanthus altissima plant extract or Ailanthone are also disclosed.

Priority: US201061427495P Applic. Date: 2010-12-28

Inventor: ROZENBLAT SHARON [IL]; JUNG DAIHYUN [KR]; MOH SANGHYUN [KR]; KIM SUJUNG [KR]; LEE JUNGHUN [KR]


Publication No.: WO2012091730A2  Published: 05/Jul/2012

Title: INDOLE ALKALOID COMPOUNDS AS MELANOGENESIS PROMOTERS AND USES THEREOF

Applicant/Assignee: NEW YORK UNIVERSITY

Application No.: WO2011US01915 (PCT/US2011/01915)   Filing Date: 16/Nov/2011

Abstract:

Provided are indole alkaloid compounds of formula I, for example, pubescine, and the use of such compounds and compositions thereof to promote (e.g., enhance) melanogenesis and pigmentation. Also provided are plant extracts containing a compound of formula I, for example, pubescine, and the use of such a plant extract to promote (e.g., enhance) melanogenesis and pigmentation. The compound or plant extract may be prepared as pharmaceutical and cosmetic compositions, and may be used for the prevention and treatment of conditions that are related to aberrant melanogenesis activity.

Priority: US20100414156P Applic. Date: 2010-11-16

Inventor: ORLOW SETH J [US]; KOMATSU LI NI [US]


Publication No.: WO2012092202A2  Published: 05/Jul/2012

Title: MODULATION OF SIDE EFFECT PROFILE OF 5-ALPHA REDUCTASE INHIBITOR THERAPY

Applicant/Assignee: SOV THERAPEUTICS

Application No.: WO2011US67204 (PCT/US2011/67204)   Filing Date: 23/Dec/2011

Abstract:

Methods for modulating one or more side effects of 5-a-reductase inhibitor therapy are provided, where the method includes administering a 5-a-reductase inhibitor and testosterone undecanoate. Also provided are methods of maintaining or restoring a DHT serum level in an individual undergoing 5-a-reductase inhibitor therapy, where the method includes administering testosterone undecanoate in addition to 5-a-reductase inhibitor. Further provided are methods of treating or preventing a DHT -related condition, such as benign prostate hyperplasia (BPH) or prostate cancer by administering a 5-a-reductase inhibitor and testosterone undecanoate.

Priority: US201113174756 Applic. Date: 2011-06-30; US2010-983216 Applic. Date: 2010-12-31

Inventor: DHINGRA OM [US]; BERNSTEIN JAMES S [US]


Publication No.: WO2012092389A2  Published: 05/Jul/2012

Title: SEBUM CONTROL AND ANTI-ACNE COMPOSITION

Applicant/Assignee: MARY KAY INC

Application No.: WO2011US67635 (PCT/US2011/67635)   Filing Date: 28/Dec/2011

Abstract:

Compositions that include Psidium guajava fruit extract or Kunzea ericoides leaf extract or both for reducing sebum production in sebaceous glands are disclosed.

Priority: US201061428740P Applic. Date: 2010-12-30; US201061427736P Applic. Date: 2010-12-28

Inventor: FLORENCE TIFFANY [US]


Publication No.: WO2012092597A2  Published: 05/Jul/2012

Title: MULTI-PURPOSE COSMETIC COMPOSITIONS

Applicant/Assignee: MARY KAY INC

Application No.: WO2011US68190 (PCT/US2011/68190)   Filing Date: 30/Dec/2011

Abstract:

Disclosed are compositions and methods of their use that include an effective amount of Silybum marianum extract and either one of or both of Momordica grosvenori fruit extract or Pseudopterogorgia elisabethae extract.

Priority: US201061428740P Applic. Date: 2010-12-30

Inventor: FLORENCE TIFFANY [US]; HINES MICHELLE [US]; GAN DAVID [US]


Publication No.: WO2012092628A2  Published: 05/Jul/2012

Title: PATCHES AND METHODS FOR THE TRANSDERMAL DELIVERY OF AGENTS TO TREAT HAIR LOSS

Applicant/Assignee: INCUBE LABS, LLC

Application No.: WO2012US20116 (PCT/US2012/20116)   Filing Date: 03/Jan/2012

Abstract:

Embodiments of the invention provide patches for the transdermal delivery of compositions to treat an individual suffering from hair loss. Many embodiments provide an iontophoretic patch for the transdermal delivery hair growth stimulating agents for the treatment of hair loss by stimulating the growth of new hair in areas of the scalp exhibiting hair loss. The patch comprises an electrode and a reservoir containing a composition comprising iron containing compound, such as a chelated iron compound for the delivery of the therapeutically effective amount of iron. The patch can be shaped to be placed and remain on the head. Various embodiments provide methods of using embodiments of the iontophoretic patch for delivering a hair growth stimulating agent such as a chelated iron compound, minoxidil and finasteride to the scalp and other areas exhibiting hair loss.

Such methods can be used for re-growing hair, and/or preventing or slowing hair loss.

Priority: US201061460385P Applic. Date: 2010-12-31

Inventor: IMRAN MIR [US]; MORGAN PHIL [US]; HASHIM MIR [US]; HARRIS JOEL [US]


Publication No.: WO2012093169A1  Published: 12/Jul/2012

Title: NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF

Applicant/Assignee: LEO PHARMA A/S

Application No.: WO2012EP50187 (PCT/EP2012/50187)   Filing Date: 06/Jan/2012

Abstract:

The invention relates to compounds of general Formula (I), Wherein R1, R2, R3, R4, R5, m, n are defined herein, and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates thereof, for use - alone or in combination with one or more other pharmaceutically active compounds- in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disesase, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immunosuppression would be desirable for example in organ transplantation.

Priority: US201161430670P Applic. Date: 2011-01-07

Inventor: SCHOU SOEREN CHRISTIAN [DK]; GREVE DANIEL RODRIGUEZ [DK]; NIELSEN SIMON FELDBAEK [DK]; JENSEN JENS BJOERN [DK]; DACK KEVIN NEIL [DK]


Publication No.: WO2012093738A1  Published: 12/Jul/2012

Title: COMPOSITION FOR COMBATING OXIDATION AND ALLEVIATING DETRIMENTAL EFFECTS ON SKIN CAUSED BY ASIAN DUST

Applicant/Assignee: AMOREPACIFIC CORPORATION

Application No.: WO2011KR00010 (PCT/KR2011/00010)   Filing Date: 03/Jan/2011

Abstract:

The present invention relates to a composition for combating oxidation and alleviating the detrimental effects on skin caused by Asian Dust, the composition containing Melia azedarach bark and Nelumbo nucifera leaf extracts as a novel skin irritation alleviating agent. More specifically, the present invention contains Melia azedarach bark and Nelumbo nucifera leaf extracts, and entails: detoxification and expulsion of toxins by increasing the expression of NQO1 which is an enzyme that detoxifies toxins and of GSTT1 which is an enzyme that expels toxins

protection of the skin by increasing the expression of the skin antimicrobial peptide hBD3 which is a natural immune factor

and suppression of the production of active oxygen by increasing expression of the antioxidant proteins GPX1, catalase, Trx1 and Prdx1. Consequently, the invention has the advantages of skin protection and ageing suppression.

Priority: WO2011KR00010 Applic. Date: 2011-01-03

Inventor: CHOI HYUN [KR]; KIM SUN MI [KR]; MOON SUNG HO [KR]; LIM HYUNG JUN [KR]; KIM JI HYUN [KR]; LEE TAE RYONG [KR]; SHIN DONG WOOK [KR]; KANG HAK HEE [KR]


Publication No.: WO2012094009A2  Published: 12/Jul/2012

Title: METHODS OF REDUCING SURGICAL SITE INFECTION

Applicant/Assignee: CAREFUSION, INC

Application No.: WO2011US20391 (PCT/US2011/20391)   Filing Date: 06/Jan/2011

Abstract:

Priority: WO2011US20391 Applic. Date: 2011-01-06

Inventor: DAROUICHE RABIH O [US]


Publication No.: WO2012096463A2  Published: 19/Jul/2012

Title: COMPOSITION CONTAINING A MIXED HERBAL EXTRACT AS AN ACTIVE INGREDIENT FOR PREVENTING AND IMPROVING ALLERGIC OR NON-ALLERGIC SKIN DISEASE, AND USES THEREOF

Applicant/Assignee: DAEJEON UNIVERSITIY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION

Application No.: WO2011KR10247 (PCT/KR2011/10247)   Filing Date: 28/Dec/2011

Abstract:

The present invention relates to a composition containing a mixed herbal extract which is effective for treating and preventing allergic or non-allergic skin disease.

Priority: KR20110003477 Applic. Date: 2011-01-13; KR20110003478 Applic. Date: 2011-01-13

Inventor: JIN MIRIM [KR]


Publication No.: WO2012097052A2  Published: 19/Jul/2012

Title: MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES

Applicant/Assignee: INTERTECH BIO, LLC

Application No.: WO2012US20920 (PCT/US2012/20920)   Filing Date: 11/Jan/2012

Abstract:

The present invention relates to compounds and methods which may be useful as inhibitors of glycolysis, inhibitors of protein glycosylation, anti-virals, and down-regulators of insulin receptor and IGF- 1 receptor for the treatment or prevention of inflammatory dermatological diseases or proliferative dermatological diseases.

Priority: US201161431731P Applic. Date: 2011-01-11

Inventor: PRIEBE WALDEMAR [US]


Publication No.: WO2012097579A1  Published: 26/Jul/2012

Title: PHARMACEUTICAL COMPOSITION FOR TREATING MELASMA AND PREPARATION METHOD THEREFOR

Applicant/Assignee: JILIN ZIXIN PHARMACEUTICAL RESEARCH INSTITUTION LLC

Application No.: WO2011CN77177 (PCT/CN2011/77177)   Filing Date: 15/Jul/2011

Abstract:

A pharmaceutical composition for treating melasma, prepared from ginseng, salvia, mint, orange peel, paeonia lactiflora, poria, licorice, semen persicae, dioscorea, penthorum chinense, and a crop fermentation solution. Also disclosed is a preparation method for the pharmaceutical composition.

Priority: CN20111023840 Applic. Date: 2011-01-21

Inventor: SUN DEJUN [CN]; YIN JINLONG [CN]; SUN MIAONAN [CN]; ZHAO YIZHUO [CN]; GUO CHUNSHENG [CN]; GAO YANHUI [CN]; LI XUE [CN]


Publication No.: WO2012098387A1  Published: 26/Jul/2012

Title: 6, 7-RING-FUSED TRIAZOLO [4, 3 - B] PYRIDAZINE DERIVATIVES AS PIM INHIBITORS

Applicant/Assignee: CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO)

Application No.: WO2012GB50091 (PCT/GB2012/50091)   Filing Date: 17/Jan/2012

Abstract:

There is provided compounds of formula I, wherein R1, R2, R3 and R4 (and the -CH2-CH2 moiety) have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PIM family kinase, such as PIM-1, PIM-2 and/or PIM-3) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.

Priority: EP20110382011 Applic. Date: 2011-01-18

Inventor: PASTOR FERNANDEZ JOAQUIN [ES]; ALVAREZ ESCOBAR ROSA MARIA [ES]; GARCIA GARCIA ANA BELEN [ES]; RIESCO FAGUNDO ROSARIO CONCEPCION [ES]; BLANCO APARICIO CARMEN [ES]


Publication No.: WO2012098546A2  Published: 26/Jul/2012

Title: ANTIOXIDANT, ANTI-INFLAMMATORY, ANTI-RADIATION, METAL CHELATING COMPOUNDS AND USES THEREOF

Applicant/Assignee: ONEDAY - BIOTECH AND PHARMA LTD, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREWUNIVERSITY OF JERUSALEM LTD

Application No.: WO2012IL00032 (PCT/IL2012/00032)   Filing Date: 19/Jan/2012

Abstract:

The present invention relates to potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties. Specifically, the present invention relates to short peptides having said properties, and to methods and uses of such short peptides in clinical and cosmetic applications.

Priority: US201161434454P Applic. Date: 2011-01-20; US201161469138P Applic. Date: 2011-03-30

Inventor: MOGRABI JOSEJ [IL]; ATLAS DAPHNE [IL]; KEYNAN SHOSHANA [IL]


Publication No.: WO2012099247A1  Published: 26/Jul/2012

Title: SKIN WHITENING AGENT

Applicant/Assignee: KAO CORPORATION

Application No.: WO2012JP51242 (PCT/JP2012/51242)   Filing Date: 20/Jan/2012

Abstract:

A dopa oxidase activity inhibitor, a melanin production inhibitor, a skin whitening agent or an external preparation for the skin, which contains, as an active ingredient, Peristrophe japonica, an organic solvent extract thereof, a compound represented by formula (I) or a salt of the compound. (In formula (I), R1 and R2 each represents a hydroxyl group or an alkoxy group having 1-4 carbon atoms, or alternatively R1 and R2 combine together to form a methylenedioxy group

R3 and R4 each represents a hydroxyl group or an alkoxy group having 1-4 carbon atoms, or alternatively R3 and R4 combine together to form a methylenedioxy group

R5 represents a hydrogen atom, a hydroxyl group, an alkoxy group having 1-5 carbon atoms, an acyl group having 1-4 carbon atoms or a sugar residue such as (D-Apio-ss-D-furanosyl)oxy

and R6 and R7 each represents a hydrogen atom and R8 and R9 combine together to represent an oxygen atom, or alternatively R8 and R9 each represents a hydrogen atom and R6 and R7 combine together to represent an oxygen atom.)

Priority: JP20110010603 Applic. Date: 2011-01-21; JP20110190517 Applic. Date: 2011-09-01

Inventor: KIKUCHI MAMIKO [JP]; MURASE DAIKI [US]; SUGIYAMA MITSURU [JP]; KAWASAKI AKIKO [JP]


Publication No.: WO2012099899A2  Published: 26/Jul/2012

Title: TOPICAL DERMATOLOGICAL COMPOSITIONS FOR THE TREATMENT OF ACNE

Applicant/Assignee: INNOVATIVE COSMETICS LTD, FEIGELSON, DANIEL

Application No.: WO2012US21593 (PCT/US2012/21593)   Filing Date: 17/Jan/2012

Abstract:

There are disclosed dermatological topical pharmaceutical compositions for the treatment of acne, comprising an efficacious amount of quince seed jelly and a pharmaceutically acceptable carrier or excipient therefor. Methods of using the compositions, and other embodiments, are also disclosed.

Priority: US201161433302P Applic. Date: 2011-01-17

Inventor: DUBNIKOV GIL [IL]


Publication No.: WO2012100097A2  Published: 26/Jul/2012

Title: TOPICAL MINOCYCLINE COMPOSITIONS AND METHODS OF USING THE SAME

Applicant/Assignee: LABORATORY SKIN CARE, INC

Application No.: WO2012US21926 (PCT/US2012/21926)   Filing Date: 19/Jan/2012

Abstract:

Topical minocycline compositions with reduced fluorescence are provided. In some instances, the compositions include an amount of a minocycline active agent associated with porous calcium particles. Also provided are methods of using the compositions, e.g., in the treatment of acne.

Priority: US201161434368P Applic. Date: 2011-01-19

Inventor: MANSOURI ZAHRA [US]


Publication No.: WO2012101032A1  Published: 02/Aug/2012

Title: TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS

Applicant/Assignee: NERVIANO MEDICAL SCIENCES S.R.L

Application No.: WO2012EP50773 (PCT/EP2012/50773)   Filing Date: 19/Jan/2012

Abstract:

The present invention relates to tricyclic pyrrolo derivatives of Formula (I), which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such these compounds or the pharmaceutical compositions containing them.

Priority: EP20110152190 Applic. Date: 2011-01-26

Inventor: CALDARELLI MARINA [IT]; ANGIOLINI MAURO [IT]; BERIA ITALO [IT]; BRASCA MARIA GABRIELLA [IT]; CASUSCELLI FRANCESCO [IT]; D ALESSIO ROBERTO [IT]; LOMBARDI BORGIA ANDREA [IT]


Publication No.: WO2012101741A1  Published: 02/Aug/2012

Title: TIE-2 ACTIVATOR, AGENT FOR MATURATION, NORMALIZATION, OR STABILIZATION OF BLOOD VESSELS, LYMPH VESSEL STABILIZING AGENT, WRINKLE PREVENTION/IMPROVEMENT AGENT, AND EDEMA IMPROVEMENT/PREVENTION AGENT

Applicant/Assignee: SHISEIDO COMPANY, LTD

Application No.: WO2011JP51234 (PCT/JP2011/51234)   Filing Date: 24/Jan/2011

Abstract:

The present invention provides: a tie-2 activator comprising the extracts of the stem branch or seed of sokakushi (Gleditsia sinensis Lam.), polygonatum rhizome (Polygonatum sibiricum Red.), Angular Solomon's Seal (Polygonatum officinalle), the fruit or seed of trichosanthes (Trichosanthes kirilowii Maxim), and/or Indian Mulberry (Morinda officinalis How.)

an agent for maturation, normalization, or stabilization of blood vessels and a lymph vessel stabilizing agent

and a wrinkle prevention/improvement agent and edema improvement/prevention agent that are characterized by being a combination of the activator and agents.

Priority: WO2011JP51234 Applic. Date: 2011-01-24

Inventor: OTA MASAHIRO [JP]; SAITO TOMOKO [JP]


Publication No.: WO2012101746A1  Published: 02/Aug/2012

Title: TIE-2 ACTIVATOR, AGENT FOR MATURATION, NORMALIZATION, OR STABILIZATION OF BLOOD VESSELS, LYMPH VESSEL STABILIZING AGENT, WRINKLE PREVENTION/IMPROVEMENT AGENT, AND EDEMA IMPROVEMENT/PREVENTION AGENT

Applicant/Assignee: SHISEIDO COMPANY, LTD

Application No.: WO2011JP51245 (PCT/JP2011/51245)   Filing Date: 24/Jan/2011

Abstract:

The present invention provides: a Tie-2 activator comprising one or more types of compounds selected from a group consisting of Eleutheroside E, Eleutheroside E1, Sesamin, Eudesmine, Sylvatesmin, Pinoresinol, Yangambin, Forsythinol, and Coumarine

an agent for maturation, normalization, or stabilization of blood vessels and a lymph vessel stabilizing agent that contain the activator

and a wrinkle prevention/improvement agent and edema improvement/prevention agent that are characterized by being a combination of the agents.

Priority: WO2011JP51245 Applic. Date: 2011-01-24

Inventor: OTA MASAHIRO [JP]


Publication No.: WO2012101747A1  Published: 02/Aug/2012

Title: Tie2 ACTIVATOR, AGENT FOR MATURING, NORMALIZING OR STABILIZING BLOOD VESSELS, AGENT FOR STABILIZING LYMPHATIC VESSELS, PREPARATION FOR PREVENTING AND REDUCING WRINKLES, AND PREPARATION FOR REDUCING AND PREVENTING SWELLING

Applicant/Assignee: SHISEIDO COMPANY, LTD

Application No.: WO2011JP51246 (PCT/JP2011/51246)   Filing Date: 24/Jan/2011

Abstract:

Provided are a Tie2 activator, an agent for maturing, normalizing or stabilizing blood vessels and an agent for stabilizing lymphatic vessels, said agents comprising an extract of Lactuca indica and/or Chrysophyllum cainito Linn. Also provided are a preparation for preventing and reducing wrinkles and a preparation for reducing and preventing swelling, said preparations being characterized by containing said agent(s).

Priority: WO2011JP51246 Applic. Date: 2011-01-24

Inventor: KAJIYA KENTARO [JP]; YAMANISHI HARUYO [JP]; NAKANO YUSUKE [JP]


Publication No.: WO2012102364A1  Published: 02/Aug/2012

Title: COMPOSITION CONTAINING POLYUNSATURATED FATTY ACID

Applicant/Assignee: SUNSTAR INC

Application No.: WO2012JP51751 (PCT/JP2012/51751)   Filing Date: 27/Jan/2012

Abstract:

The purpose of the present invention is to provide a composition for external applications, in which the long-term stability of a polyunsaturated fatty acid is further increased. The present invention provides a composition as mentioned below. In the composition, the long-term stability of a polyunsaturated fatty acid is improved. A composition comprising components (A) and (B) as mentioned below, wherein the component (B) is dispersed in a continuous phase containing the component (A): (A) at least one component selected from the group consisting of tocopherol and phytic acid

and (B) a liposome containing a polyunsaturated fatty acid or a derivative thereof.

Priority: JP20110015331 Applic. Date: 2011-01-27

Inventor: HAYASHI NAOKO [JP]; MASUDA KENJI [JP]


Publication No.: WO2012102404A1  Published: 02/Aug/2012

Title: TOPICAL ANTIFUNGAL AGENT

Applicant/Assignee: MEIJI SEIKA PHARMA CO., LTD

Application No.: WO2012JP51991 (PCT/JP2012/51991)   Filing Date: 30/Jan/2012

Abstract:

Provided is an anti-Trichophyton agent having as an active ingredient a compound having a 2-(1H-pyrazol-1-yl)phenol backbone represented by formula (I) or (II), or a salt of the compound.

Priority: JP20110017347 Applic. Date: 2011-01-30

Inventor: OHYAMA MAKOTO; TABATA YUJI; IIDA MAIKO; KANEDA KAORI; TAKAHATA SHO


Publication No.: WO2012103011A1  Published: 02/Aug/2012

Title: STABLE SILVER OXIDE FORMULATIONS

Applicant/Assignee: AIDANCE SKINCARE AND TOPICAL SOLUTIONS LLC

Application No.: WO2012US22220 (PCT/US2012/22220)   Filing Date: 23/Jan/2012

Abstract:

A topical formulation for application to exposed body tissue, the formulation containing: (a) a silver oxide, and (b) at least one inorganic whitener

selected from the group of inorganic whiteners consisting of an inorganic magnesium compound and an inorganic calcium compound, said silver oxide and said inorganic whitener compound intimately dispersed within a carrier medium, and wherein a ratio of said inorganic whitener compound, to said silver oxide, is at least 0.2:1, by weight.

Priority: GB20110001193 Applic. Date: 2011-01-24

Inventor: MADHAVAN BHARAT [US]; ANTELMAN PERRY [US]; LAMPERT SHALOM [IL]


Publication No.: WO2012104025A2  Published: 09/Aug/2012

Title: BALNEOTHERAPEUTIC LIPID-CONTAINING PROBIOTIC PREPARATIONS AND THEIR APPLICATIONS

Applicant/Assignee: MERZ PHARMA GMBH & CO. KGAA

Application No.: WO2012EP00250 (PCT/EP2012/00250)   Filing Date: 19/Jan/2012

Abstract:

The present invention relates to solid or liquid cosmetic, dermatological or medicinal balneotherapeutic preparations for bathing or showering which are essentially anhydrous (with a low water content of less than 1% by weight) and have a lipid content with preferably at least one liquid lipid, furthermore dispersants, and which have a content of probiotic active substances, selected mainly among bacteria of the genus Lactobacillus and Bifidobacteria. When applying these preparations, skin regions which are brought into contact with them can, surprisingly, be provided topically with the probiotic active substances in the meaning of a care effect by maintaining and, if appropriate, restoring the healthy microbial status of the skin while in additional simultaneously cleansing and providing the skin with lipids. In this context, the stability of the microorganisms in the preparations which is required for the above-described effect does not require any further special measures.

Priority: DE201110009798 Applic. Date: 2011-01-31

Inventor: EBINGER JUERGEN [DE]; HOLZEM MARTINA [DE]


Publication No.: WO2012104516A1  Published: 09/Aug/2012

Title: MODULATION OF EPIDERMO-PILOSEBACEOUS UNIT EPITHELIAL CELL PROLIFERATION VIA RANK

Applicant/Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -

Application No.: WO2012FR50119 (PCT/FR2012/50119)   Filing Date: 20/Jan/2012

Abstract:

The present invention relates to the modulation of homeostasis and/or the growth of epidermo-pilosebaceous unit epithelial cells, via modulation of the RANK receptor. The present invention has in particular a therapeutic use (imflammatory diseases such as psoriasis or atopic dermatitis, alopecia, hirsutism) and cosmetic use (head hair and body hair homeostasis and/or growth).

Priority: FR20110050713 Applic. Date: 2011-01-31

Inventor: MUELLER GEORGE [FR]; DUHERON VINCENT [FR]; WILLIAMS IFOR [US]


Publication No.: WO2012105467A1  Published: 09/Aug/2012

Title: OLIGONUCLEIC ACID COMPOSITION AND ANTIALLERGIC AGENT

Applicant/Assignee: CEOLIA PHARMA CO., LTD

Application No.: WO2012JP51916 (PCT/JP2012/51916)   Filing Date: 30/Jan/2012

Abstract:

An oligonucleic acid composition which contains: an oligonucleic acid having antiallergic activity and antimicrobial activity (such as an siRNA that suppresses transcription factor NF-?B)

a cell-penetrating peptide (a basic peptide which comprises arginine, histidine, and cysteine at both ends and which is modified with a higher fatty acid)

and if necessary, a tight junction opening peptide. The cell-penetrating peptide may electrostatically form a composite with the oligonucleic acid, or may form a crosslinked composite by a disulfide bond. Since the oligonucleic acid composition has high stability of the oligonucleic acid, high cutaneous permeability and high mucosal permeability and is thus capable of delivering an oligonucleic acid to a target cell, allergic diseases and infectious diseases can be effectively treated by administration of the oligonucleic acid composition through skin or mucosa.

Priority: JP20110018640 Applic. Date: 2011-01-31

Inventor: OKADA HIROAKI [JP]; KANAZAWA TAKANORI [JP]


Publication No.: WO2012105521A1  Published: 09/Aug/2012

Title: EXTERNALLY-USED DRUG FOR TREATING SKIN DISORDER AND METHOD FOR PRODUCING SAME

Applicant/Assignee: OSAKA UNIVERSITY

Application No.: WO2012JP52047 (PCT/JP2012/52047)   Filing Date: 30/Jan/2012

Abstract:

This externally-used drug contains an ointment composition or a gel composition containing sirolimus and/or a derivative thereof, and as a result, provided is an externally-used drug that enables a quantity of sirolimus sufficient for treating a skin disorder to be absorbed by the affected area without causing side effects.

Priority: JP20110018273 Applic. Date: 2011-01-31

Inventor: KANEDA MARI; KATAYAMA ICHIRO


Publication No.: WO2012105542A1  Published: 09/Aug/2012

Title: EXTERNAL PREPARATION FOR SKIN

Applicant/Assignee: KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO

Application No.: WO2012JP52118 (PCT/JP2012/52118)   Filing Date: 31/Jan/2012

Abstract:

The present invention addresses the problem of providing an external preparation for the skin having a sustainable antiwrinkle effect, which has an action of promoting the proliferation and differentiation of keratinocytes and an action of enhancing the collagen production in the skin at the same time, and which assists maintenance and improvement of the tissue structures and the physiological functions of the epidermis and the dermis, thereby providing an excellent skin improving effect. The problem is solved by providing an external preparation for the skin, which contains, as an effective ingredient, a-D-glucopyranosyl-(1?3')-adenosine and/or a-D-glucopyranosyl-(1?5')-adenosine.

Priority: JP20110020233 Applic. Date: 2011-02-01

Inventor: ISHIHARA TATSUYA [JP]; USHIO SHIMPEI [JP]; YAMAMOTO ROHKO [JP]; OHKURA TAKANORI [JP]; FUKUDA SHIGEHARU [JP]


Publication No.: WO2012105706A1  Published: 09/Aug/2012

Title: KELOID THERAPEUTIC AGENT

Applicant/Assignee: SAPPORO MEDICAL UNIVERSITY

Application No.: WO2012JP52559 (PCT/JP2012/52559)   Filing Date: 03/Feb/2012

Abstract:

The present invention relates to a composition for inhibiting the proliferation of a keloid fibroblast, which contains a polyphenol represented by formula (I).

Priority: US201161439600P Applic. Date: 2011-02-04

Inventor: IKEDA KANAE [JP]; TORIGOE TOSHIHIKO [JP]; MATSUMOTO YOSHITAKA [JP]; FUJITA TATSUYA [JP]; YOTSUYANAGI TAKATOSHI [JP]; SATO NORIYUKI [JP]


Publication No.: WO2012105982A1  Published: 09/Aug/2012

Title: SKIN RENEWAL ENHANCER

Applicant/Assignee:

Application No.: WO2011US23614 (PCT/US2011/23614)   Filing Date: 03/Feb/2011

Abstract:

A composition is provided that capitalizes on the biological activity of trichloroacetic acid, but effectively reduces or eliminates TCA induced irritation allowing the composition to be used as a wrinkle effacer or stimulant of skin cell turnover

uses previously thought as commercially impossible with TCA. Also provided are processes of effacing wrinkles or stimulating skin cell turnover including applying the inventive composition to the skin of a subject.

Priority: WO2011US23614 Applic. Date: 2011-02-03

Inventor: KULESZA JOHN E [US]; RUBIN MARK [US]


Publication No.: WO2012105990A1  Published: 09/Aug/2012

Title: BAKUCHIOL COMPOSITIONS FOR TREATMENT OF POST INFLAMMATORY HYPERPIGMENTATION

Applicant/Assignee: UNIGEN, INC

Application No.: WO2011US26594 (PCT/US2011/26594)   Filing Date: 01/Mar/2011

Abstract:

Methods for treating excess pigmentation, including treatment of post inflammatory hyperpigmentation (PIH), are disclosed. The disclosed methods comprise administration of a composition comprising bakuchiol substantially free of furanocoumarins to a patient in need thereof. Compositions comprising bakuchiol and methods for their preparation are also disclosed.

Priority: US201161438890P Applic. Date: 2011-02-02

Inventor: HONG MEI FENG [US]; JIA QI [US]; BROWNELL LIDIA ALFARO [US]


Publication No.: WO2012106551A1  Published: 09/Aug/2012

Title: BAKUCHIOL COMPOSITIONS FOR TREATMENT OF POST INFLAMMATORY HYPERPIGMENTATION

Applicant/Assignee: UNIGEN, INC

Application No.: WO2012US23686 (PCT/US2012/23686)   Filing Date: 02/Feb/2012

Abstract:

Methods for treating excess pigmentation, including treatment of post inflammatory hyperpigmentation (PIH), are disclosed. The disclosed methods comprise administration of a composition comprising bakuchiol substantially free of furanocoumarins to a mammal. Compositions comprising bakuchiol and methods for their preparation are also disclosed.

Priority: WO2011US26594 Applic. Date: 2011-03-01; US201161438890P Applic. Date: 2011-02-02

Inventor: HONG MEI FENG [US]; JIA QI [US]; BROWNELL LIDIA ALFARO [US]


Publication No.: WO2012106990A1  Published: 16/Aug/2012

Title: CHINESE MEDICINE FUMING AND WASHING AGENT FOR TREATING TINEA CAPITIS

Applicant/Assignee:

Application No.: WO2012CN70977 (PCT/CN2012/70977)   Filing Date: 09/Feb/2012

Abstract:

A Chinese medicine fuming and washing agent for treating tinea capitis, which is formulated using Chinese herbal medicine raw materials in the following weight proportions: 10-20 parts of radix sophorae flavescentis, 8-15 parts of Cinnamomum camphora root, 10-25 parts of capillary artemisia, 15-25 parts of Coptis chinensis, 15-25 parts of radix stemonae, 15-30 parts of liquorice, 15-30 parts of Symplocos sumuntia, 10-20 parts of Stellera chamaejasme, 10-20 parts of realgar, 15-25 parts of herba schizonepetae, 15-25 parts of Ledebouriella seseloides, 15-25 parts of Angelica polyclada, 15-25 parts of Lithospermum purpurocaeruleum, 15-30 parts of Angelica sinensis, 15-20 parts of Ligusticum wallichii, 8-15 parts of dandelion, 15-20 parts of cortex dictamni, 10-25 parts of Portulaca oleracea, 15-25 parts of fructus kochiae, and 5-10 parts of Lonicera japonica. The Chinese medicine fuming and washing agent of the present invention is convenient to use, has no toxic or side effects, and has the effect of killing bacteria, of resisting inflammation and allergies and of relieving itch

it can also increase the hydration of the cuticles and eliminate unbearable itch, redness and swelling caused by a local inflammation, and can dissolve keratin and increase proteins, so as to prevent skin keratinization and increase the penetrability and flexibility of the skin.

Priority: CN20111036646 Applic. Date: 2011-02-12

Inventor: LI YUN [CN]


Publication No.: WO2012107153A1  Published: 16/Aug/2012

Title: AMINO STATIN DERIVATIVESFOR THE TREATMENT OF ARTHROSIS

Applicant/Assignee: MERCK PATENT GMBH

Application No.: WO2012EP00069 (PCT/EP2012/00069)   Filing Date: 09/Jan/2012

Abstract:

The invention relates to compositions of formula (I), and in particular medications containing at least one composition of formula (I), for use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions triggered in part by cathepsin D, in particular for use in the treatment and/or prophylaxis of arthrosis, traumatic cartilage injuries, arthritis, pain, allodynia, or hyperalgesia.

Priority: EP20110000974 Applic. Date: 2011-02-08

Inventor: KLEIN MARKUS [DE]; TSAKLAKIDIS CHRISTOS [DE]; GUEHRING HANS [DE]; LEUTHNER BIRGITTA [DE]


Publication No.: WO2012107244A1  Published: 16/Aug/2012

Title: PEPTIDE FOR USE IN THE TREATMENT OF SKIN CONDITIONS

Applicant/Assignee: ORGANOBALANCE GMBH

Application No.: WO2012EP00697 (PCT/EP2012/00697)   Filing Date: 03/Feb/2012

Abstract:

The present invention relates to a peptide of the following formula (I) X1(X2)-X3-X4 or a salt or solvate thereof, wherein is an amino acid comprising two or more NH-functionalities, and X2, X3, and X4 are, independently from one another, an amino acid residue, and wherein the salt or solvate is preferably a physiologically acceptable salt or solvate.

Priority: EP20110153771 Applic. Date: 2011-02-09

Inventor: LANG CHRISTINE [DE]


Publication No.: WO2012108410A1  Published: 16/Aug/2012

Title: SKIN COLLAGEN PRODUCTION PROMOTER

Applicant/Assignee: MEGMILK SNOW BRAND CO., LTD

Application No.: WO2012JP52690 (PCT/JP2012/52690)   Filing Date: 07/Feb/2012

Abstract:

The purpose of the present invention is to provide a skin collagen production promoter which has no problem in safety. Another purpose of the present invention is to provide a food or drink for promoting skin collagen production and a cosmetic for promoting skin collagen production, said food or drink and cosmetic containing the aforesaid substance. TGF-ss and/or a TGF-ss digestion product, which is obtained by digesting TGF-ss with a protease such as pepsin, pancreatin, etc., are used as a skin collagen production promoter or the active ingredient of a food or drink for promoting skin collagen production and a cosmetic for promoting skin collagen production. The aforesaid TGF-ss and/or TGF-ss digestion product have an effect of increasing the collagen content of the skin.

Priority: JP20110026446 Applic. Date: 2011-02-09

Inventor: UENO HIROSHI [JP]; MORITA YOSHIKAZU [JP]; ONO AIKO [JP]; KATOH KEN [JP]; UEDA NORIKO [JP]


Publication No.: WO2012108495A1  Published: 16/Aug/2012

Title: AGENT TO SUPPRESS OLD PERSON SMELL, CONTAINING OOLONG TEA EXTRACT AND/OR CHINESE BLACKBERRY TEA EXTRACT

Applicant/Assignee: SUNTORY HOLDINGS LIMITED

Application No.: WO2012JP52952 (PCT/JP2012/52952)   Filing Date: 09/Feb/2012

Abstract:

The problem addressed by the present invention is the provision of a deodorant for the suppression of body odor, particularly the "old person smell" which is inherent to people of middle- and old-age, the deodorant being safe to use and having a strong deodorizing effect. By having the agent contain oolong tea extract and/or Chinese blackberry tea extract as active ingredients, it is possible to deodorize unsaturated aldehydes, which are the main cause of "old person smell".

Priority: JP20110135696 Applic. Date: 2011-06-17; JP20110026836 Applic. Date: 2011-02-10

Inventor: TATSUGUCHI IWAO [JP]; MATSUOKA TATSUO [JP]


Publication No.: WO2012108676A2  Published: 16/Aug/2012

Title: NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR

Applicant/Assignee: PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION

Application No.: WO2012KR00898 (PCT/KR2012/00898)   Filing Date: 08/Feb/2012

Abstract:

The present invention relates to a novel compound having skin-whitening, anti-oxidizing and PPAR activities and to a medical use therefor. Compounds according to the present invention can be used to advantage in skin-whitening pharmaceutical compositions or cosmetics as they have a skin-whitening activity whereby tyrosinase is inhibited, and can be used to advantage in the prevention or treatment of skin ageing or the like as they have an anti-oxidizing activity, and can also be used as pharmaceutical compositions or health foods which are useful in preventing and treating obesity, metabolic disease or cardiovascular disease as they have PPAR activity and, more particularly, PPARa and PPAR? activity.

Priority: KR20110011545 Applic. Date: 2011-02-09

Inventor: CHUNG HAE-YOUNG [KR]; PARK MIN-HI [KR]; CHUNG KI-WUNG [KR]; KIM JIN-AH [KR]; PARK JI-YOUNG [KR]; PARK YUN-JUNG [KR]; MOON HYUNG-RYONG [KR]


Publication No.: WO2012108689A2  Published: 16/Aug/2012

Title: NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR

Applicant/Assignee: PUSAN NATIONAL UNIVERSITY INDUSTRYUNIVERSITY

Application No.: WO2012KR00935 (PCT/KR2012/00935)   Filing Date: 08/Feb/2012

Abstract:

The present invention relates to a novel compound having skin-whitening, anti-oxidizing and PPAR activities and to a medical use therefor. Compounds according to the present invention can be used to advantage in skin-whitening pharmaceutical compositions or cosmetics as they have a skin-whitening activity whereby tyrosinase is inhibited, and can be used to advantage in the prevention or treatment of skin ageing or the like as they have an anti-oxidizing activity, and can also be used as pharmaceutical compositions or health foods which are useful in preventing and treating obesity, metabolic disease or cardiovascular disease as they have PPAR activity and, more particularly, PPARa and PPAR? activity.

Priority: KR20110011544 Applic. Date: 2011-02-09

Inventor: CHUNG HAE-YOUNG [KR]; PARK MIN-HI [KR]; HA YOUNG-MI [KR]; HAN YU-KYEONG [KR]; PARK JI-YOUNG [KR]; PARK YUN-JUNG [KR]; KIM JIN-AH [KR]; LEE JI-YEON [KR]; SONG YU-MIN [KR]; MOON HYUNG-RYONG [KR]


Publication No.: WO2012111187A1  Published: 23/Aug/2012

Title: SKIN COLLAGEN PRODUCTION PROMOTER

Applicant/Assignee: J-OIL MILLS, INC

Application No.: WO2011JP68123 (PCT/JP2011/68123)   Filing Date: 09/Aug/2011

Abstract:

[Problem] To provide a medicine, cosmetic and supplement comprising food constituents or nutrients which have been used extensively as food and are safe, and having skin collagen production promoting effects. [Solution] The skin collagen production promoter according to the present invention includes menaquinone-7 as an active ingredient. This skin collagen production promoter is administered transdermally or orally, and is provided as a medicine, cosmetic and supplement.

Priority: JP20110028189 Applic. Date: 2011-02-14

Inventor: SATO TOSHIRO [JP]; KAWAHARA RUMI [JP]; KAMO SHUICHI [JP]


Publication No.: WO2012112566A1  Published: 23/Aug/2012

Title: PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA

Applicant/Assignee: ALLERGAN, INC

Application No.: WO2012US25068 (PCT/US2012/25068)   Filing Date: 14/Feb/2012

Abstract:

The present invention is directed to: a) a method of treating telangiectasia

b) a method of treating inflammatory lesions

and c) a method of treating two or more symptoms of rosacea selected from erythema, telangiectasia, or inflammatory lesions comprising topical administration of a pharmaceutical composition comprising oxymetazoline and a pharmaceutically acceptable excipient.

Priority: US201161443210P Applic. Date: 2011-02-15

Inventor: SHANLER STUART D [US]; POWALA CHRISTOPHER [US]


Publication No.: WO2012112796A2  Published: 23/Aug/2012

Title: PERFLUORO(N-BUTYLCYCLOHEXANE) COMPOSITIONS AND USES THEREOF

Applicant/Assignee: OXYGEN BIOTHERAPEUTICS, INC

Application No.: WO2012US25486 (PCT/US2012/25486)   Filing Date: 16/Feb/2012

Abstract:

A perfluoro (n-butylcyclohexane) composition is disclosed with numerous uses including topical and cosmetic applications, e.g., for application to the periocular skin or for the topical treatment of pruritus.

Priority: US201161443664P Applic. Date: 2011-02-16

Inventor: GROSSMAN AHARON [US]; KIRAL RICHARD [US]; KLEIN GERALD [US]; STERN CHRIS [US]; CLAUSON GARY [US]


Publication No.: WO2012114051A1  Published: 30/Aug/2012

Title: CUTANEOUS PHARMACEUTICAL COMPOSITIONS FOR THE LOCAL TREATMENT OF CANINE ATOPIC DERMATITIS

Applicant/Assignee: PHYSICA PHARMA SAS

Application No.: WO2012FR50392 (PCT/FR2012/50392)   Filing Date: 24/Feb/2012

Abstract:

The invention relates to a topical pharmaceutical composition which can be administered by applying same to the skin, for the use thereof as a cutaneous veterinary drug for the local treatment of canine atopic dermatitis. The composition contains cyclosporin A as an active ingredient. In a particular embodiment, said composition contains sodium N-cocoyl alaninate.

Priority: FR20110000579 Applic. Date: 2011-02-24

Inventor: POUGNAS JEAN-LUC [FR]; COURIERE LAURIE [FR]; BEUVRY VINCENT [FR]; BROUSSAUD OLIVIER [FR]


Publication No.: WO2012115241A1  Published: 30/Aug/2012

Title: FCGRIIB-SPECIFIC FC ANTIBODY

Applicant/Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHA

Application No.: WO2012JP54624 (PCT/JP2012/54624)   Filing Date: 24/Feb/2012

Abstract:

The purpose of the present invention is to provide: a polypeptide containing an Fc region of which the activity of binding to both of genetic polymorphism types H and R of Fc?RIIa is maintained or reduced compared with that of a parent polypeptide and of which the activity of binding to Fc?RIIb is enhanced compared with that of the parent polypeptide

a pharmaceutical composition containing the polypeptide

a therapeutic or prophylactic agent for immune/inflammatory diseases, which comprises the pharmaceutical composition

processes for producing those products

and a method for maintaining or reducing the activity of binding to both of the above-mentioned genetic polymorphism types of Fc?RIIa or enhancing the activity of binding to Fc?RIIb. Specifically, it is found that a polypeptide which contains an antibody Fc region that contains a mutation produced by substituting Pro located at 238th position as numbered in accordance with the EU numbering method by Asp and a mutation produced by substituting Leu located at 328th position as numbered in accordance with the EU numbering method by Glu is enhanced with respect to the activity of binding to Fc?RIIb and is maintained or reduced with respect to the activity of binding to both of genetic polymorphism types H and R of Fc?RIIa. It is also found that a polypeptide which contains an antibody Fc region that contains a mutation produced by substituting Pro located at 238th position as numbered in accordance with the EU numbering method by Asp and another type of mutation is enhanced with respect to the activity of binding to Fc?RIIb and is maintained or reduced with respect to the activity of binding to both of genetic polymorphism types H and R of Fc?RIIa.

Priority: JP20110040923 Applic. Date: 2011-02-25; JP20110219835 Applic. Date: 2011-10-04

Inventor: MIMOTO FUTA [JP]; KURAMOCHI TAICHI [JP]; IGAWA TOMOYUKI [JP]; KATADA HITOSHI [JP]; KADONO SHOJIRO [JP]


Publication No.: WO2012115247A1  Published: 30/Aug/2012

Title: STRATUM CORNEUM PEELING ACCELERATOR

Applicant/Assignee: SHISEIDO COMPANY, LTD

Application No.: WO2012JP54638 (PCT/JP2012/54638)   Filing Date: 24/Feb/2012

Abstract:

Provided are a mesotrypsin expression enhancer selected from the group consisting of Gingko biloba extract, Saxifraga stolonifera extract, Rosa roxburghii extract, dipotassium glycyrrhizate, and ectoine, and a stratum corneum peeling accelerator including the mesotrypsin expression enhancer.

Priority: JP20110039978 Applic. Date: 2011-02-25

Inventor: HIBINO TOSHIHIKO [JP]; YAMADA AKIKO [JP]


Publication No.: WO2012115906A1  Published: 30/Aug/2012

Title: CELL THERAPY FOR LIMITING OVERZEALOUS INFLAMMATORY REACTIONS IN TISSUE HEALING

Applicant/Assignee: ACTX, INC

Application No.: WO2012US25814 (PCT/US2012/25814)   Filing Date: 20/Feb/2012

Abstract:

Cells of the B cell lineage including pre-pro-B cells, pro-B cells, pre- B cells, immature B cells, and some mature B cells, and/or cells of the T cell lineage, especially those with helper or regulatory function, most preferably autologous to the recipient, can be transplanted into damaged tissue to enhance recovery following injury. In a preferred embodiment, the cells are selected based on those cells which appear at the site of injury a few days after injury, such as macrophages, lymphocytes, which accelerate clean up and repair of the injured site and to mitigate the overzealous inflammatory response, presumably by inhibiting the inflammatory cells such as neutrophils and signals released thereby immediately following injury.

Priority: US201113031431 Applic. Date: 2011-02-21

Inventor: POZNANSKY MARK C [US]; CHRONOS NICOLAS A F [US]


Publication No.: WO2012116210A2  Published: 30/Aug/2012

Title: PEPTIDE FOR THE INDUCTION OF IMMUNE TOLERANCE AS TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: WO2012US26364 (PCT/US2012/26364)   Filing Date: 23/Feb/2012

Abstract:

The present invention relates to amino acid peptides comprising the sequence FIEWNKLRFRQGLEW and their use in methods for the diagnosis and/ or treatment of immune disorders such as systemic lupus erythematosus. Typically, at least one amino acid moiety in the peptide is a D-amino acid

and/ or the peptide is in a head-to-tail cyclic configuration

and/ or multiple copies of the peptide are coupled to a non-immunogenic polymeric matrix such as polylysine (as a multiple antigen peptide or MAP). Typically the peptide is capable of inhibiting the production of autoantibodies that bind double stranded DNA in a mammal having systemic lupus erythematosus (SLE).

Priority: US201161445769P Applic. Date: 2011-02-23

Inventor: HAHN BEVRA H [US]; SKAGGS BRIAN J [US]; SINGH RAM RAJ [US]; EBLING FANNY M [US]; LA CAVA ANTONIO [US]; SINGH RAM PYARE [US]


Publication No.: WO2012116282A2  Published: 30/Aug/2012

Title: PROTEIN NANOCARRIERS FOR TOPICAL DELIVERY

Applicant/Assignee: SOUTH DAKOTA STATE UNIVERSITY

Application No.: WO2012US26520 (PCT/US2012/26520)   Filing Date: 24/Feb/2012

Abstract:

The invention encompasses nanoparticle assemblies and methods for preparing nanoparticle assemblies and compositions comprising such assemblies. The invention further encompasses methods of complexing various molecular and cellular entities to the nanoparticles using the resulting nanoparticles of the invention as delivery devices. The nanoparticle assemblies can be used for a variety of applications, such as treating cancer, targeting tumors, reducing the toxicity of a drug in vivo, increasing the efficacy of an complexed agent in vivo, protecting an complexed agent against degradation, and enhancing the water solubility of a drug or other agent.

Priority: US201161446934P Applic. Date: 2011-02-25

Inventor: PERUMAL OMATHANU P [US]; AVERINENI RANJITH KUMAR [US]; PODARALLA SATHEESH [US]; ALQAHTANI MOHAMMED [US]


Publication No.: WO2012117340A1  Published: 07/Sep/2012

Title: METHOD FOR THE COSMETIC TREATMENT OF SKIN REDNESS

Applicant/Assignee: L'OREAL

Application No.: WO2012IB50907 (PCT/IB2012/50907)   Filing Date: 28/Feb/2012

Abstract:

The invention relates to a cosmetic treatment method for reducing or preventing skin redness, characterized in that an effective amount of at least one compound of formula I is applied to the skin: R1-CHOH-CH(NH-COR2)(CH2OH) (I) in which R1 denotes a C13 to C17 alkoyl or alkenyl radical, R2 denotes a linear C13-C19 hydrocarbon-based radical which may comprise one or more ethylenically unsaturated groups, especially one or two ethylenically unsaturated groups, or a composition containing the compound of formula I in a physiologically acceptable medium.1 The invention also relates to the cosmetic use of the compound as a calmative.

Priority: FR20110051669 Applic. Date: 2011-03-01; US201161449217P Applic. Date: 2011-03-04

Inventor: DE LACHARRIERE OLIVIER [FR]; TRAN CHRISTIAN [FR]


Publication No.: WO2012118097A1  Published: 07/Sep/2012

Title: CELL SHEET HAVING HYALURONIC ACID PRODUCTION ABILITY AND METHOD FOR PRODUCING SAME

Applicant/Assignee: CELLSEED INC, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY

Application No.: WO2012JP54987 (PCT/JP2012/54987)   Filing Date: 28/Feb/2012

Abstract:

On a cell culture support having a surface covered with a polymer that changes hydration force within a temperature range of 0-80 DEG C, cells are cultured in a temperature zone in which the hydration force of the polymer is weak, in a state where, for example, the stem cell content has been increased. Thereafter, the cells are detached by changing the culture broth to a temperature at which the hydration force of the polymer becomes strong, thereby making it possible to obtain a cell sheet having a high ability to produce hyaluronic acid.

Priority: JP20110058515 Applic. Date: 2011-02-28

Inventor: SUGIYAMA HIROAKI [JP]; SAKAI HIDEAKI [JP]; SHINOHARA YASURO; TAKEGAWA YASUHIRO


Publication No.: WO2012119056A1  Published: 07/Sep/2012

Title: PROTEASOME INHIBITOR DELANZOMIB FOR USE IN THE TREATMENT OF LUPUS

Applicant/Assignee: CEPHALON, INC

Application No.: WO2012US27440 (PCT/US2012/27440)   Filing Date: 02/Mar/2012

Abstract:

The present invention provides a method for treating lupus in a subject, comprising the step of administering to the subject Compound A.

Priority: US201161448743P Applic. Date: 2011-03-03

Inventor: RUGGERI BRUCE A [US]; SEAVEY MATTHEW M [US]


Publication No.: WO2012119780A2  Published: 13/Sep/2012

Title: NOVEL LIPIDS AND NOVEL PHOSPHOLIPIDS STRUCTURES

Applicant/Assignee: UNIVERSITY OF GENEVA

Application No.: WO2012EP01052 (PCT/EP2012/01052)   Filing Date: 09/Mar/2012

Abstract:

The invention relates to a lipids comprising or consisting of 1,3-diamidolipids or/and 1,2-diamidolipids or/and 2,3-diamidolipids or/and 1,3-diurealipids or/and 1,2-diurealipids or/and 2,3-diurealipids or/and 1,3 -dithiourealipids or/and 1,2-dithiourealipids or/and 2,3-dithiourealipids or/and 1,3-diacylurealipids or/and 1,2-diacylurealipids or/and 2,3-diacylurealipids or/and 1 -amidolipids or/and 1-urealipids or/and 1-thiourealipids or/and 1-acylurealipids or/and cyclic-amidolipids or/and cyclic urealipids or/and cyclic thiourealipids or/and cyclic acylurealipids, and their medical and non-medical use.

Priority: US201161451153P Applic. Date: 2011-03-10

Inventor: ZUMBUEHL ANDREAS [CH]; ZAFFALON PIERRE-LEONARD [FR]; FEDOTENKO ILLYA [CH]


Publication No.: WO2012121286A1  Published: 13/Sep/2012

Title: SKIN-BEAUTIFYING AGENT

Applicant/Assignee: MEGMILK SNOW BRAND CO., LTD

Application No.: WO2012JP55811 (PCT/JP2012/55811)   Filing Date: 07/Mar/2012

Abstract:

The invention addresses the problem of providing a skin-beautifying agent with beautifying effects such as skin moisturizing, skin beautification, prevention of rough skin, wrinkle prevention, prevention of reduced elasticity, etc., and a skin-beautifying product such as a cosmetic, food or drink, feed, medicine, etc. that contains said skin-beautifying agent. The skin-beautifying agent is characterized in containing a hydrolyzate of whey protein as an active ingredient. Using a whey protein hydrolyzate having the characteristics of a molecular weight distribution of 10 kDa or less, a main peak of 200 Da - 3 kDa, APL (average peptide length) of 2 - 8, free amino acid content of 20% or less, and a ss-lactoglobulin antigenicity of 1/10,000 or less, in particular, provides a skin-beautifying agent of low allergenicity and low bitterness.

Priority: JP20110053276 Applic. Date: 2011-03-10

Inventor: KATOH KEN [JP]; UENO HIROSHI [JP]; ONO YUKO [JP]; UEDA NORIKO [JP]


Publication No.: WO2012121423A1  Published: 13/Sep/2012

Title: PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING COMPLICATIONS OF DIABETES CONTAINING A TRADITIONAL ORIENTAL MEDICINE EXTRACT OR A FRACTION THEREOF AS AN ACTIVE INGREDIENT

Applicant/Assignee: KOREA INSTITUTE OF ORIENTAL MEDICINE

Application No.: WO2011KR00896 (PCT/KR2011/00896)   Filing Date: 07/Mar/2011

Abstract:

The present invention relates to a pharmaceutical composition for preventing and treating complications of diabetes containing Homonoia riparia Lour. extract or a fraction thereof as an active ingredient, and, more specifically, the Homonoia riparia Lour. extract or the fraction thereof suppresses the action of aldose reductase and the production of advanced glycosylated end products which are indicators of complications of diabetes, and exhibits a powerful action in suppressing complications of diabetes via its effects in countering cataracts, retinopathy and nephropathy, and thus can be used to advantage as an active ingredient in a pharmaceutical composition for preventing and treating complications of diabetes.

Priority: WO2011KR00896 Applic. Date: 2011-03-07

Inventor: KIM JIN SOOK [KR]; KIM JUNG HYUN [KR]; KIM YOUNG SOOK [KR]; KIM CHAN-SIK [KR]; KIM OHN SOON [KR]; KIM KI MO [KR]; SHON EUN JIN [KR]; YOO NAM-HEE [KR]; LEE YUN MI [KR]; JUNG DONG HO [KR]


Publication No.: WO2012121988A2  Published: 13/Sep/2012

Title: METHODS FOR TREATING DISEASES USING ISOINDOLINE COMPOUNDS

Applicant/Assignee: CELGENE CORPORATION

Application No.: WO2012US27368 (PCT/US2012/27368)   Filing Date: 02/Mar/2012

Abstract:

Methods of treating a disease selected from dermatomyositis, prurigo nodularis, pyoderma gangrenosum, alopecia areata, hidradenitis suppurtiva, rosacea, lichen planus, giant cell arteritis, Sjogren's syndrome, gout, chronic prostatitis, posterior uveitis, vulvodynia and interstitial cystitis in a human are disclosed. Specific methods encompass the administration of (+)-2-[l-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4- acetylaminoisoindoline-l,3-dione, cyclopropyl {2-[(15)-l-(3-ethoxy-4-methoxyphenyl)-2- (methylsulfonyl)ethyl]-3-oxoisoindolin-4-yl}carboxamide or a combination thereof, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate or clathrate thereof.

Priority: US201161449716P Applic. Date: 2011-03-07

Inventor: SCHAFER PETER H [US]; SHANKAR SAI [US]


Publication No.: WO2012122082A2  Published: 13/Sep/2012

Title: METHODS FOR ACTIVATING CASPASE-14 EXPRESSION IN HUMAN SKIN

Applicant/Assignee: ELC MANAGEMENT LLC

Application No.: WO2012US27676 (PCT/US2012/27676)   Filing Date: 05/Mar/2012

Abstract:

A method for treating human skin comprising the steps of a) identifying a subject deficient in caspase-14

wherein the caspase-14 deficiency is identified by the presence of a skin condition selected from the group consisting of eczema, xerotic skin, and skin dryness in at least one skin zone of the subject

and b) activating caspase-14 in human skin by administering to a subject in need thereof a therapeutically effective amount of a composition comprising one or more extracts selected from the group consisting of litchi, glasswort, peach, soja seed, sweet basil, cucumber, chanterelle, leek, kiwi fruit, rhubarb, grapefruit, wheat, raspberry, plum, and mixtures thereof.

Priority: US201113042887 Applic. Date: 2011-03-08

Inventor: CORSTJENS HUGO A [BE]; DECLERCQ LIEVE [BE]; EYCKMANS GERRY [BE]; VAN OVERLOOP LUC F J [BE]


Publication No.: WO2012122451A2  Published: 13/Sep/2012

Title: POLYMORPHS OF MAXACALCITOL AND PROCESS FOR THE PREPARATION OF MAXACALCITOL

Applicant/Assignee: TEVA PHARMACEUTICAL INDUSTRIES LTD, TEVA PHARMACEUTICALS USA, INC

Application No.: WO2012US28426 (PCT/US2012/28426)   Filing Date: 09/Mar/2012

Abstract:

The present invention relates to Maxacalcitol polymorphs and Maxacalcitol having low residual solvent content as well as processes for their preparation. The present invention also relates to pharmaceutical compositions containing Maxacalcitol polymorphs or Maxacalcitol having low residual solvent content and treatment methods using the pharmaceutical compositions.

Priority: US201161450770P Applic. Date: 2011-03-09; US201161482477P Applic. Date: 2011-05-04; US201161487123P Applic. Date: 2011-05-17

Inventor: SCHWARTZ ANCHEL [IL]; WOLFMAN KOBY [IL]; RAFILOVICH-GIVON MICHAL [IL]; RADCHENKO OLEG [IL]


Publication No.: WO2012122452A1  Published: 13/Sep/2012

Title: 2,4 SUBSTITUTED PYRIMIDINEDIAMINES FOR USE IN DISCOID LUPUS

Applicant/Assignee: RIGEL PHARMACEUTICALS, INC

Application No.: WO2012US28429 (PCT/US2012/28429)   Filing Date: 09/Mar/2012

Abstract:

Compounds I and II as well as salts and pharmaceutical compositions containing them are useful for treating diseases and/or disorders of the skin, such cutaneous lupus, for example acute cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus, or discoid lupus erythematosus. In certain embodiments, the compounds are provided in topical compositions.

Priority: US201161451531P Applic. Date: 2011-03-10

Inventor: MAGILAVY DANIEL [US]; PINE POLLY [US]


Publication No.: WO2012122604A1  Published: 20/Sep/2012

Title: PHARMACEUTICAL COMPOSITIONS AND TOPICAL USE THEREOF

Applicant/Assignee: CELL IDEAS PTY LTD

Application No.: WO2012AU00274 (PCT/AU2012/00274)   Filing Date: 15/Mar/2012

Abstract:

The present invention relates to methods for the preparation of compositions comprising adipose tissue-derived secretions, for example those derived from bovine adipose tissue, and the use of such compositions in the preparation of a pharmaceutical composition for topical use. The invention also relates to the use of adipose tissue-derived secretions and pharmaceutical compositions thereof for the topical treatment of a non-inflammatory condition, for example the treatment of a skin condition, and for the stimulation of hair growth in a subject by topical application. The invention also relates to the use of adipose tissue-derived secretions and pharmaceutical compositions thereof for the topical treatment of acne.

Priority: AU20110900932 Applic. Date: 2011-03-15; AU20120900140 Applic. Date: 2012-01-13

Inventor: VESEY GRAHAM [AU]; WEBSTER REBECCA ANNE [AU]


Publication No.: WO2012124696A1  Published: 20/Sep/2012

Title: GUANIDINE COMPOUND

Applicant/Assignee: ASTELLAS PHARMA INC

Application No.: WO2012JP56429 (PCT/JP2012/56429)   Filing Date: 13/Mar/2012

Abstract:

[Problem] To provide a compound which is useful as an active ingredient of a pharmaceutical composition, especially of a pharmaceutical composition for the prophylaxis and/or treatment of VAP-1 associated diseases. [Solution] As a result of intensive studies on a compound having VAP-1 inhibitory activity, the inventors have achieved the present invention by discovering that a compound of the present invention or a salt thereof has excellent VAP-1 inhibitory activity and is thus useful for the prophylaxis and/or treatment of VAP-1 associated diseases, especially for the prophylaxis and/or treatment of diabetic nephropathy or diabetic macular edema. The present invention also relates to a pharmaceutical composition, particularly a pharmaceutical composition for the prophylaxis and/or treatment of VAP-1 associated diseases, said pharmaceutical composition containing a compound of the present invention or a salt thereof and an excipient.

Priority: JP20110056031 Applic. Date: 2011-03-15

Inventor: YOSHIHARA KOUSEI [JP]; SUZUKI DAISUKE [JP]; YAMAKI SUSUMU [JP]; YAMADA HIROYOSHI [JP]; MIHARA HISASHI [JP]; SEKI NORIO [JP]


Publication No.: WO2012124743A1  Published: 20/Sep/2012

Title: METHOD FOR PRODUCING POLYGONUM TINCTORIUM EXTRACT

Applicant/Assignee: SUNSTAR INC

Application No.: WO2012JP56598 (PCT/JP2012/56598)   Filing Date: 14/Mar/2012

Abstract:

The present invention addresses the problem of providing a tryptanthrin-containing Polygonum tinctorium extract particularly suitable for dermal applications. The present invention provides a method for producing a tryptanthrin-containing Polygonum tinctorium extract, the method comprising a step for filtering a mixture comprising an ethanol-extracted concentrate of Polygonum tinctorium and a polyhydric alcohol, and recovering the filtrate. Also provided is the Polygonum tinctorium extract produced by this production method.

Priority: JP20110055942 Applic. Date: 2011-03-14

Inventor: KUSAKARI TAKASHI [JP]; YAMASHITA KENTARO [JP]


Publication No.: WO2012125183A1  Published: 20/Sep/2012

Title: USE OF ANOGEISSUS EXTRACT FOR FIBRILLIN PRODUCTION IN SKIN

Applicant/Assignee: ELC MANAGEMENT LLC

Application No.: WO2011US52188 (PCT/US2011/52188)   Filing Date: 19/Sep/2011

Abstract:

Use of at least one extract from the Anogeissus genus for treating human skin by producing fibrillin and thereby increasing skin elasticity.

Priority: US201161451654P Applic. Date: 2011-03-11

Inventor: DALY SUSAN M [US]; DECLERCQ LIEVE [BE]


Publication No.: WO2012125772A2  Published: 20/Sep/2012

Title: ORAL FORMULATIONS FOR PROMOTING CELLULAR PURIFICATION

Applicant/Assignee: NSE PRODUCTS, INC

Application No.: WO2012US29136 (PCT/US2012/29136)   Filing Date: 14/Mar/2012

Abstract:

An oral formulation includes a plurality of agents that promote cellular detoxification. Agents can be included that modulate expression of Nrf2-associated genes upon ingestion of the oral formulation by a subject, wherein the Nrf2-associated genes include at least one gene encoding intrinsic antioxidants, and at least one gene encoding cellular detoxifiers. In addition, at least one of the plurality of agents attenuates inflammation.

Priority: US201161452478P Applic. Date: 2011-03-14

Inventor: MASTALOUDIS ANGELA [US]; WOOD STEVE [US]; BARGER JAIME LOUIS [US]; WEINDRUCH RICHARD [US]; POLLA TOMAS ALBERTO [US]; BARTLETT MARK [US]; FERGUSON SCOTT B [US]


Publication No.: WO2012125886A1  Published: 20/Sep/2012

Title: PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY

Application No.: WO2012US29334 (PCT/US2012/29334)   Filing Date: 16/Mar/2012

Abstract:

Disclosed are compounds of Formula (I), and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.

Priority: US201161453609P Applic. Date: 2011-03-17

Inventor: WROBLESKI STEPHEN T [US]; BROWN GREGORY D [US]; DOWEYKO LIDIA M [US]; DUAN JINGWU [US]; GUO JUNQING [US]; HYNES JOHN [US]; JIANG BIN [US]; KEMPSON JAMES [US]; LIN SHUQUN [US]; LU ZHONGHUI [US]; SPERGEL STEVEN H [US]; TOKARSKI JOHN S [US]; WU HONG [US]; YANG BINGWEI VERA [US]


Publication No.: WO2012125887A1  Published: 20/Sep/2012

Title: PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY

Application No.: WO2012US29337 (PCT/US2012/29337)   Filing Date: 16/Mar/2012

Abstract:

Disclosed are compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.

Priority: US201161453620P Applic. Date: 2011-03-17

Inventor: WROBLESKI STEPHEN T [US]; JAGABANDHU DAS [US]; DOWEYKO LIDIA M [US]; GUO JUNQING [US]; HYNES JOHN [US]; JIANG BIN [US]; KEMPSON JAMES [US]; LIN SHUQUN [US]; SPERGEL STEVEN H [US]; TOKARSKI JOHN S [US]; WU HONG [US]; YANG BINGWEI VERA [US]


Publication No.: WO2012125893A1  Published: 20/Sep/2012

Title: PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY

Application No.: WO2012US29366 (PCT/US2012/29366)   Filing Date: 16/Mar/2012

Abstract:

The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.

Priority: US201161453616P Applic. Date: 2011-03-17

Inventor: WROBLESKI STEPHEN T [US]; DAS JAGABANDHU [US]; DUAN JINGWU [US]; GUO JUNQING [US]; HYNES JOHN [US]; JIANG BIN [US]; KEMPSON JAMES [US]; LIN SHUQUN [US]; LU ZHONGHUI [US]; PITTS WILLIAM J [US]; SPERGEL STEVEN H [US]; WU HONG [US]; YANG BINGWEI VERA [US]


Publication No.: WO2012126047A1  Published: 27/Sep/2012

Title: AGENT AND METHOD FOR TREATING PAIN AND REDUCING INFLAMMATION

Applicant/Assignee: ADISTEM LTD

Application No.: WO2012AU00281 (PCT/AU2012/00281)   Filing Date: 16/Mar/2012

Abstract:

The invention provides a method of treating pain, reducing inflammation and reducing skin irritation particularly itching, the method comprising administering a polypeptide comprising thymosin, or an active fragment or variant thereof or a peptidomimetic thereof. Also provided are compositions for use in the methods.

Priority: AU20110900991 Applic. Date: 2011-03-18

Inventor: PASPALIARIS VASILIS [AU]


Publication No.: WO2012127037A2  Published: 27/Sep/2012

Title: A COMPOSITION COMPRISING LIPID NANOPARTICLES AND A CORTICOSTEROID OR VITAMIN D DERIVATIVE

Applicant/Assignee: LEO PHARMA A/S

Application No.: WO2012EP55222 (PCT/EP2012/55222)   Filing Date: 23/Mar/2012

Abstract:

A pharmaceutical composition comprises, as a therapeutically active ingredient, a corticosteroid and/or vitamin D derivative incorporated as a solid solution or dispersion in lipid nanopartides, said lipid nanopartides being solid at ambient temperature and comprising a first lipid with a melting point above body temperature, the first lipid being a wax selected from the group consisting of esters of C12-24 alcohols and C12-24 fatty acids, glyceryl mono-, di- or triesters of C12-24 fatty acids, C12-24 fatty alcohols, and cholesterol, optionally a second lipid which is an oil at ambient temperature and miscible with the first lipid, and a pharmaceutically acceptable surfactant.

Priority: US201161467192P Applic. Date: 2011-03-24

Inventor: JENSEN LOUISE BASTHOLM [DK]; PETERSSON KARSTEN [DK]


Publication No.: WO2012127352A2  Published: 27/Sep/2012

Title: MIA (MELANOMA INHIBITORY ACTIVITY) INHIBITORS FOR DETECTING, PREVENTING AND CURING VITILIGO

Applicant/Assignee:

Application No.: WO2012IB51141 (PCT/IB2012/51141)   Filing Date: 12/Mar/2012

Abstract:

Peptides, modified peptides and antibody or antibody fragment, which inhibit the activity of MIA(Melanoma Inhibitory Activity), for detecting, preventing and curing vitiligo are disclosed.

Priority: IT2011RM00134 Applic. Date: 2011-03-22

Inventor: BORDIGNON MATTEO [IT]


Publication No.: WO2012127885A1  Published: 27/Sep/2012

Title: TETRAHYDROCARBOLINE DERIVATIVE

Applicant/Assignee: ONO PHARMACEUTICAL CO., LTD

Application No.: WO2012JP50050 (PCT/JP2012/50050)   Filing Date: 05/Jan/2012

Abstract:

The invention addresses the problem of providing a drug with inhibitory activity against ENPP2, which is a different target from prior drugs, as a pharmaceutical product that is useful in patients with urinary retention in whom the efficacy of previous drugs was unsatisfactory. The present invention provides a compound represented by formula (I) that has ENPP2-inhibiting activity (in the formula, the definitions of the various groups are the same as described in the Specifications), a salt or solvate thereof, a prodrug thereof, and an agent for preventing, treating and/or mitigating the symptoms of urinary retention containing same as an active ingredient.

Priority: JP20110060765 Applic. Date: 2011-03-18

Inventor: OHATA AKIRA [JP]; NAKATANI SHINGO [JP]; SUGIYAMA TETSUYA [JP]; MORIMOTO TAKASHI [JP]


Publication No.: WO2012128418A1  Published: 27/Sep/2012

Title: EXTRACTS OBTAINED FROM CORDYCEPS BASSIANA FOR PREVENTING OR TREATING ATOPIC DERMATITIS, AND COMPOSITION INCLUDING SAME FOR PREVENTING OR TREATING ATOPIC DERMATITIS

Applicant/Assignee: SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATION, INDUSTRY ACADEMIC COOPERATION

Application No.: WO2011KR02989 (PCT/KR2011/02989)   Filing Date: 25/Apr/2011

Abstract:

The present invention relates to a method for extracting, from Cordyceps bassiana, an ingredient suppressing atopic dermatitis, and to a composition and personal care product for preventing or treating atopic dermatitis characterized in that they comprise the ingredient. According to the present invention, Cordyceps bassiana extracts are obtained by hot-water extraction, then polysaccharides are removed from the extracts using ethanol, and the ingredient having the effect of suppressing atopic dermatitis is obtained. The method of the present invention is advantageous in that the method is simple and easy, does not use toxic substances, and the ingredient suppressing atopic dermatitis can be extracted at a high yield from Cordyceps bassiana.

Priority: KR20110025336 Applic. Date: 2011-03-22

Inventor: SUNG JAE MO [KR]; WU GUANG [KR]; PARK HYOUNG JIN [KR]


Publication No.: WO2012129073A2  Published: 27/Sep/2012

Title: COMPOSITIONS AND METHODS FOR TISSUE ENGINEERING AND CELL BASED THERAPIES

Applicant/Assignee: UNIVERSITY OF VIRGINIA PATENT FOUNDATION

Application No.: WO2012US29369 (PCT/US2012/29369)   Filing Date: 16/Mar/2012

Abstract:

The present application discloses strategies to recruit and mobilize stem cells using S1P receptor selective agonists and antagonists as wells as regulators of chemokine receptors. In an in vivo ischemic model, S1P1/S1P3 activation with FTY720 impeded inflammatory cell infiltration and recruited endothelial progenitor cells (EPCs) with the potential to increase microvascular remodeling. S1P3 expression on marrow-derived cells was essential for this remodeling. Concurrent systemic S1P3 and CXCR4 antagonism mobilized hematopoietic stem cells (HSCs) with the ability to engraft and repopulate blood cells. Pre-treatment of donor HSCs with FTY720 increased homing toward SDF-1 and improved engraftment in marrow. FTY720-coated bone allografts coupled with systemic administration of VPC01091 enhanced bone allograft integration and new bone formation in bone defects. MSCs pre-treated with FTY720 exhibited increased migration toward SDF-1, a CXCR4+ ligand. The results show that S1P is a very powerful role player in pharmacological marrow-derived stem cell mobilization and recruitment.

Priority: US201161454169P Applic. Date: 2011-03-18; US201161547357P Applic. Date: 2011-10-14

Inventor: BOTCHWEY III EDWARD A [US]; LAUGHLIN MARY J [US]; LYNCH KEVIN R [US]; DAS ANUSUYA [US]; AWOJOODU ANTHONY [US]


Publication No.: WO2012129429A2  Published: 27/Sep/2012

Title: TRANSDERMAL COMPOSITIONS COMPRISING AN ACTIVE AGENT LAYER AND AN ACTIVE AGENT CONVERSION LAYER

Applicant/Assignee: TEIKOKU PHARMA USA, INC

Application No.: WO2012US30171 (PCT/US2012/30171)   Filing Date: 22/Mar/2012

Abstract:

Transdermal compositions are provided. Aspects of the transdermal compositions include: an active agent layer and a conversion layer, where the conversion layer includes a weak base and, optionally, a carboxylated component. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.

Priority: US201161467337P Applic. Date: 2011-03-24

Inventor: HAMLIN RICHARD [US]; WEN JIANYE [US]


Publication No.: WO2012129957A1  Published: 04/Oct/2012

Title: SEVERAL PHARMACEUTICAL FORMULATIONS

Applicant/Assignee:

Application No.: WO2012CN00061 (PCT/CN2012/00061)   Filing Date: 13/Jan/2012

Abstract:

Several pharmaceutical formulations, including pharmaceutical formulation for treating skin roughness, with estrogen as the main component

modified formulation of Huanglian Shangqing tablet for treating cancers, hemiplegia caused by cerebral haemorrhage, psychosis and hemorrhoids

pharmaceutical formulation for treating beriberi, with vitamin C as the main component and with a pharmaceutically acceptable base as an adjuvant to prepare a powder formulation or an aqueous formulation

pharmaceutical formulation for treating common cold, an anti-cold drug is mixed with a pharmaceutically acceptable base, vitamin C for increasing the efficacy against common cold, and other traditional Chinese medicinal herbs to prepare a powder formulation or a tablet formulation.

Priority: CN20111086621 Applic. Date: 2011-03-28; CN20111085976 Applic. Date: 2011-03-30; CN20111090748 Applic. Date: 2011-04-02

Inventor: ZHAO WENZHI [CN]


Publication No.: WO2012130609A1  Published: 04/Oct/2012

Title: NEW COMBINATION COMPRISING N-ACETYL-L-CYSTEINE AND ITS USE

Applicant/Assignee: IASOMAI AB

Application No.: WO2012EP54360 (PCT/EP2012/54360)   Filing Date: 13/Mar/2012

Abstract:

The present invention relates to a combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin, and a medical product or pharmaceutical composition comprising such combination,useful for the treatment of a variety of diseases and conditions, e.g. benign and malign neoplasia including various types of cancers, autoimmune diseases, neurodegenerative diseases, endocrinological diseases, type 2 diabetes, all types of fibrosis, amyloidosis, endometriosis, polycystic ovary syndrome, dysmenorrhea, dermatological diseases. The combination of N-acetyl-L-cysteine, seleniumin the form of selenomethionine and melatoninis also useful for cosmetic treatment of skin and as an antibacterial agent.

Priority: US201161508262P Applic. Date: 2011-07-15; SE20110050696 Applic. Date: 2011-07-15; US201161471162P Applic. Date: 2011-04-03; SE20110000238 Applic. Date: 2011-04-01

Inventor: PARASASSI TIZIANA [IT]; COSTA GRAZIELLA [IT]; KRASNOWSKA EWA [IT]; PITTALUGA EUGENIA [IT]


Publication No.: WO2012131069A1  Published: 04/Oct/2012

Title: SHORT CHAIN FATTY ACIDS AND THEIR DERIVATIVES FOR USE IN TREATMENT IMMUNOGENIC DISORDERS

Applicant/Assignee: PROPONENT BIOTECH GMBH

Application No.: WO2012EP55878 (PCT/EP2012/55878)   Filing Date: 30/Mar/2012

Abstract:

The present invention relates to short chain fatty acids (SCFA) for modulating a Th2 immune response towards a Th1 immune response for prevention and/or amelioration of viral infections and as an adjuvant for promoting the efficiency of vaccines and/or prevention of allergic diseases or disorders, particularly of a disease or disorder mediated by T helper 2 (Th2) cell-derived cytokines, including, without being limited to, !L-4. IL-5, IL-6, IL-8, IL-10 and IL-13, but particularly for use in the treatment of IL-4 and/or IL-8 and/or IgE mediated diseases or disorders and/or eosinophilic diseases or disorders.

Priority: EP20110160558 Applic. Date: 2011-03-31; EP20110160595 Applic. Date: 2011-03-31

Inventor: ERNST BETTINA [CH]


Publication No.: WO2012131090A1  Published: 04/Oct/2012

Title: METHOD FOR TREATMENT OF XERODERMA PIGMENTOSUM

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT

Application No.: WO2012EP55955 (PCT/EP2012/55955)   Filing Date: 02/Apr/2012

Abstract:

This invention relates to a method of treating xeroderma pigmentosum and related symptoms in patients by administering a MC1R before or after exposing them to visible light.

Priority: US201161470190P Applic. Date: 2011-03-31

Inventor: ANDRES PHILIPPE [FR]


Publication No.: WO2012131341A2  Published: 04/Oct/2012

Title: TIGHT JUNCTIONS MODULATORS

Applicant/Assignee: THE UNIVERSITY OF MANCHESTER

Application No.: WO2012GB50655 (PCT/GB2012/50655)   Filing Date: 23/Mar/2012

Abstract:

The present invention relates to a new therapy targeted at the restoration or improvement of tight junction function. Aberrant TJ function, is characteristic of many chronic skin diseases. The inventors demonstrated that plant polyphenols or flavonoids and Cis-urocanic acid modulates tight junction structure and function in mammalian keratinocytes and provided tight junction modulators, pharmaceutical compositions and methods for preventing or treating impaired tight junction function in stratified mammalian epithelia.

Priority: GB20110005411 Applic. Date: 2011-03-31

Inventor: O'NEILL CATHERINE ANNE [GB]; GIBBS NEIL KERSLAKE [GB]


Publication No.: WO2012134433A1  Published: 04/Oct/2012

Title: HEAT-EXTRACTED OMENTUM EXTRACTS, COMPOSITIONS, METHODS OF PREPARING AND USES THEREOF

Applicant/Assignee: COOPERLABS LIMITED

Application No.: WO2011US30059 (PCT/US2011/30059)   Filing Date: 25/Mar/2011

Abstract:

Disclosed herein are compositions including an extract of mammalian omentum wherein the extract is a liquid portion of the mammalian omentum, such as an oil, extracted when the omentum is heated to a temperature of between 210 and 240 degrees Fahrenheit. Also disclosed are methods of making a composition including an extract of mammalian omentum wherein the method includes heating mammalian omentum to a temperature of between 212 degrees Fahrenheit and 225 degrees Fahrenheit, such as 215 degrees Fahrenheit and 220 degrees Fahrenheit. Methods of use of the disclosed extracts and compositions are provided including methods of inducing or enhancing angiogenesis, methods of improving skin quality and methods of promoting hair growth and/or inhibiting hair loss.

Priority: WO2011US30059 Applic. Date: 2011-03-25

Inventor: GREENE JAMES A [US]; BUSCH JERAD [US]; WRAPE GEORGE JR [US]; KLEIN JONATHAN D [US]


Publication No.: WO2012135337A2  Published: 04/Oct/2012

Title: TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTS

Applicant/Assignee: MARY KAY INC

Application No.: WO2012US30936 (PCT/US2012/30936)   Filing Date: 28/Mar/2012

Abstract:

Disclosed are topical skin compositions and corresponding methods for their use that include plant extracts. One such composition can include a TNF-a inhibitor, wherein said inhibitor is an aqueous extract from the whole plant of Polygonum multiflorum, an antioxidant and a tyrosinase inhibitor, wherein said antioxidant and tyrosinase inhibitior is an aqueous extract from the whole plant of Lonicera japonica, and a dermatologically acceptable carrier, wherein the composition can include at least 50% by weight of water.

Priority: US201161468437P Applic. Date: 2011-03-28

Inventor: FLORENCE TIFFANY [US]; GAN DAVID [US]; HINES MICHELLE [US]


Publication No.: WO2012135597A2  Published: 04/Oct/2012

Title: NOVEL, PROTECTIVE, ANTI-INFLAMMATORY RECEPTOR AND ITS USE IN PRESERVATION OF MITOCHONDRIAL FUNCTION, WOUND HEALING AND REPAIR

Applicant/Assignee: THE JOHNS HOPKINS UNIVERSITY

Application No.: WO2012US31406 (PCT/US2012/31406)   Filing Date: 30/Mar/2012

Abstract:

Provided herein is a novel mitochondrial Angiotensin II type 1 and type 2 AT1R and AT2R receptor which plays a role in protection of mitochondria against oxidative damage. Evidence from animal studies indicates a role for this receptor in preservation of mitochondria and up-regulation of survival genes, anti-inflammatory action, and improvement of wound healing in the skin and soft tissues. Pharmaceutical compositions for treatment directed to preserving mitochondrial function, anti-inflammation, wound healing and decreasing the signs of aging, as well as medicaments and their use are also provided.

Priority: US201161469421P Applic. Date: 2011-03-30; US201161490312P Applic. Date: 2011-05-26

Inventor: ABADIR PETER M [US]; WALSTON JEREMY D [US]


Publication No.: WO2012135812A2  Published: 04/Oct/2012

Title: TREATMENT FOR DERMATOLOGICAL PATHOLOGIES

Applicant/Assignee: XBIOTECH, INC

Application No.: WO2012US31803 (PCT/US2012/31803)   Filing Date: 02/Apr/2012

Abstract:

Skin inflammation in a human subject is reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-la aa

Priority: US201161470538P Applic. Date: 2011-04-01

Inventor: SIMARD JOHN [US]


Publication No.: WO2012136711A1  Published: 11/Oct/2012

Title: ANILIDE-ALKYL THIOETHERS AS ACAT INHIBITORS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES

Applicant/Assignee: PIERRE FABRE MEDICAMENT

Application No.: WO2012EP56177 (PCT/EP2012/56177)   Filing Date: 04/Apr/2012

Abstract:

The present invention relates to novel alkyl thioethers for the preparation of a medicament intended to prevent or to treat a disorder due to a dysfunction of the sebaceous glands in humans or animals. The compounds according to the present invention exert a strong inhibition of acyl CoA: cholesterol O-acyl transferase (ACAT): (I) in which - R1 represents a hydroxyl or amino group, - R2 represents a hydrogen or a methyl radical, - A represents a group chosen from: (II) - n represents an integer from 5 to 13.

Priority: FR20110052889 Applic. Date: 2011-04-04

Inventor: CLERC THIERRY [FR]; JUNQUERO DIDIER [FR]; PEREZ MICHEL [FR]; AUTIN JEAN-MARIE [FR]


Publication No.: WO2012138441A1  Published: 11/Oct/2012

Title: COMPOSITION AND METHOD FOR TOPICAL TREATMENT OF SKIN LESIONS

Applicant/Assignee: WINLIND SKINCARE, LLC

Application No.: WO2012US27738 (PCT/US2012/27738)   Filing Date: 05/Mar/2012

Abstract:

Disclosed herein is a composition containing a high concentration of PG is unexpectedly capable of quickly killing other bacteria, fungi, and/or virus in vitro that is indicative of its potential high efficacy in treating various skin infection. Embodiments disclosed herein relate to a composition and method for effective topical treatment of inflammatory skin lesions in mammals, comprising of a high concentration of propylene glycol alone, or in combination with an astringent. The PG at high concentrations can be regarded as an extremely effective, safe, topical, universal, microbicide.

Priority: US201113079964 Applic. Date: 2011-04-05

Inventor: CHIOU WIN L [US]


Publication No.: WO2012140095A1  Published: 18/Oct/2012

Title: PEPTIDYL ARGININE DEIMINASE 1 AND/OR 3 ACTIVATOR COMPOUNDS IN THE EPIDERMIS AND USES THEREOF

Applicant/Assignee: PIERRE FABRE DERMO-COSMETIQUE

Application No.: WO2012EP56596 (PCT/EP2012/56596)   Filing Date: 11/Apr/2012

Abstract:

The present invention relates to the activation of peptidyl arginine deiminase (PADs) 1 and/or 3 in the epidermis by at least one active agent used alone or in combination, namely caffeine, acefylline and/or theobromine in a cosmetic and/or pharmaceutical composition. The present invention also relates to the use of the aforementioned active agents in cosmetics and/or therapeutics, alone or in combination, in order to improve the barrier functions of the epidermis, to prevent and/or treat symptoms related to dry skin or to improve and/or promote hydration of the keratinous layer. Finally, the invention relates to increasing the activity of PAD1 and/or PAD3 in the epidermis.

Priority: FR20110053135 Applic. Date: 2011-04-11

Inventor: DUPLAN HELENE [FR]; DAUNES-MARION SYLVIE [FR]; POIGNY STEPHANE [FR]; MECHIN MARIE-CLAIRE [FR]; SERRE GUY [FR]; SIMON MICHEL [FR]


Publication No.: WO2012140351A2  Published: 18/Oct/2012

Title: CAFFEINE AND TRIACANTHINE COMPOSITION FOR TREATING EXCESS FAT

Applicant/Assignee: LABORATOIRE NUXE

Application No.: WO2012FR50746 (PCT/FR2012/50746)   Filing Date: 05/Apr/2012

Abstract:

The invention relates to a composition that can be used in dermatology and/or cosmetics. The composition includes a combination of sufficient amounts of caffeine and triacanthine. The invention is useful in cosmetic and dermatological compositions for treating excess fat and cellulite.

Priority: FR20110053126 Applic. Date: 2011-04-11

Inventor: LECONTE NADINE [FR]; LECLERE JACQUES [FR]


Publication No.: WO2012140352A2  Published: 18/Oct/2012

Title:

Applicant/Assignee: LABORATOIRE NUXE

Application No.: WO2012FR50747 (PCT/FR2012/50747)   Filing Date: 05/Apr/2012

Abstract:

The invention relates to a composition that can be used in dermatology and/or cosmetics. The composition includes a sufficient amount of Gleditsia mucilage optionally combined with a venotonic agent. The invention can be used in cosmetic or dermatological compositions for treating excess fat and cellulite.

Priority: FR20110053127 Applic. Date: 2011-04-11

Inventor: LECONTE NADINE [FR]; LECLERE JACQUES [FR]


Publication No.: WO2012142059A2  Published: 18/Oct/2012

Title: PARTICLES COMPRISING VOLATILE MATERIALS AND PARTICLE GAS SATURATED SOLUTION PROCESSES FOR MAKING SAME

Applicant/Assignee: THE PROCTER & GAMBLE COMPANY

Application No.: WO2012US32958 (PCT/US2012/32958)   Filing Date: 11/Apr/2012

Abstract:

Particles containing a polymer and a volatile material, such as a perfume, and particle gas saturated solution (PGSS) processes for making such particles are provided.

Priority: US201161474007P Applic. Date: 2011-04-11

Inventor: RAUCKHORST HOLLY BALASUBRAMANIAN [US]; D ACCHIOLI VINCENZO [IT]; DREHER ANDREAS JOSEF [US]


Publication No.: WO2012143143A1  Published: 26/Oct/2012

Title: HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS

Applicant/Assignee: ORIGENIS GMBH

Application No.: WO2012EP01736 (PCT/EP2012/01736)   Filing Date: 23/Apr/2012

Abstract:

The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

Priority: US201161517581P Applic. Date: 2011-04-21

Inventor: ALMSTETTER MICHAEL [DE]; THORMANN MICHAEL [DE]; TREML ANDREAS [DE]; KOESTLER ROLAND [DE]; YEHIA NASSER [DE]


Publication No.: WO2012143856A1  Published: 26/Oct/2012

Title: USE OF A COMBINATION OF CAROTENOID, PHYTOESTROGEN AND VITAMIN C FOR THE PREVENTION AND/OR TREATMENT OF PIGMENTATION DISORDERS

Applicant/Assignee: LABORATOIRES INNEOV

Application No.: WO2012IB51924 (PCT/IB2012/51924)   Filing Date: 17/Apr/2012

Abstract:

The present invention relates to the use, for preventing and/or treating pigmentation disorders, for the preparation of a cosmetic composition suitable for orally administering a dailydose of from 1 to 25 mg of a carotenoid, from 10 to 300 mg of a phytooestrogen and from 10 to 1000 mg of vitamin C.

Priority: US201161499196P Applic. Date: 2011-06-21; FR20110053392 Applic. Date: 2011-04-19

Inventor: PICCARDI NATHALIE [FR]; BRU CAROLE [FR]


Publication No.: WO2012143868A1  Published: 26/Oct/2012

Title: SUSPENSION TYPE TOPICAL FORMULATIONS COMPRISING CYCLIC DEPSIPEPTIDE

Applicant/Assignee: NOVARTIS AG

Application No.: WO2012IB51946 (PCT/IB2012/51946)   Filing Date: 18/Apr/2012

Abstract:

The invention relates to novel topical pharmaceutical compositions in which the active agent is a cyclic depsipeptide of formula (II) and to methods for manufacturing such compositions. The application discloses in particular hydrophobic ointments comprising a hydrophobic base and a consistency agent, preferably isopropyl myristate

Priority: US201161477297P Applic. Date: 2011-04-20

Inventor: HAUG CLAIRE [CH]


Publication No.: WO2012144080A1  Published: 26/Oct/2012

Title: SKIN BARRIER FUNCTION IMPROVING AGENT

Applicant/Assignee: INTER-UNIVERSITY RESEARCH INSTITUTE CORPORATION NATIONAL INSTITUTES OF NATURAL SCIENCES, POLA CHEMICAL INDUSTRIES, INC

Application No.: WO2011JP59985 (PCT/JP2011/59985)   Filing Date: 22/Apr/2011

Abstract:

The purpose of the present invention is to provide a novel TRPV receptor activator which is suitable for the improvement in a skin barrier function. The purpose can be achieved by providing a TRPV receptor activator which comprises at least one compound selected from compounds respectively represented by the formulae or a plant extract containing the at least one compound in an effective amount for acting as a TRPV receptor activator. (In the formulae, a hydroxy group may be substituted by a methoxy group or an ethoxy group

and a methoxy group may be substituted by a hydroxy group or an ethoxy group.)

Priority: WO2011JP59985 Applic. Date: 2011-04-22

Inventor: TOMINAGA MAKOTO [JP]; SOKABE TAKAAKI [JP]; KIDA NAOKO [JP]; OBA AI [JP]; KANAMARU AKIKO [JP]; FUKUDA TOSHIYUKI [JP]


Publication No.: WO2012144546A1  Published: 26/Oct/2012

Title: NOVEL PEPTIDE

Applicant/Assignee: ROHTO PHARMACEUTICAL CO., LTD

Application No.: WO2012JP60538 (PCT/JP2012/60538)   Filing Date: 19/Apr/2012

Abstract:

The purpose of the present invention is to provide a novel substance which has an activity of inhibiting an angiotensin-converting enzyme and/or an activity of promoting the adhesion between a fibroblast and collagen. A peptide comprising an amino acid sequence represented by formula (I): Xaa1-Asp-Leu-Asp-Val-Xaa2 (SEQ ID NO: :1) [wherein Xaa1 and Xaa2 may be present or absent and, if present, independently represent an arbitrary amino acid residue], a derivative of the peptide, or a salt of the peptide or the derivative.

Priority: JP20110095945 Applic. Date: 2011-04-22

Inventor: ABE MASAMICHI [JP]; KUMAZAWA MASUNORI [JP]; MATSUMOTO KOSUKE [JP]


Publication No.: WO2012144661A1  Published: 26/Oct/2012

Title: AROMATIC HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY

Applicant/Assignee: SHIONOGI & CO., LTD

Application No.: WO2012JP61621 (PCT/JP2012/61621)   Filing Date: 18/Apr/2012

Abstract:

A compound having TRPV4 inhibitory activity or a pharmaceutically acceptable salt thereof is provided. The present invention is related to a compound represented by the formula (I). wherein R1a is substituted or unsubstituted alkyl or the like

R1b is hydrogen or substituted or unsubstituted alkyl

R1c is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted nonaromatic heterocyclic group or the like

-L- is -C(=0)-NR2- or the like

X is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or the like, or a pharmaceutically acceptable salt thereof.

Priority: JP20110093633 Applic. Date: 2011-04-20; US201161485943P Applic. Date: 2011-05-13

Inventor: YUKIMASA AKIRA [JP]


Publication No.: WO2012145258A1  Published: 26/Oct/2012

Title: HAIR LOSS TREATMENT

Applicant/Assignee: POP TEST CORTISOL LLC

Application No.: WO2012US33731 (PCT/US2012/33731)   Filing Date: 16/Apr/2012

Abstract:

This invention relates to the use of Cortisol blockers (glucocorticoid receptor [GR] antagonists) for the prevention or treatment of stress induced hair loss.

Priority: US201161517343P Applic. Date: 2011-04-18

Inventor: ALTSCHUL RANDICE LISA [US]; THEISE NEIL DAVID [US]; RAPKIN MYRON [US]; O'BRIEN REBECCA [US]


Publication No.: WO2012147470A1  Published: 01/Nov/2012

Title: PEPTIDE FOR INDUCING REGENERATION OF TISSUE AND USE THEREOF

Applicant/Assignee: GENOMIX CO., LTD, OSAKA UNIVERSITY

Application No.: WO2012JP59113 (PCT/JP2012/59113)   Filing Date: 03/Apr/2012

Abstract:

[Problem] To provide a therapeutic agent which can promote the recruitment of PDGFRa-positive cells such as bone marrow-derived mesenchymal stem cells in blood and the accumulation of the PDGFRa-positive cells in damaged tissues, both of which are caused by the stimulation of the PDGFa-positive cells, thereby inducing the regeneration of tissues in vivo. [Solution] Multiple peptides are synthesized, and it is tried to assess the migration activity of each of the peptides. As a result, multiple peptides having a migration activity on a PDGFRa-positive bone marrow-derived mesenchymal stem cell strain (MSC-1) are successfully identified. Further, it is confirmed that the identified peptides also have a migration activity on skin fibroblasts that are PDGFRa-positive cells and the like.

Priority: JP20110098270 Applic. Date: 2011-04-26; JP20110219454 Applic. Date: 2011-10-03

Inventor: TAMAI KATSUTO [JP]; YAMAZAKI TAKEHIKO [JP]; KANEZAKI TSUTOMU [JP]; SAKURAI SHIGERU [JP]; NOGUCHI YUKIKO [JP]; ENDO MAYUMI [JP]; HAMABUCHI NATSUMI [JP]; NAITO KANA [JP]


Publication No.: WO2012149439A2  Published: 01/Nov/2012

Title: IL4/IL13 BINDING REPEAT PROTEINS AND USES

Applicant/Assignee: JANSSEN BIOTECH, INC, MOLECULAR PARTNERS AG

Application No.: WO2012US35613 (PCT/US2012/35613)   Filing Date: 27/Apr/2012

Abstract:

IL4/IL13-binding proteins comprise binding domains, which inhibit IL4/IL13 binding to IL4Ralpaha and common gamma chain complexes (Type 1 ) and inhibit IL4 binding to IL4Ralpha and IL13Ralpha1 complexes (Type 2), and IL13 binding to IL13Ralpha1 and/or IL13Ralpha2, are useful in the treatment of cancer, inflammatory, and other pathological conditions, such as allergic or fibrotic conditions, especially pulmonary conditions.

Priority: US201161481008P Applic. Date: 2011-04-29; US201161481021P Applic. Date: 2011-04-29; US201161480999P Applic. Date: 2011-04-29

Inventor: JACOBS STEVEN A [US]; O'NEIL KARYN T [US]; BAUMANN MICHAEL [CH]; SENNHAUSER GABY [CH]


Publication No.: WO2012149600A1  Published: 08/Nov/2012

Title: AVIAN-BASED TREATMENT FOR MICROBIAL INFECTIONS

Applicant/Assignee: COCKY SMART PTY LTD

Application No.: WO2012AU00459 (PCT/AU2012/00459)   Filing Date: 02/May/2012

Abstract:

A method for treating or preventing microbial skin infections comprising the step of: administering to a subject in need thereof a composition comprising avian extract EP-2 in a therapeutically effective concentration together with a pharmaceutically acceptable carrier and/or diluent.,

Priority: AU20110901619 Applic. Date: 2011-05-02

Inventor: CHAMBERLAIN JOHN [AU]


Publication No.: WO2012149601A1  Published: 08/Nov/2012

Title: AVIAN-BASED TREATMENT

Applicant/Assignee: COCKY SMART PTY LTD

Application No.: WO2012AU00460 (PCT/AU2012/00460)   Filing Date: 02/May/2012

Abstract:

A method for treating or preventing proliferative skin disorders, cancers or pre-cancers comprising the step of: administering to a subject in need thereof a composition comprising comprising avian extract EP-2 in a therapeutically effective concentration together with a pharmaceutically acceptable carrier and/or diluent.

Priority: AU20110901620 Applic. Date: 2011-05-02; AU20120900513 Applic. Date: 2012-02-13

Inventor: CHAMBERLAIN JOHN [AU]


Publication No.: WO2012150486A1  Published: 08/Nov/2012

Title: A COMPOSITION FOR TREATING AUTOIMMUNE DISORDERS AND METHODS THEREOF

Applicant/Assignee: INDUS BIOTECH PRIVATE LIMITED

Application No.: WO2011IB52592 (PCT/IB2011/52592)   Filing Date: 15/Jun/2011

Abstract:

The present disclosure relates to a composition comprising Trigoneoside Ib and Vicenin-1 for treatment and management of Goodpasture's disease, Glomerulonephritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus and Idiopathic Thrombocytopenia Purpura. The present disclosure also relates to a method of obtaining the said composition from Trigonella foenum-graecum.

Priority: IN2011MU01367 Applic. Date: 2011-05-02

Inventor: BHASKARAN SUNIL [IN]; VISHWARAMAN MOHAN [IN]


Publication No.: WO2012151346A1  Published: 08/Nov/2012

Title: EXPRESSION SIGNATURES OF GENES AND GENE NETWORKS ASSOCIATED WITH SKIN AGING

Applicant/Assignee: DERMACHIP INC

Application No.: WO2012US36226 (PCT/US2012/36226)   Filing Date: 03/May/2012

Abstract:

Described herein are expression signatures of genes and coordinately expressed gene networks associated with skin aging, methods used to determine the physiological age of skin, and methods used to screen for compounds used to reduce the visible signs of aging of the skin.

Priority: US201161482071P Applic. Date: 2011-05-03

Inventor: GIULIANI GIAMMARIA [IT]; RODRIGUEZ RAYMOND [US]; NANDI SOMEN [US]


Publication No.: WO2012152615A1  Published: 15/Nov/2012

Title: COSMETIC COMPOSITIONS COMPRISING DITERPENOIC ACIDS, E.G. GIBBERELLIC ACIDS

Applicant/Assignee: CUTECH SRL

Application No.: WO2012EP57952 (PCT/EP2012/57952)   Filing Date: 01/May/2012

Abstract:

Suggested are new cosmetic compositions comprising diterpenoic acids.

Priority: EP20110165475 Applic. Date: 2011-05-10

Inventor: PERTILE PAOLO [IT]; MASSIRONI MICHELE [IT]


Publication No.: WO2012152940A2  Published: 15/Nov/2012

Title: SMALL MOLECULE INHIBITORS OF TRPA1

Applicant/Assignee: B.R.A.I.N. BIOTECHNOLOGY RESEARCH AND INFORMATIONNETWORK AG

Application No.: WO2012EP58839 (PCT/EP2012/58839)   Filing Date: 11/May/2012

Abstract:

The present invention relates to the use of compounds which are capable of attenuating skin irritation when they are applied to the skin. Skin irritation can be caused, inter alia, by ingredients of cosmetic or pharmaceutical compositions and/or environmental irritants. In particular, the present invention relates to compounds having the property of antagonizing the activation of the transient receptor potential (TRP) ankyrin 1 (TRPA1) ion channel and the use of said compounds as soothing agents. Such compounds can be used in many fields, particularly in personal-care products, cosmetics, textile and packaging products, pharmaceutical compositions, medical devices,and foodstuffs. The present invention further relates to products and/or pharmaceutical compositions containing said compounds.

The present invention also relates to the use of the compounds described herein for the modulation of the taste of a food product.

Priority: EP20110165879 Applic. Date: 2011-05-12

Inventor: KROHN MICHAEL [DE]; SOMBROEK DIRK [DE]


Publication No.: WO2012153064A2  Published: 15/Nov/2012

Title: COSMETIC OR DERMATOLOGICAL COMPOSITION MADE FROM EXTRACTS OF EVERLASTING AND USE THEREOF

Applicant/Assignee: LABORATOIRES M&L

Application No.: WO2012FR51028 (PCT/FR2012/51028)   Filing Date: 09/May/2012

Abstract:

The present invention relates to a cosmetic or dermatological anti-ageing composition. In particular, the present invention relates to a cosmetic or dermatological composition including at least one aqueous extract of everlasting, at least one oily extract of everlasting and at least essential oil of everlasting. The present invention also relates to the cosmetic use of the composition in an anti-ageing treatment and to an anti-ageing cosmetic treatment method which includes applying a cosmetic composition according to the invention to the skin. The present invention offers a complete solution for daily skincare needs, in order effectively to control the signs of ageing.

Priority: FR20110053960 Applic. Date: 2011-05-09

Inventor: DEVILARD ELISABETH [FR]; TOUREL CECILE [FR]; PIERRISNARD LAURE [FR]; PIERRISNARD JEAN-LOUIS [FR]


Publication No.: WO2012153076A2  Published: 15/Nov/2012

Title: COSMETIC SKIN TREATMENT METHOD COMPRISING TWO SUCCESSIVE STEPS

Applicant/Assignee:

Application No.: WO2012FR51065 (PCT/FR2012/51065)   Filing Date: 14/May/2012

Abstract:

The invention relates to a method for the cosmetic treatment of the skin and/or mucous membranes, consisting in successively applying two cosmetic compositions to the skin and/or mucous membranes, namely: a first composition containing a single active ingredient that can correct a skin dysfunction, optionally in the presence of a pro-penetrator system

and, immediately following the application of the first composition, a second composition which, depending on skin type, has a nourishing and/or hydrating and/or protective action and/or enhances complexion radiance and/or elasticity and/or matt appearance.

Priority: FR20110054114 Applic. Date: 2011-05-12

Inventor: THOREL JEAN-NOEL [FR]


Publication No.: WO2012153832A1  Published: 15/Nov/2012

Title: COMPOSITION FOR EXTERNAL SKIN USE FOR INFLAMMATORY DISEASES

Applicant/Assignee: NIPPON SUISAN KAISHA, LTD

Application No.: WO2012JP62114 (PCT/JP2012/62114)   Filing Date: 11/May/2012

Abstract:

[Problem] To provide a composition for external skin use that has anti-inflammatory and antiallergic activity, and is very safe. [Solution] A composition for external skin use for inflammatory diseases contains dihomo-gamma-linolenic acid (DGLA) as the active ingredient thereof. It is preferable for the DGLA to be present as a glyceride, a phospholipid, or an alkyl ester. The amount of DGLA contained in the composition for external use is 0.1-50 wt%.

Priority: JP20110107512 Applic. Date: 2011-05-12

Inventor: TAKEO JIRO [JP]; KAWAHARA HIROYUKI [JP]


Publication No.: WO2012153884A1  Published: 15/Nov/2012

Title: COMPOSITION HAVING IMPROVED STABILITY FOR AMELIORATING ACNE

Applicant/Assignee: AMOREPACIFIC CORPORATION

Application No.: WO2011KR03502 (PCT/KR2011/03502)   Filing Date: 12/May/2011

Abstract:

The present invention provides a composition for preventing or treating acne, comprising: benzoyl peroxide, a derivative thereof, a hydrous form thereof or pharmaceutically acceptable salts thereof

clindamycin, a derivative thereof, a hydrous form thereof or pharmaceutically acceptable salts thereof

and sodium pyrosulfite. The composition has high stability due to inclusion of sodium pyrosulfite. Also, said composition includes pulverized benzoyl peroxide, thereby providing high stability and an excellent perception of utility.

Priority: WO2011KR03502 Applic. Date: 2011-05-12

Inventor: YI CHANG GEUN [KR]; JEON SANG HOON [KR]; JEONG YEON SU [KR]; KIM JEONG HWAN [KR]; KIM HYOUNG JUN [KR]; KIM SUNG SOO [KR]; BAIK SOO JUNG [KR]; SHIN HONG JU [KR]; HAN JIN TAE [KR]; CHA NA RI [KR]; KIM DO HOON [KR]; PARK JONG HEE [KR]; PARK WON SEOK [KR]


Publication No.: WO2012154075A1  Published: 15/Nov/2012

Title: ANTIBACTERIALLY ACTIVE PHARMACEUTICAL COMPOSITION FOR EXTERNAL USE, AND METHOD FOR THE PRODUCTION OF SAID COMPOSITION

Applicant/Assignee:

Application No.: WO2011RU00778 (PCT/RU2011/00778)   Filing Date: 05/Oct/2011

Abstract:

The invention relates to pharmacology, medicine, veterinary medicine and to the pharmaceutical industry, in particular to a method for producing original composite antibacterial preparations for external use, said preparations having increased therapeutic effectiveness in the treatment of infections of the skin and soft tissues. The proposed pharmaceutical composition comprises mechanically activated chloramphenicol, phosphomycin and highly dispersed nano-structured silicon dioxide as the active substance. The claimed method for the production of the pharmaceutical composition consists in mixing the chloramphenicol, phosphomycin and highly dispersed nano-structured silicon dioxide, characterized in that the mixture of the above-mentioned substances in a weight ratio of 1:5:5, respectively, is subjected to mechanical processing by means of impact-abrading actions, after which said mixture is mixed with an ointment base (polyethylene oxide).

Priority: EA20110000734 Applic. Date: 2011-05-11

Inventor: LIMONOV VIKTOR LVOVICH [RU]; GAIDUL KONSTANTIN VALENTINOVICH [RU]; DUSHKIN ALEKSANDR VALEREVICH [RU]


Publication No.: WO2012156319A1  Published: 22/Nov/2012

Title: NOVEL ANTI-REDNESS ACTIVE AGENT AND COSMETIC COMPOSITIONS COMPRISING SAME

Applicant/Assignee: LABORATOIRES EXPANSCIENCE

Application No.: WO2012EP58798 (PCT/EP2012/58798)   Filing Date: 11/May/2012

Abstract:

The present application relates to a cosmetic method for preventing and/or treating skin redness, characterized in that a composition comprising arabinogalactan is administered to a person who may form or who is displaying redness. This cosmetic composition can be administered topically or orally.

Priority: FR20110054181 Applic. Date: 2011-05-13

Inventor: MSIKA PHILIPPE [FR]; BAUDOUIN CAROLINE [FR]; MENU FRANCK [FR]


Publication No.: WO2012156877A1  Published: 22/Nov/2012

Title: EPICUTANEOUS. SKIN CANCER, BASAL, SQUAMOUS, MELANOMA, COLLAGEN, PROCOLLA1, MMP1

Applicant/Assignee: UNIVERSITY OF MANITOBA

Application No.: WO2012IB52341 (PCT/IB2012/52341)   Filing Date: 10/May/2012

Abstract:

The present invention includes methods for treating sun-exposed skin, such as treating photoaging and treating skin cancer. Also included are methods for altering a cell's response to ultraviolet radiation. The methods include administration of quetiapine or an analog thereof or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

Priority: US201161485908P Applic. Date: 2011-05-13

Inventor: LI XIN-MIN [CA]; KONG JIMING [CA]; ZHANG HANDI [CA]; HARTLE KELLY [CA]


Publication No.: WO2012156917A2  Published: 22/Nov/2012

Title: METHOD FOR OBTAINING EPSILON-VINIFERIN AND/OR RESVERATROL AND CORRESPONDING PRODUCTS

Applicant/Assignee: CAUDALIE

Application No.: WO2012IB52444 (PCT/IB2012/52444)   Filing Date: 16/May/2012

Abstract:

The invention relates to a method for obtaining purified e-viniferin (Vf-Dry) and/or resveratrol which has a low content or is even free of e-viniferin (Rv-Dry), from an extract, which is crude (EBPS), dry (EBPS-dry), or in solution (EBPS-Sol), of a plant material rich in stilbenoid polyphenols, characterized in that it comprises at least one cycle of adsorption-desorption on a solid substrate such as poly(vinylidene fluoride) or PVDF with EBPS-Sol, and/or partition of this EBPS-Sol solution with ethyl acetate. Applications in particular in the cosmetics industry and in therapy.

Priority: FR20110054395 Applic. Date: 2011-05-19

Inventor: VERCAUTEREN JOSEPH [FR]; SALMI CECILE [FR]


Publication No.: WO2012156927A1  Published: 22/Nov/2012

Title: METHOD TO MODULATE PIGMENTATION PROCESS IN THE MELANOCYTES OF SKIN

Applicant/Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH

Application No.: WO2012IB52456 (PCT/IB2012/52456)   Filing Date: 16/May/2012

Abstract:

The invention describes a method to modulate melanosome maturation process in melanocytes. Further, it describes a method to reversibly alter the process of pigmentation in the human epidermal skin. The method targets melanosome maturation and its transfer to keratinocytes, which are key processes involved in the pigmentation for its potential use in predictable and controlled regulation of pigmentation in human skin.

Priority: IN2011DE01420 Applic. Date: 2011-05-16

Inventor: GOKHALE RAJESH SUDHIR [IN]; NATARAJAN VIVEK TIRUNELVELI [IN]; GANJU PARUL [IN]


Publication No.: WO2012157479A1  Published: 22/Nov/2012

Title: CTRP6 WHICH CAN BE USED AS THERAPEUTIC AND PROPHYLACTIC AGENT FOR AUTOIMMUNE DISEASES

Applicant/Assignee: THE UNIVERSITY OF TOKYO

Application No.: WO2012JP61827 (PCT/JP2012/61827)   Filing Date: 09/May/2012

Abstract:

[Problem] The purpose of the present invention is to elucidate the biological function of CTRP6 and to put CTRP6 into practice. [Solution] A pharmaceutical composition for preventing or treating autoimmune diseases, which comprises CTRP6. Particularly preferably provided is a pharmaceutical composition for preventing or treating inflammations associated with autoimmune diseases, such as rheumatoid arthritis or type-I diabetes.

Priority: US201161485746P Applic. Date: 2011-05-13; JP20110219350 Applic. Date: 2011-10-03

Inventor: IWAKURA YOICHIRO [JP]; MURAYAMA MASANORI [JP]; ISHIGAME HARUMICHI [JP]; KAKUTA SHIGERU [JP]


Publication No.: WO2012157587A1  Published: 22/Nov/2012

Title: ANTI-WRINKLE AGENT, MATRIX METALLOPROTEINASE (MMP) INHIBITOR AND/OR LAMININ 5 PRODUCTION PROMOTER, EACH COMPRISING 1-PIPERIDINE PROPIONATE

Applicant/Assignee: SHISEIDO COMPANY, LTD

Application No.: WO2012JP62222 (PCT/JP2012/62222)   Filing Date: 11/May/2012

Abstract:

The purpose of the invention is to provide a novel and effective anti-wrinkle agent. The invention relates to a matrix metalloproteinase (MMP) inhibitor and/or laminin 5 production promoter, as well as an anti-wrinkle agent, each of which comprises 1-piperidine propionate and/or a salt thereof.

Priority: JP20110108801 Applic. Date: 2011-05-13

Inventor: KATAGIRI CHIKA [JP]; MATSUMOTO KAYO [JP]; AOKI HIROFUMI [JP]


Publication No.: WO2012157674A1  Published: 22/Nov/2012

Title: CYCLIC PEPTIDE COMPOUND OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PRODUCING CYCLIC PEPTIDE COMPOUND OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF, AND USE OF CYCLIC PEPTIDE COMPOUND OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF

Applicant/Assignee: KWANSEI GAKUIN EDUCATIONAL FOUNDATION, KNC LABORATORIES CO., LTD

Application No.: WO2012JP62513 (PCT/JP2012/62513)   Filing Date: 16/May/2012

Abstract:

Provided are: a cyclic peptide compound which is capable of suppressing parakeratosis of the skin or a pharmacologically acceptable salt of the cyclic peptide compound

and a method for producing the cyclic peptide compound or a pharmacologically acceptable salt of the cyclic peptide compound. The present invention is a cyclic peptide compound which is represented by formula (I) (SEQ ID NO: 1) or a pharmacologically acceptable salt of the cyclic peptide compound. (In the formula, Xaa1 represents an optionally substituted alanyl group or glycyl group

Xaa2 represents an optionally substituted isoleucyl group or leucyl group

Xaa3 represents an optionally substituted glutamyl group or aspartyl group

Xaa4 represents an optionally substituted prolyl group or glycyl group

Xaa5 represents an optionally substituted glutaminyl group or asparaginyl group

Xaa6 represents an optionally substituted lysyl group or arginyl group

R1 represents a group represented by formula (II) (wherein n represents an integer of 1-10)

m represents an integer of 0 or 1

R2 represents a cystine residue

and l represents an integer of 0 or 1. In this connection, m and l are not 0 at the same time.)

Priority: JP20110110828 Applic. Date: 2011-05-17

Inventor: KADONO NANAKO [JP]; NAKAJIMA KIICHIRO [JP]; HIRAI YOHEI [JP]


Publication No.: WO2012157734A1  Published: 22/Nov/2012

Title: WRINKLE-IMPROVING COMPOSITION CONTAINING PLACENTA-DERIVED COMPONENT

Applicant/Assignee: NICHIREI BIOSCIENCES INC

Application No.: WO2012JP62738 (PCT/JP2012/62738)   Filing Date: 18/May/2012

Abstract:

The present invention addresses the problem of providing a wrinkle-improving composition having a moisturizing effect and having excellent wrinkle-improving efficacy. The present invention relates to a wrinkle-improving composition containing a liquid fraction of a high-pressure-treated product of placenta or a treated product of the fraction, in particular, to a wrinkle-improving composition for imparting moisture to the skin and for obscuring wrinkles caused by dryness.

Priority: JP20110111299 Applic. Date: 2011-05-18

Inventor: TANABE HIDEYA [JP]; NAGAMINE KENICHI [JP]


Publication No.: WO2012157817A1  Published: 22/Nov/2012

Title: ACNE TREATMENT COMPOSITION USING MAL

Applicant/Assignee: GENERAL BIO CO., LTD

Application No.: WO2011KR06967 (PCT/KR2011/06967)   Filing Date: 21/Sep/2011

Abstract:

The present invention relates to an acne treatment composition for enhancing the effects of skin-related photodynamic therapy (PDT), skin improvement, and alleviation of skin trouble, by improving the long-term stability of methyl-aminolevulinic acid (MAL) in a liquid form, which can improve the side effects such as skin erythema during the PDT treatment using ALA, which is useful as a photo sensitizing material. The acne treatment composition according to the present invention comprises: 0.01-87.5 wt% purified water

1.0-52.99 wt% glycerin

2.0-10.0 wt% propylene glycol

0.1-5.0 wt% PEG-12

0.05-0.5 wt% zinc chloride

0.05-0.5 wt% citric acid

0.1-1.0 wt% ascorbic acid

0.1-20.0 wt% methyl aminolevulinic acid

and 0.1-10.0 wt% anhydrous alcohol.

Priority: KR20110047411 Applic. Date: 2011-05-19

Inventor: SEO JEONG-HUN [KR]


Publication No.: WO2012157921A2  Published: 22/Nov/2012

Title: COMPOSITION FOR TRANSDERMAL ADMINISTRATION, CONTAINING RIVASTIGMINE OR SALT THEREOF

Applicant/Assignee: SK CHEMICALS CO., LTD

Application No.: WO2012KR03756 (PCT/KR2012/03756)   Filing Date: 14/May/2012

Abstract:

The present invention relates to a composition for transdermal administration with improved storage stability, containing rivastigmine or a salt thereof. The composition for transdermal administration of the present invention uses gentisic acid as a stabilizer of rivastigmine, wherein gentisic acid has greater rivastigmine stability than tocopherol, a formulation used on the market, is easy to handle and is commercially cheap. According to the present invention, the composition has improved stability, and thus can be stored for a long time as a drug for transdermal administration.

Priority: KR20110045023 Applic. Date: 2011-05-13

Inventor: HWANG YONG-YOUN [KR]; CHOI WON-JAE [KR]; KIM JAE-SUN [KR]; YOUN WON-NO [KR]; PARK YEO-JIN [KR]; OJ JOON-GYO [KR]; IM JONGSEOB [KR]


Publication No.: WO2012157978A2  Published: 22/Nov/2012

Title: DAPHNE GENKWA EXTRACTS, AND PHARMACEUTICAL COMPOSITION CONTAINING FRACTIONS OF THE EXTRACTS OR COMPOUNDS SEPARATED FROM THE EXTRACTS AS ACTIVE INGREDIENTS FOR PREVENTING OR TREATING ATOPIC DERMATITIS

Applicant/Assignee: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Application No.: WO2012KR03903 (PCT/KR2012/03903)   Filing Date: 17/May/2012

Abstract:

The present invention relates to Daphne genkwa extracts and to a pharmaceutical composition containing fractions of the extracts or compounds separated from the extracts as active ingredients for preventing or treating atopic dermatitis, expressed in the following chemical formula 1. More particularly, Daphne genkwa extracts, fractions thereof, or Genekwadapnin or yuanhuacine, which are compounds separated from the extracts, may effectively increase the secretion of immune cell Th1 cytokine and may exhibit inhibitory effects on atopic dermatitis in an atopic dermatitis mouse model, and therefore, may be valuably used in the prevention or treatment of atopic dermatitis.

Priority: KR20110046274 Applic. Date: 2011-05-17; KR20120052441 Applic. Date: 2012-05-17

Inventor: KIM JAE WHA [KR]; AHN KYUNG SEOP [KR]; KANG HO BUM [KR]; OH SEI RYANG [KR]; GO JAE JONG [KR]; KIM JOO HEON [KR]; SUN JANG MI [KR]; SONG JAE SUNG [KR]; OH HYUN WOO [KR]; JI DA JUNG [KR]


Publication No.: WO2012158018A2  Published: 22/Nov/2012

Title: COMPOSITIONS COMPRISING EXTRACTS OR MATERIALS DERIVED FROM PALM OIL VEGETATION LIGUOR FOR INHIBITION OF VISION LOSS DUE TO ANGIOGENESIS AND METHOD OF PREPARATION THEREOF

Applicant/Assignee: MALAYSIAN PALM OIL BOARD

Application No.: WO2012MY00102 (PCT/MY2012/00102)   Filing Date: 18/May/2012

Abstract:

The present invention relates generally to a composition comprising palm fruit juice for use in a method of preventing and inhibiting vision loss due to angiogenesis related diseases. The composition of the present invention aids to decrease in CNV size using confocal microscopy, in addition to reduction in macrophage infiltration using immune staining

decrease in VEGF- A-induced angiogenesis using established cornea pocket assay, inhibition of IKB-D phosphorylation in laser treated choroidal tissues and reduction in macrophage recruitment to CNV lesions.

Priority: MY2011PI02220 Applic. Date: 2011-05-18

Inventor: MOGHADAM ALI HAFEZI [US]; SAMBANTHAMURTHI RAVIGADEVI [MY]; TAN YEW AI [MY]; P MANICKAM KALYANA SUNDRAM [MY]; HAYES KENNETH C [US]; SOUSKA ZANDI [DE]


Publication No.: WO2012158312A2  Published: 22/Nov/2012

Title: SKIN AND HAIR REGENERATION USING POLYSACCHARIDE-BASED HYDROGELS

Applicant/Assignee: THE JOHNS HOPKINS UNIVERSITY

Application No.: WO2012US34802 (PCT/US2012/34802)   Filing Date: 24/Apr/2012

Abstract:

Methods for promoting skin regeneration, promoting hair follicle regeneration, and reducing scarring by topically administering polysaccharide-based hydrogel compositions to injured skin are presented.

Priority: US201161483518P Applic. Date: 2011-05-06; US201161563954P Applic. Date: 2011-11-28

Inventor: SUN GUOMING [US]; ZHANG XIANJIE [US]; HARMON JOHN W [US]; GERECHT SHARON [US]


Publication No.: WO2012162461A1  Published: 29/Nov/2012

Title: PHENYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION

Applicant/Assignee: JANSSEN PHARMACEUTICA NV

Application No.: WO2012US39270 (PCT/US2012/39270)   Filing Date: 24/May/2012

Abstract:

This invention relates to phenyl thiazole I and its therapeutic and prophylactic uses, wherein the variables Rz, Q, J, R1, R3, R5, R6, and R7 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis. Formula (I)

Priority: US201161489722P Applic. Date: 2011-05-25

Inventor: JACKSON PAUL FRANCIS [US]; LEONARD KRISTI ANNE [US]; BARBAY JOSEPH KENT [US]; WANG AIHUA [US]; TOUNGE BRETT ANDREW [US]; ZHANG YAN [US]; MAHAROOF UMAR S M [US]


Publication No.: WO2012162536A2  Published: 29/Nov/2012

Title: SKIN TREATMENT METHOD

Applicant/Assignee:

Application No.: WO2012US39409 (PCT/US2012/39409)   Filing Date: 24/May/2012

Abstract:

River rocks are used in a therapy regime whereby the river rocks are used to absorb excess oils from the skin of a user. In one method, river rocks arc collected from a source (e.g.. river or supplier), sorted for size and color, engraved with logo or other content, packaged and shipped to customers or retailers with instructions on use. Use comprises placement of the river rocks on oily portions of the user's skin for an appropriate time period allowing the river rock to absorb the excess oils. The river rocks are reusable after being washed with mild soap and water.

Priority: US201113116992 Applic. Date: 2011-05-26

Inventor: SUTORIUS ANNE [US]


Publication No.: WO2012163928A2  Published: 06/Dec/2012

Title: WASH COMPOSITION

Applicant/Assignee: GALDERMA S.A

Application No.: WO2012EP60072 (PCT/EP2012/60072)   Filing Date: 29/May/2012

Abstract:

The present invention relates to wash compositions for topical application, stable and well tolerated and to their uses thereof as cosmetic or pharmaceutical products, said compositions being used for cleansing the skin, preferably of acne patients, without compromising the skin barrier or resulting in over-compensation of sebum production. More preferably the invention relates to a topical wash composition comprising:10 a) at least one surfactant, b) a zinc salt of gluconic acid, c) a salt or derivative of glycyrrhizic acid or of glycyrrhetinic acid.

Priority: US201161490850P Applic. Date: 2011-05-27; FR20110058869 Applic. Date: 2011-09-30

Inventor: NADAU FOURCADE KARINE [FR]


Publication No.: WO2012164488A2  Published: 06/Dec/2012

Title: NEW COSMETIC OR DERMOPHARMACEUTICAL TOPICAL USE OF A MIXTURE OF A GHK TRIPEPTIDE AND GQPR TETRAPEPTIDE

Applicant/Assignee: SEDERMA

Application No.: WO2012IB52681 (PCT/IB2012/52681)   Filing Date: 29/May/2012

Abstract:

According to the invention, a mixture of A-GHK-B tripeptide and A-GQPR-B tetrapeptide (SEQ ID NO: 1), or their derivatives or analogs, for the therapeutical treatment of the papillary dermis, with: A = H, CO-R1, SO2-R1

B = OH, OR1, NH2, NHR1, NR1R2

R1 and R2 being, independently of one another, selected from an alkyl, aryl, aralkyl, alkylaryl, alkoxy and aryloxy group, which may be linear, branched, cyclic, polycyclic, unsaturated, hydroxylated, carbonylated, phosphorylated and/or sulfured, said group which may have a heteroatom in its skeleton including O, S and/or N

is used to prevent damage to the papillary dermis and/or repair the dermis papillary, to prevent and/or treat skin aging, in particular photo-induced aging.

Priority: FR20110054834 Applic. Date: 2011-06-01

Inventor: FOURNIAL ARNAUD [FR]; MONDON PHILIPPE [FR]


Publication No.: WO2012165468A1  Published: 06/Dec/2012

Title: METHOD FOR MANUFACTURING LIQUID CRYSTALLINE COMPOSITION CONTAINING LIPOPHILIC COMPOUND IN HIGH CONCENTRATION, AND LIQUID CRYSTALLINE COMPOSITION MANUFACTURED BY SAID METHOD

Applicant/Assignee: ST.MARIANNA UNIVERSITY SCHOOL OF MEDICINE, NANOEGG RESEARCH LABORATORIES, INC

Application No.: WO2012JP63903 (PCT/JP2012/63903)   Filing Date: 30/May/2012

Abstract:

Provided are: a method for manufacturing a liquid crystalline composition which contains a lipophilic compound, said composition having an enhanced lipophilic compound content

and a liquid crystalline composition manufactured by the method. The method comprises a liquid crystal preparation step of adding and mixing amphiphilic molecules and water and is characterized in that: either a lipophilic compound having an ionically dissociable group or a combination of the lipophilic compound with a surfactant is added and mixed as the amphiphilic molecules

and the lipophilic compound is added and mixed in the form of an alkali metal salt or an alkaline earth metal salt or subjected to a subsequent reaction with a hydroxide of an alkali or alkaline earth metal or a phosphate thereof.

Priority: JP20110121820 Applic. Date: 2011-05-31

Inventor: YAMAGUCHI YOKO [JP]; YAMASHITA YUJI [JP]; KUBOTA YOSHIKI [JP]


Publication No.: WO2012165610A1  Published: 06/Dec/2012

Title: COMPOSITION FOR MAINTAINING OR IMPROVING SKIN BARRIER FUNCTION

Applicant/Assignee: TAISHO PHARMACEUTICAL CO., LTD

Application No.: WO2012JP64259 (PCT/JP2012/64259)   Filing Date: 01/Jun/2012

Abstract:

An oral composition for maintaining or improving a skin barrier function, characterized by containing taurine as an active ingredient

or an oral composition for preventing or ameliorating age-related wrinkling, characterized by containing taurine as an active ingredient.

Priority: JP20110124927 Applic. Date: 2011-06-03; JP20120088128 Applic. Date: 2012-04-09

Inventor: TAKANO NORIKAZU [JP]; TAKEI TAKUTO [JP]; INOKUCHI YUKI [JP]; MUTOH CHIKAKO [JP]; MANABE CHIKA [JP]


Publication No.: WO2012166005A1  Published: 06/Dec/2012

Title: PROTEIN-POLYPEPTIDE COMPLEX WITH A SPECIFIC ACTIVITY ON SKIN TISSUE, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITION ON THE BASIS THEREOF

Applicant/Assignee: ZAKRYTOE AKTSIONERNOE OBSCHESTVO "PHARM-SINTEZ"

Application No.: WO2012RU00140 (PCT/RU2012/00140)   Filing Date: 28/Feb/2012

Abstract:

The invention relates to biotechnology. The protein-polypeptide complex having a tissue-specific reparative activity and a rejuvenating activity on the skin tissue is prepared from the nerve and skin tissues of embryos of ungulate livestock during gestation from the middle of the first trimester to the middle of the last trimester of pregnancy by homogenization in a buffer solution with simultaneous extraction in the presence of non-ionic detergents at a ?? of 5.2-8.5. The resultant homogenate is centrifuged and filtered. The proteins are isolated on a chromatography column with an anion exchange medium. The resultant fractions are combined and subjected to sterilizing filtration. The complex comprises negatively charged, weakly acidic, neutral proteins and polypeptides with molecular masses of from 5 to 200 kDa. Furthermore, at least 70% of the total mass of protein has a molecular mass in the range of from 20 to 160 kDa. The pharmacological composition comprises, as active ingredient, a complex with a concentration of 0.05-2.0 mg/ml and a pharmaceutically acceptable diluent.

Priority: RU20110121685 Applic. Date: 2011-05-30

Inventor: NAZARENKO ANNA BORISOVNA [RU]; SOKOLOV MIKHAIL ANATOLEVICH [RU]


Publication No.: WO2012166006A1  Published: 06/Dec/2012

Title: PROTEIN-POLYPEPTIDE COMPLEX WITH A SPECIFIC EFFECT ON SKIN TISSUE, METHOD FOR PRODUCING SAID COMPLEX AND PHARMACEUTICAL COMPOSITION ON THE BASIS THEREOF

Applicant/Assignee: ZAKRYTOE AKTSIONERNOE OBSCHESTVO "PHARM-SINTEZ"

Application No.: WO2012RU00141 (PCT/RU2012/00141)   Filing Date: 28/Feb/2012

Abstract:

The invention relates to biotechnology. The protein-polypeptide complex which has a tissue-specific regenerative, reparative and rejuvenating effect on skin tissue is produced from nerve and skin tissues of embryos of hoofed agricultural animals within a gestation period from the middle of the first trimester to the middle of the final trimester of pregnancy by homogenizing said tissue in a buffer solution with simultaneous extraction in the presence of reversible proteolysis inhibitors, non-ionic detergents and solubilizers at a pH of 5.2-8.5. The homogenate produced is centrifuged and filtered. The proteins are separated out on a chromatography column using an anion-exchange medium. The fractions produced are combined and subjected to sterilizing filtration. The complex comprises negatively charged, weakly acid, neutral proteins and polypeptides having molecular masses of from 0.5 to 200 kDa. The complex is characterized by an absorption peak at a wavelength of 215+-5 nm upon plotting of the ultraviolet spectrum in a wavelength range of from 200 to 500 nm. The pharmaceutical composition comprises, as active ingredient, the protein-polypeptide complex in a concentration of 0.01-2.0 mg/ml, polynucleotides in the form of a sodium salt of deoxyribonucleic acid, and a pharmaceutically acceptable diluent.

Priority: RU20110121684 Applic. Date: 2011-05-30

Inventor: NAZARENKO ANNA BORISOVNA [RU]; SOKOLOV MIKHAIL ANATOLEVICH [RU]


Publication No.: WO2012167606A1  Published: 13/Dec/2012

Title: PYRIDONAPHTHYRIDINE PI3K/MTOR DUAL INHIBITORS AND PREPARATION AND USE THEREOF

Applicant/Assignee: KBP BIOSCIENCES CO., LTD

Application No.: WO2012CN00761 (PCT/CN2012/00761)   Filing Date: 04/Jun/2012

Abstract:

The present invention relates to pyridonaphthyridine compounds as shown by general formula (I), and pharmaceutically acceptable salts, stereoisomers, and deuterated derivatives thereof, which have PI3K/mTOR dual inhibiting activities, wherein R1, R2, R3, R4, R5, R6, R7 and X are defined as description

The present invention also relates to the preparative process of said compounds, the pharmaceutical composition and pharmaceutical preparation containing said compounds, as well as uses of said compounds in the treatment and/or prophylaxis of proliferative diseases and in the manufacture of medicaments for the treatment and/or prophylaxis of proliferative disease.

Priority: CN20111159903 Applic. Date: 2011-06-04; CN20111365829 Applic. Date: 2011-11-04

Inventor: WU FRANK [CN]; ZHANG YAN [CN]


Publication No.: WO2012168226A1  Published: 13/Dec/2012

Title: DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS

Applicant/Assignee: CHIESI FARMACEUTICI S.P.A

Application No.: WO2012EP60579 (PCT/EP2012/60579)   Filing Date: 05/Jun/2012

Abstract:

The invention relates to inhibitors of the phosphodiesterase 4 (PDE4) enzyme. More particularly, the invention relates to compounds that are derivatives of 1-phenyl-2-pyridinyl alkyl alcohols of formula (I), methods of preparing such compounds, compositions containing them and therapeutic use thereof.

Priority: EP20110168853 Applic. Date: 2011-06-06

Inventor: ARMANI ELISABETTA [IT]; AMARI GABRIELE [IT]; CARZANIGA LAURA [IT]; CAPALDI CARMELIDA [IT]; ESPOSITO ORIANA [IT]; VILLETTI GINO [IT]; DE FANTI RENATO [IT]


Publication No.: WO2012169541A1  Published: 13/Dec/2012

Title: TRPV3 ACTIVATOR

Applicant/Assignee: KAO CORPORATION

Application No.: WO2012JP64579 (PCT/JP2012/64579)   Filing Date: 06/Jun/2012

Abstract:

Provided are a TRPV3 activator for imparting heat sensitivity to a cosmetic material, pharmaceutical product, or oral composition, and a heat sensitivity imparting method using the same. A TRPV3 activator in which the active ingredient is an alkylphenol derivative represented by formula (A1) or (B1) [in formula (A1), R represents a hydrogen atom, a C1-4 alkyl group, or a C2-4 alkenyl group

in formula (B1), R1 represents the group -CH(CH3)CH2CH2CH=C(CH3)2 or the group -CH(CH3)CH2CH2CH2CH(CH3)2].

Priority: JP20110128914 Applic. Date: 2011-06-09; JP20110128924 Applic. Date: 2011-06-09

Inventor: SHIRAI TOMOHIRO [JP]; KUSUOKU HIROSHI [JP]; KUMIHASHI KENTARO [JP]


Publication No.: WO2012169649A1  Published: 13/Dec/2012

Title: INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF

Applicant/Assignee: DAINIPPON SUMITOMO PHARMA CO., LTD

Application No.: WO2012JP65052 (PCT/JP2012/65052)   Filing Date: 06/Jun/2012

Abstract:

The present invention relates to a novel indazole- or pyrrolopyridine-derivative, represented by the formula (1) below, that has an agonistic action or a partial agonistic action against serotonin-4 receptor, and a pharmaceutical composition comprising the same. Formula (1) [wherein each substituent is as defined in claim 1]

Priority: JP20110127688 Applic. Date: 2011-06-07

Inventor: MIZUNO KAZUHIRO [JP]; IKEDA JUNYA [JP]; NAKAMURA TAKANORI [JP]; IWATA MASATO [JP]; OTAKA HIROMICHI [JP]; GOTO NANA [JP]


Publication No.: WO2012169664A1  Published: 13/Dec/2012

Title: EXTERNAL DERMAL AGENT AND FUNCTIONAL FOOD CONTAINING ROSE PLACENTA TISSUE-CULTURED PRODUCT OR EXTRACT THEREOF

Applicant/Assignee: BIO-FD&C CO., LTD, GINZA TOMATO CO.,LTD

Application No.: WO2011KR04120 (PCT/KR2011/04120)   Filing Date: 07/Jun/2011

Abstract:

The present invention relates to an external dermal agent and a functional food containing a rose placenta tissue-cultured product or an extract thereof, and more specifically, to an external dermal agent and a functional food containing a rose placenta tissue culture extract as an active ingredient. The external dermal agent and the functional food containing the rose placenta tissue-cultured product or the extract thereof, according to the present invention, activates skin cells by means of growth or proliferation of skin cells, thereby effectively regenerating the skin and smoothing wrinkles, and exhibits a superior antioxidant effect by containing a physiological activation substance.

Priority: KR20110054325 Applic. Date: 2011-06-07

Inventor: MOH SANG HYUN [KR]; SEO HYO HYUN [KR]; KANG HYO SEOK [KR]; LEE JEONG HUN [KR]; JUNG DAI HYUN [KR]; KIM SU JUNG [KR]; KIM HYOUNG SHIK [KR]; MIN JI AEE [KR]; SHIN DONG SUN [KR]; CHO MOON JIN [KR]; LEE YU RI [KR]; MOH JI HONG [KR]; LEE JIN HYEONG [KR]; KONDO CHIEKO [JP]; KONDO YOSHITAKA [JP]


Publication No.: WO2012170392A2  Published: 13/Dec/2012

Title: SHK-BASED PHARMACEUTICAL COMPOSITIONS AND METHODS OF MANUFACTURING AND USING THE SAME

Applicant/Assignee: KINETA ONE, LLC

Application No.: WO2012US40857 (PCT/US2012/40857)   Filing Date: 05/Jun/2012

Abstract:

Disclosed herein are pharmaceutical compositions having the sequence Arg-Ser-Cys-lle-Asp-Thr-lle-Pro-Lys-Ser-Arg-Cys-Thr-Ala-Phe-Gln-Cys-Lys-His-Ser-Xaa-Lys-Tyr-Arg-Leu-Ser-Phe-Cys-Arg-Lys-Thr-Cys-Gly-Thr-Cys (SEQ ID NO:1 ). The disclosed compositions can include an acid or amide at the C-terminus of SEQ ID NO: 1 and the polypeptide can be attached to an organic or inorganic chemical entity that has an anionic charge. The polypeptide can be detectably labeled for diagnostic purposes. Methods of manufacturing and using the pharmaceutical compounds are also disclosed.

Priority: US201161493868P Applic. Date: 2011-06-06; US201261625578P Applic. Date: 2012-04-17

Inventor: IADONATO SHAWN P [US]; TARCHA ERIC J [US]


Publication No.: WO2012172057A2  Published: 20/Dec/2012

Title: USE OF A COMPOUND COMPRISING AT LEAST ONE NUCLEOPHILIC FUNCTION FOR CAPTURING CARBONYL COMPOUNDS RESULTING FROM THE REACTION BETWEEN ONE OR MORE COMPOUNDS CONSTITUTING SEBUM AND OZONE

Applicant/Assignee: L'OREAL

Application No.: WO2012EP61457 (PCT/EP2012/61457)   Filing Date: 15/Jun/2012

Abstract:

The invention relates to a process for capturing one or more carbonyl compounds B resulting from the reaction between one or more compounds constituting sebum and ozone on the surface of a material or in a material, characterized in that one or more compounds A having one or more nucleophilic functions FA forming in situ on the surface o f said material or in said material a layer capturing said compound(s) B is (are) applied to the surface o f said material. The invention also relates to the cosmetic use o f one or more compounds A having one or more nucleophilic functions FA capable o f reacting with one or more carbonyl compounds B resulting from the reaction between one or more compounds constituting sebum and ozone, as a soothing agent, said compound(s) with nucleophilic functions(s) being intended for preventing and/or treating discomforting reactions o f keratin materials induced by the carbonyl compounds B.

Priority: FR20110055291 Applic. Date: 2011-06-16; US201161564727P Applic. Date: 2011-11-29

Inventor: SAMAIN HENRI [FR]


Publication No.: WO2012173383A2  Published: 20/Dec/2012

Title: SKIN COMPOSITION FOR EXTERNAL USE CONTAINING CRYPTOTANSHINONE AS ACTIVE INGREDIENT

Applicant/Assignee: AMOREPACIFIC CORPORATION

Application No.: WO2012KR04647 (PCT/KR2012/04647)   Filing Date: 13/Jun/2012

Abstract:

The present invention provides a skin composition for external use containing cryptotanshinone, an isomer thereof, a precursor thereof, a salt thereof, a hydrate thereof, or a solvate thereof as an active ingredient. The composition according to the present invention has the effects of suppressing skin aging, smoothing skin wrinkles, skin whitening, skin moisturizing, improving atopic dermatitis, and improving skin tone and skin transparency.

Priority: KR20110058903 Applic. Date: 2011-06-17

Inventor: LEE OK CHAN [KR]; YEOM MYEONG HUN [KR]; CHO GA YOUNG [KR]; LEE JIN YOUNG [KR]


Publication No.: WO2012176792A1  Published: 27/Dec/2012

Title: PHARMACEUTICAL COMPOSITION FOR INFLAMMATORY DISEASES, ALLERGIC DISEASES AND AUTOIMMUNE DISEASES

Applicant/Assignee: R-TECH UENO, LTD

Application No.: WO2012JP65706 (PCT/JP2012/65706)   Filing Date: 20/Jun/2012

Abstract:

The present invention relates to a method and a pharmaceutical composition for suppressing immunity, in each of wherein a fatty acid derivative represented by general formula (I) is utilized. The present invention also relates to a method and a pharmaceutical composition for treating inflammatory diseases, allergic diseases and autoimmune diseases, in each of wherein the fatty acid derivative is utilized.

Priority: JP20110137213 Applic. Date: 2011-06-21

Inventor: MASHIMA YUKIHIKO [JP]; TAJIMA MASAHIRO [JP]; TABUCHI REIKO [JP]


Publication No.: WO2012177031A1  Published: 27/Dec/2012

Title: METHOD FOR MANUFACTURING BUBBLES FOR PROMOTING THE TRANSFER OF A FUNCTIONAL MATERIAL, AND FUNCTIONAL-MATERIAL TRANSFER DEVICE USING SAME

Applicant/Assignee: PACIFIC SYSTEM CO., LTD

Application No.: WO2012KR04839 (PCT/KR2012/04839)   Filing Date: 19/Jun/2012

Abstract:

The present invention relates to a method for manufacturing bubbles for promoting the transfer of a functional material, and to a functional-material transfer device using same. The functional-material transfer device comprises: a main body

and a probe. The main body outputs an ultrasonic wave oscillation having a wavelength linked to the size of a bubble which is mixed with the functional material and transferred, as a mixture, into an object. The probe is connected to the main body so as to enable the ultrasonic wave oscillation to contact the object coated with the mixture, thereby applying the ultrasonic wave oscillation to the object. The ultrasonic wave oscillation having the wavelength linked to the size of the bubble may generate a hollowing phenomenon in the bubble applied to the object.

Priority: KR20110059923 Applic. Date: 2011-06-21

Inventor: SEO JONG WOO [KR]; KIM KI DOO [KR]


Publication No.: WO2012177081A2  Published: 27/Dec/2012

Title: PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING INFLAMMATORY DISEASE CONTAINING AN ARDISIA TINCTORIA EXTRACT OR A FRACTION THEREOF AS AN ACTIVE INGREDIENT

Applicant/Assignee: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Application No.: WO2012KR04957 (PCT/KR2012/04957)   Filing Date: 22/Jun/2012

Abstract:

The present invention relates to a composition for preventing and treating inflammatory disease containing an Ardisia tinctoria (Ardisia tinctoria Pit.) extract or a fraction thereof as an active ingredient. More specifically, it has been confirmed that an Ardisia tinctoria extract or a fraction thereof suppresses the production of nitric oxide which is sharply increased by inflammation induction, and it has been confirmed that the Ardisia tinctoria extract is effective in markedly reducing the amount of PGE2, IL-6 (interleukin-6) and IL-1 beta cytokine in a dose dependent fashion, and that it inhibits the expression of iNOS and the COX2 gene and protein and inhibits nuclear translocation of p65 protein and phosphorylation of signal transducers. Also, it has been confirmed that the Ardisia tinctoria extract and an ethyl acetate fraction are effective in suppressing inflammation in a carrageenan-induced mouse podedema model as well. Consequently, the Ardisia tinctoria extract or fraction can be used to advantage as an active ingredient in compositions for preventing and treating or alleviating inflammatory related diseases, or compositions for topical skin preparations, cosmetic compositions and health foods.

Priority: KR20110061685 Applic. Date: 2011-06-24; KR20120067342 Applic. Date: 2012-06-22

Inventor: AHN KYUNG SEOP [KR]; KWON OK-KYOUNG [KR]; OH SEI RYANG [KR]; KIM JUNG HEE [KR]; LE XUAN CANH [VN]; PARK JI WON [KR]; LEE SANG WOO [KR]; LEE JOONGKU [KR]; LEE HYEONG KYU [KR]; CHOI SANG HO [KR]; TRAN THE BACH [VN]


Publication No.: WO2012177714A1  Published: 27/Dec/2012

Title: SUBSTITUTED 6-AZA-ISOINDOLIN-1-ONE DERIVATIVES

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: WO2012US43276 (PCT/US2012/43276)   Filing Date: 20/Jun/2012

Abstract:

Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, p, R1, R2, R3a, R4, and R5 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, cancer, and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

Priority: US201161500094P Applic. Date: 2011-06-22

Inventor: NIE ZIE [US]; CHEN RON [US]; KONO MITSUNORI [JP]; LAM BETTY [US]; LARDY MATTHEW [US]; REDDY SRINI [US]; WILKINS STEVE [US]

Clck to enlarge and view details
World  Patents Published  in 2013
 
World  Patents Published  in 2011
...or use our Search Engine to
search for patent documents by
number.
Search for anything. Simply
type the words in the box..